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ABSTRACT
A New Member of the AFAP Family, AFAP1L1,
Binds to Cortactin and Localizes to Invadosomes
Brandi Nicole Snyder

Cellular motility and invasion in normal cellular processes and disease states such
as cancer are dependent upon the ability of a cell to efficiently interact with its
microenvironment, rearrange its cytoskeleton and degrade tissue barriers for purposes of
cell movement. The AFAP family of adaptor proteins, AFAP1, AFAP1L1 and
AFAP1L2, integrates signals received from the microenvironment into coordinated
cytoskeletal changes. While there have been many reports on the functions and binding
partners of AFAP1 and AFAP1L2, this work aimed to determine the cellular location and
function of newly discovered AFAP1L1. The overall amino acid and protein structures of
AFAP family members were compared so as to determine similarities and differences as
well as to propose an evolutionary link between all three family members. As AFAP1
and AFAP1L1 have been shown to be more closely related, studies focused on a detailed
comparison of these two family members. AFAP1 and AFAP1L1 were shown to have
similar cellular localization in the cell by associating with stress filaments and cortical
actin and also showing localization to invadosomes. Immunohistochemistry demonstrated
differential expression of AFAP1L1 in the brain, particularly surrounding the Purkinje
neurons, granular cells and neurons of the dentate nucleus. Although AFAP1 is a well
known cSrc binding partner and activator, AFAP1L1 was determined to be a binding
partner for cortactin, possibly through the SH3 domain. As other AFAP family members
have been shown to be increased in various cancers, AFAP1L1 expression levels are
upregulated in a number of cancers, particularly neuroblastoma and glioblastoma. While
the similar amino acid sequence and modular domain identifies AFAP1L1 as a previously
undescribed member of the AFAP family, the ability of AFAP1L1 to interact with
cortactin and localize to distinct areas of the brain implies that AFAP1L1 has unique
functions separate from AFAP1 and AFAP1L2.
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CHAPTER 1

Introduction and Review of Literature
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I. Introduction and Significance
Cells have the ability to take instructional cues from their environment and
convert them into a complex and intricate cascade of information directed by signaling
proteins so as to perform a large array of cellular processes. At the heart of these
signaling complexes are adaptor proteins, proteins with no intrinsic enzymatic activity
themselves but which do have the ability to link proteins together by virtue of their
protein binding domains. These protein binding domains, identified through consensus
amino acid sequence, allow a single adaptor protein to interact with a variety of other
proteins so as to create a sophisticated signaling complex (Pawson and Nash, 2003). The
functions of these signaling complexes are diverse and include apoptosis, actin dynamics
and cell cycle regulation, among many others (Duncan et al., 2010; Qian et al., 2000;
Roberts et al., 2002). The Actin Filament-Associated Protein (AFAP) family of adaptor
proteins is involved in signaling cascades that regulate cell shape, motility and
cytoskeletal integrity and are associated with cSrc kinase activity, protein kinase C alpha
(PKCα) activation and activation of the phosphatidylinositol-3 kinase (PI3K) pathway
(Baisden et al., 2001b; Lodyga et al., 2009; Xu et al., 2007). As the discovery of multiple
AFAP family members is a relatively new area of research, this literature review will
serve as an in depth comparison of the AFAP family structure and function.

II. Actin Filaments and Cell Morphology
It is well known that many cells have the ability to migrate during processes such
as embryonic development, wound closure, and inflammation (Ho et al., 2008; Le
Clainche and Carlier, 2008; Parsons et al., 2010; Rathinam and Alahari, 2010). It is
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through rearrangement of the actin cytoskeleton that cells are able to effectively respond
to mechanical forces, extracellular matrix proteins or external cues (Parsons et al., 2010).
The ability of a cell to remodel the cytoskeleton is important in normal cellular processes
such as embryogenesis, immune cell motility and adhesion; however, cancer cells can
also acquire the ability to undergo abnormal cell migration (Le Clainche and Carlier,
2008; Weed and Parsons, 2001). Mediated through a number of proteins such as the Rho
family of small guanosine triphosphatases (GTPases), cells move towards a signal by first
extending the cell body and creating a variety of adhesions to their substratum.

Rho Family Members
Rho family members Rho, Rac and Cdc42 are GTPases that are regulators of cell
movement. Small GTPases are activated to GTP bound forms through guanine nucleotide
exchange factors (GEFs) which exchange bound GDP for GTP and are inactivated to
GDP bound forms through GTPase activating proteins (GAPs) which hydrolyze GTP.
Activation of different Rho family members can lead to the formation of different actin
structures within the cell. The activation of Rho is known to induce the formation of
stress fibers, contractile bundles of anti-parallel cross-linked actin that have the ability to
contract due to association with non-muscle myosin (Parsons et al., 2010). Rac activation
is known to induce the formation of lamellipodia, a thin cytoplasmic protrusion at the
leading edge of the cell that is 1-5µm in width. Lamellipodia contain branched actin
structures and are vital to the formation of cellular adhesions while Cdc42 activation
results in the formation of actin-rich finger-like protrusions which extend outside of the
lamellipodium called filopodia (Small et al., 2002). Filopodia play multiple roles in the
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cell by directing cell migration through sensing of the microenvironment, forming sheets
of cells for both embryonic development and wound healing through cell adhesion and
forming the precursors of dendritic spines in neurons (Mattila and Lappalainen, 2008). It
is through activation of various Rho family GTPases and their subsequent signaling
pathways that a cell can transform extra- and intracellular cues into a coordinated cell
movement.

Focal Adhesions
As a cell begins the process of migration, it begins by forming transient contacts
with the substratum called focal contacts (Zamir and Geiger, 2001). These immature
nascent adhesions of bundled actin have the ability to mature into larger and longer
lasting focal adhesions; a complex array of proteins along the ventral plasma membrane
rich in cytoskeletal proteins such as paxillin and talin and protein kinases such as Src,
focal adhesion kinase (FAK) and protein kinase C (PKC), as well as many others that link
the actin cytoskeleton to the substratum (Zamir and Geiger, 2001). Key players in focal
adhesions are integrins, transmembrane proteins whose cytoplasmic tails bind to the array
of proteins in the focal adhesion and whose extracellular domains bind to proteins in the
extracellular matrix (ECM) such as fibronectin and collagen (Parsons et al., 2010). The
fast growing filamentous actin lamellipodium at the protruding edge of the cell undergoes
actin polymerization that pushes the lamellipodium forward, forming immature focal
contacts with the extracellular matrix. These early contacts mature into integrincontaining focal adhesions through mechanical tension applied to the contact by myosinII mediated contractile forces from the cytoskeleton. The application of force at a
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maturing contact establishes new binding sites for adhesion-associated proteins through
conformational changes in proteins involved in the immature contact. An additional result
of myosin-II activation is cross-linking and bundling of actin filaments, combined with
myosin-II mediated contractility results in the maturation of focal adhesions at the
leading edge of the cell which signals for actin filament polymerization and protrusion of
the leading edge while this protrusive force causes actin filament depolymerization and
disassembly of the focal adhesions at the rear of the cell (Parsons et al., 2010; Ridley et
al., 2003; Small and Resch, 2005). The forward movement of the cell is mediated by
these contractile forces between the cellular adhesions and stress fibers. Three types of
stress fibers have been described: ventral, dorsal and transverse arcs (Pellegrin and
Mellor, 2007). Ventral stress fibers extend between focal adhesions at the leading edge of
the cell to the central cell body (Small et al., 1998). Contraction of these ventral stress
fibers causes a pulling towards the newly formed lamellipodium and away from the
trailing edge of the cell. Dorsal stress fibers are attached at one end to a focal adhesion
and rise into the dorsal surface of the cell where they interact with a meshwork of actin.
Although they do not have the ability to contract themselves, dorsal stress fibers may
function to transmit the contraction of transverse arcs which are not tethered to focal
adhesions and form behind the lamellipodium (Pellegrin and Mellor, 2007).

Invadosomes
In addition to focal adhesions, some highly motile cells such as macrophages,
osteoclasts, dendritic cells and also smooth muscle cells exhibit podosomes, dynamic
cellular contacts with the substratum that consist of an F-actin core surrounded by a ring
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of proteins involved in cytoskeletal organization such as actin-related protein (Arp)2/3,
cortactin, integrins, cSrc and many others. Found on the ventral membrane of cells,
podosomes have a half-life longer than focal contacts ranging from approximately 2 to 12
minutes and form a structure approximately 0.5-1µm in diameter with a depth of 0.20.4µm (Linder and Kopp, 2005). Although focal adhesions and podosomes share some
of their integral proteins such as protein kinases, RhoGPTases and integrins, podosomes
have the ability to secrete matrix metalloproteases (MMPs) which focal adhesions do not
(Linder and Aepfelbacher, 2003). The ability of podosomes to secrete MMPs allows them
to remodel the surrounding extracellular matrix for purposes of motility and crossing of
tissue barriers (Linder and Kopp, 2005). Similar to podosomes are invadopodia,
podosome-like structures found in transformed cells (cancer cells) which are longer lived
(minutes to hours) and actively degrade matrix, which is required for tumor invasion
(Yamaguchi et al., 2006). Invadopodia are larger than podosomes, reaching diameters of
up to 8µm and extending projections deep into the extracellular matrix (Linder and Kopp,
2005). A well-known feature of transformed cells is epithelial to mesenchymal transition
(EMT) which involves the detachment of tumor cells from their place of origin, invasion
through their surroundings, intravasation into and extravasation from the blood and
lymphatic vessels and colonization of a secondary metastatic site in which this temporary
cell phenotype is reversed (Yilmaz and Christofori, 2009). Naturally, loss of cellular
contacts and rearrangement of the actin cytoskeleton are dynamic activities in the EMT
process. Invadopodia play a role in EMT by degrading the extracellular matrix and
providing a pathway for invasion of malignant cells.
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Collectively termed invadosomes for their ability to degrade components of the
extracellular matrix, podosomes and invadopodia share some common characteristics
while there are also identifiable differences between the two (Linder, 2009). It is
hypothesized that podosomes may be a precursor to invadopodia, and, as such, both
contain similar cellular location and machinery such as their dot-like shape and
localization to the ventral membrane as well as their association with actin and other
focal complex regulators (Linder, 2009; Saltel et al., 2010). While many podosomes may
form in a single cell and have a lifetime of a few minutes, fewer and longer-lived
invadopodia are usually found in transformed cells (Linder, 2009). Podosomes are
commonly characterized as adhesive structures that may play a role in migration and
ECM remodeling while also serving a sensory function for guidance (Gimona et al.,
2008; Saltel et al., 2010). Invadopodia have an increased ability to degrade the ECM and
are a hallmark of highly invasive cancers as it is by virtue of this matrix degradation that
highly motile cancer cells are able to metastasize throughout the body. The origin of and
an in vivo role for invadosomes is currently a subject of exploration (Gimona et al., 2008;
Linder, 2009).

cSrc and the Actin Cytoskeleton
cSrc is a well-known and well-studied non-receptor protein tyrosine kinase whose
activation affects cellular transformation through the tyrosine phosphorylation of cellular
proteins thus resulting in a transformed phenotype in which the cells are rounded, lose
their integrin-based substrate attachment, become more motile and can degrade and
invade through cellular matrix (Frame et al., 2002; Yeatman, 2004). The cSrc structure
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consists of a kinase domain, a Src homology 2 (SH2) domain, a Src homology 3 (SH3)
domain and a myristoylation site that is necessary for membrane localization (Yeatman,
2004).

cSrc

remains

in

an

intramolecularly

autoinhibited

conformation

by

phosphorylation of a tyrosine residue at Y527 in chicken (Y530 in human) that interacts
with its’ own SH2 domain. An additional interaction of the SH3 domain with the kinase
domain acts as a second level of intramolecular regulation to insure the proper
functioning of cSrc (Yeatman, 2004). As activation of cSrc is a hallmark of cancer and
results in a transformed cellular phenotype, this tight regulation of activation is necessary
for the proper functioning of the cell. Phosphatases that dephosphorylate the regulatory
tyrosine in the C-terminus are also highly regulated as dephosphorylation of phosphoY527 (Y530 in humans) allows cSrc to open into an active conformation and
autophosphorylate itself and cellular substrates. While inactive cSrc resides around the
perinuclear region, active cSrc indirectly associates with actin and can move to the cell
periphery where the myristoylation site is necessary for association with the plasma
membrane. From here, cSrc has the ability to phosphorylate a variety of proteins. FAK,
for example, is a non-receptor tyrosine kinase that associates with integrins and is
activated when phosphorylated by cSrc which results in a loss of and turnover of focal
adhesions. This turnover results in the regulated process of assembly and disassembly of
cell-matrix adhesions and allows the cell to increase its motility. Also a result of cSrc
activation, cells develop the ability to invade through matrix by the activation of MMPs
(Yeatman, 2004).
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Classical Protein Kinase C and the Cytoskeleton
The Protein Kinase C family are serine/threonine kinases divided into classical
(PKC α,βI,βII (splice variants from a single gene) and γ), novel (PKC δ,ε,η and θ) and
atypical (PKC ι/λ and ξ) designations which each contain a catalytic and regulatory
domain (Larsson, 2006). The classical PKCs have a necessary activation site that can
bind phosphatidylserine, diacylglycerol and phorbol esters, a calcium binding region, an
ATP binding region and a catalytic domain (Brandt et al., 2002; Martiny-Baron and
Fabbro, 2007). While PKCβ and PKCγ are known to have roles in inflammation,
angiogenesis and neuronal tissues, the PKCα isoform is a general promoter of cell
migration, proliferation and apoptosis (Larsson, 2006; Martiny-Baron and Fabbro, 2007).
In A7r5 smooth muscle cells, classical PKCs, PKCα in particular, were shown to be
responsible for phorbol ester-induced cytoskeletal remodeling of stress fibers into
podosomes (Hai et al., 2002). Activation of PKCs by phorbol ester in these cells resulted
in a decrease in RhoA activity and subsequent dissolution of stress fibers by virtue of the
upregulation of p190RhoGAP (Brandt et al., 2002). P190RhoGAP is activated by
phosphorylation, possibly by cSrc. Indeed, cSrc activity is also increased upon
stimulation of A7r5 cells with phorbol ester. It is hypothesized that activation of classical
PKC family members, PKCα in particular in A7r5 cells, can result in the activation of
cSrc which in turn phosphorylates and activates p190RhoGAP which results in the
downregulation of Rho, the dissolution of stress fibers and the formation of podosomelike structures (Brandt et al., 2002; Fincham et al., 1999). In addition, the activation of
cSrc can also have a profound effect on the phenotype and motility of the cell.
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In addition to its role in cell shape, motility and, in the case of cancer cells,
invasion, the actin cytoskeleton also plays a role in cell signaling, transport and cell
division, among others. It is therefore through highly conserved and concerted pathways
involving the actin cytoskeleton that a cell is able to perform all of its necessary
processes.

III. The AFAP Family: A Historical Perspective
The first AFAP family member discovered was described as a tyrosine
phosphorylated protein of approximately 110 kilodaltons (kDa) which could coimmunoprecipitate with active cSrc and was referred to as pp110 for phosphoprotein of
110kDa (Kanner et al., 1991; Reynolds et al., 1989). Although cells expressing active
cSrc were known to have a transformed phenotype demonstrated by a loss of focal
adhesions and bundled actin filaments, as well as an increase in motility and invasion
(Frame et al., 2002), it was unknown through which proteins these signals were relayed.
While overexpression of cSrc is not enough to induce such a transformed phenotype, a
mutated form of activated avian Src, cSrc527F, contains a mutation in the C-terminus
regulatory tyrosine which disrupts internal regulation by changing this tyrosine to a
phenylalanine. In the cSrc527F mutant, cSrc is not able to be held in its intramolecular
inhibition state and is thus constitutively activated. To determine proteins involved in
cSrc cellular transformation, cSrc527F was transfected into chicken embryo fibroblasts
(CEF), immunoprecipitated using the cSrc-specific antibody EC10 and immune
complexes were analyzed through the use of phosphotyrosine antibodies leading to the
discovery of two tyrosine phosphorylated proteins, pp130 (later known as pp130Cas) and
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pp110, that interacted directly with active cSrc (Reynolds et al., 1989). Expression of
deletion variants of cSrc in CEF cells in which amino acids 155-157 of the SH2 domain
and amino acids 92-95 were removed confirmed the phosphorylated proteins involvement
in binding and activation of the cSrc molecule. Monoclonal antibodies were raised
against pp110 (Kanner et al., 1990). Antibody 4C3 against pp110 was used to screen
cDNA λgt11 peptide and λgt10 cDNA expression libraries derived from chicken embryo
brains and chick embryo fibroblasts, thus resulting in the identification of various
overlapping cDNA sequences which were analyzed so as to construct the overall cDNA
coding sequence of pp110 (Flynn et al., 1993). A rabbit polyclonal antibody created using
this cDNA, F1, identified pp110’s association with stress fibers and cortical actin in chick
embryo cells, thus pp110 was named Actin Filament Associated Protein of 110kDa,
hereinafter known as AFAP1 (Flynn et al., 1993). The human homologue of chicken
AFAP1 is also associated with cortical actin and stress fibers. Human AFAP1 is found at
chromosomal location 4p16.1 and contains 16 exons which encode 730 amino acids with
an approximate molecular mass of 80,725 daltons (Da) as identified by the Ensembl and
UniProt databases. A second alternatively spliced isoform of AFAP1, AFAP-120,
contains an additional 86 amino acids encoded by a novel exon near the carboxy terminus
and has been shown to have a regulated expression pattern during the development of the
mouse brain. AFAP-120 is thought to direct signaling through the protein tyrosine
kinases cSrc and Fyn during neural development (Clump et al., 2003; Flynn et al., 1995).
Work by Han et al. identified that AFAP1 and cSrc were in complex after
mechanical stretch-induced cytoskeletal deformation and that this was dependent upon
the integrity of the N-terminal SH3 binding motif of AFAP1. Once bound, cSrc had the
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ability to phosphorylate AFAP1 on multiple tyrosine residues to enhance the interaction
(Guappone and Flynn, 1997; Guappone et al., 1998; Han et al., 2004; Qian et al., 1998).
Further studies on the role of AFAP1 in mechanical stretch-induced cSrc activation by
Xu et al. identified several human expressed sequence tag (EST) clones that shared
similarities with AFAP1, including a transcript containing a partial C-terminal open
reading frame (Xu et al., 2007). Analysis of this transcript by reverse transcription and
polymerase chain reaction amplification resulted in the identification of a novel protein of
818 amino acids with a predicted mass of 91,300 Da. An antibody created against this
protein revealed a relative mobility (Mr) of 130kDa, thus this protein was titled XB130
which will hereinafter be referred to as AFAP1L2 for Actin Filament Associated Protein
1-like 2 (Xu et al., 2007). AFAP1L2 is predicted to be a paralogue of AFAP1 by the
Ensembl database and contains 19 exons found on chromosome 10q25.3.
A third paralogue of AFAP1, identified as Actin Filament Associated Protein 1like 1 or AFAP1L1, is also predicted in the Ensembl database although very little is
known aside from general sequence knowledge. AFAP1L1 is found at chromosomal
position 5q33.1 and contains 19 exons which encode 768 amino acids with an
approximate mass of 86,432 Da. A second isoform of AFAP1L1 encodes 725 amino
acids and is lacking the 43 amino acids encoded by exon 18.

IV: The AFAP Family: A Genomic Study
While AFAP family members are found on separate chromosomes, there may be
an evolutionary link between their locations. First proposed in 1970, the hypothesis that
two rounds of whole genome duplication occurred in the evolution of the vertebrate
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genome from invertebrate is known as the 2R hypothesis (Ohno, 1970). The 2R
hypothesis suggests that the presence of paralogous genes in a species that are located on
different chromosomes is due to regional duplication during evolution (Ohno, 1970). The
theory originated with an early observation that gene families which have one member in
invertebrates can have up to four members in vertebrates (Dehal and Boore, 2005).
Although this “4:1” rule does not hold up in many vertebrates, this can be attributed to
the many deletions, translocations and other genetic anomalies that can occur throughout
evolution (Dehal and Boore, 2005; Ohno, 1970). Various groups have still shown that in
some gene families, one family member exists in invertebrates while multiple members
exist in the vertebrate lineage and can be mapped to predictable sites within
chromosomes. Of particular interest to the AFAP family is the work of Pebusque et al.
Through the study of various genes on human chromosome 8 (PA family, ANK family
and FGFR family among others), it was found that paralogous regions exist between
human chromosomes 4p16, 5q33-35, 8p12-21 and 10q24-26 (Pebusque et al., 1998).
AFAP family members are found in these regions: AFAP1 at 4p16.1, AFAP1L1 at
5q33.1 and AFAP1L2 at 10q25.3. The 2R hypothesis would predict that only one AFAP
family member would be found in invertebrates while the evolution of the vertebrate
lineage would produce multiple family members. To study the AFAP family, the defining
characteristic which establishes these three proteins as a family, the amino acid sequence
of the AFAP1 pleckstrin homology 1 (PH1) domain, was used to determine paralogous
genes in the Ensenbl database.
Urochordates, also known as tunicates or sea squirts, are thought to be the
invertebrate most closely related to vertebrates (Delsuc et al., 2006; Kasahara, 2007).
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Indeed, Ciona intestinalis, the vase tunicate, has a 493 amino acid PH domain containing
protein predicted to be an orthologue of the AFAP family by the Ensembl database which
shares 13% overall identity (40% similarity) with AFAP1, 13% overall identity (37%
similarity) with AFAP1L1 and 14% overall identity (35% similarity) with AFAP1L2
(Figure 1A). Similarity is particularly strong between all three AFAP family member
PH1 domains and the Ciona intestinalis PH domain containing protein with 29% identity
(68% similarity) with the AFAP1 PH1 domain, 21% identity (59% similarity) with the
AFAP1L1 PH1 domain and 27% identity (63% similarity) with the AFAP1L2 PH1
domain (Figure 1B). Ciona intestinalis, while predicted by Ensembl to have an
orthologous relationship with all three AFAP family members in vertebrate lineages, is
not predicted to have any paralogous genes in its genome. Flajnik et al. predict that the
first round of whole genome duplication took place after the split of jawless vertebrates
and protochordates. It is then predicted that a second round of whole genome duplication
took place upon the split of cartilaginous fish from all other jawed vertebrates (Flajnik
and Kasahara, 2001). This would be consistent with the finding of one orthologous PH
domain containing protein in urochordates, the closest invertebrate ancestor to
vertebrates, and the finding of all three paralogous AFAP family members in higher
vertebrates. Taking into account similarity with the PH domain containing protein in
Ciona intestinalis, one could predict, upon evolution of the vertebrate genome, that
AFAP1 was the first AFAP family member. It can then be predicted that AFAP1L2 was
the second AFAP family member to arise. AFAP1L1 shares more overall similarity with
Ciona intestinalis than AFAP1L2, but the core factor that makes AFAP family members
a family, the PH domains, is more conserved between AFAP1L2 and Ciona intestinalis.
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A possible reason for AFAP1L1 to have higher overall similarity, though lower similarity
in the PH1 domain, is the fact that AFAP1L1 is more closely related to AFAP1 than to
AFAP1L2. It could be predicted that after the appearance of AFAP1L2 from AFAP1,
AFAP1L1 then appeared after a second round of whole genome duplication, being
duplicated from AFAP1 and not AFAP1L2. This is supported by both cladistic analysis
of the AFAP family members, showing a closer relationship between AFAP1L1 and
AFAP1 than AFAP1L1 and AFAP1L2 (Figure 2A) and also an Ensembl generated
phylogram using all Ensembl AFAP family member sequence data (Figure 2B) (Larkin et
al., 2007). Ciona intestinalis, which is predicted to be the closest invertebrate available in
the ENSEMBL database that is related to the AFAP family, is indeed shown to have
come from an ancestor earlier than any vertebrate AFAP family member. Red nodes in
Figure 2B indicate predicted duplication events while blue nodes indicate predicted
speciation events. A predicted duplication event occurred in a vertebrate ancestor that
lead to two arms, one from which AFAP1L2 arose and another from which AFAP1 arose.
A second predicted duplication event occurred in the arm of AFAP1 which effectively
split that arm again into two, one from which the AFAP1 lineage arose and a second from
which the AFAP1L1 lineage arose. This supports our hypothesis that AFAP1L1 and
AFAP1 are more closely related and came from a more common ancestor than
AFAP1L2. Interestingly, a third duplication event is predicted to have occurred in the
AFAP1L1 lineage of Clupeocephala, or bony fish (Kasahara, 2007). In support of this
hypothesis, AFAP1L1 has two predominant isoforms in the Ensembl database that are
found in the bony fish Tetraodon nigroviridis, Takifugu rubripes, Gasterosteus aculeatus,
Oryzias latipes, and Danio rerio while AFAP1 and AFAP1L2 only contain one isoform
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in these species (Figure 2B). Though there are multiple AFAP family members in the
vertebrate lineage, the closest predicted invertebrate ancestor has only one homologous
PH domain containing protein and shares closest homology with AFAP1.
We hypothesize that AFAP1 arose in vertebrates from the invertebrate line and
two rounds of whole genome duplication gave rise to the similar family members,
AFAP1L1 and AFAP1L2. A third round of whole genome duplication may have
occurred in the Clupeocephala lineage of AFAP1L1, leading to a possible second isoform
of AFAP1L1 in bony fish. Across species, AFAP family members are well conserved. A
detailed phylogram of AFAP1 (Figure 3) shows the sequential relationship between
various vertebrates. Both AFAP1 and AFAP1L1 share 99% identity with their nearest
ancestor sequence, chimpanzee, with only a one amino acid change while AFAP1L2 has
five amino acid changes between chimpanzee and human sequence. In a simpler
description of the amino acid sequences across human, chimpanzee, mouse, lizard and
zebrafish, AFAP1 sequences show a high level of identity and similarity throughout the
entire AFAP1 sequence (Figure 4). While AFAP1 shares the most identity across species,
a similar analysis of AFAP1L1 (Figure 5) and AFAP1L2 (Figure 6) also shows a high
level of consensus amino acid sequence across species in these family members. This
consensus amino acid sequence in the AFAP family encodes for multiple protein binding
domains which establish the AFAP proteins as a family of adaptor proteins.

V: The AFAP Family: Protein Structure
Protein binding domains and their complementary protein binding motifs play a
key role in regulating cellular processes. While numerous protein binding domains have
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been described, each binding domain can interact with multiple ligands thus creating an
even larger array of signaling possibilities. A single protein binding domain may be
prevalent throughout various proteins, as is characterized by the many phosphotyrosinebinding SH2 and poly-proline binding SH3 domains that have been identified (Pawson
and Nash, 2003). These protein binding domains, in conjunction with numerous others,
allow proteins to create signaling complexes that are not only specific with regard to
associated proteins but also to the spaciotemporal patterns of cellular processes.
In its earliest studies, AFAP1 was found to be associated with actin filaments via
an actin binding domain in the carboxy terminus and was composed of both aminoterminal and carboxy-terminal SH2 binding motifs and two juxtaposed SH3 binding
motifs of which the N-terminal motif is required for cSrc binding (Guappone and Flynn,
1997; Guappone et al., 1998; Qian et al., 1998). Two PH domains are found within the
interior of AFAP1. The PH1 domain has been shown to be involved in binding of the
serine/threonine kinase PKCα and in the intra-molecular regulation of AFAP1 by binding
to a downstream leucine zipper (Qian et al., 2004). Both PH domains are involved in the
stabilization of AFAP1 multimers (Clump et al., 2010). The amino acid sequence
between the PH domains (substrate domain, SD) is rich in serine and threonine residues.
Phosphorylation of AFAP1 in this region by PKCα plays a role in podosome formation
(Dorfleutner et al., 2008; Gatesman et al., 2004). The leucine zipper, an alpha-helical
structure containing a heptad repeat of leucine residues found amino-terminal to the actin
binding domain, is necessary for both an inhibitory intramolecular interaction with the
AFAP1 PH1 domain and also to multimerize with other AFAP1 molecules (Kouzarides
and Ziff, 1988). AFAP1 has the ability to cross-link actin filaments by binding via its
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actin binding domain and then interacting with other AFAP1 molecules via the leucine
zipper motif and possibly other internal sequences.
A similarity search of AFAP1 in the Ensembl database identified AFAP1L1 and
AFAP1L2 which share 71% and 64% overall similarity with AFAP1 respectively (Xu et
al., 2007) (Figure 7). Of interest between these proteins was both similarity in the
modular domain structure (Figure 8A) and conservation of amino acid sequence in the
PH domains (Figure 8B). While the approximately 250 known PH domain containing
proteins have a highly conserved structure in these domains, a β-barrel with four
β strands on one side and three β strands on the other connected by three variable loops
connecting β1/β2, β3/β4 and β6/β7, they do not have conserved amino acid sequences
(DiNitto and Lambright, 2006). The PH domains of AFAP1, AFAP1L1 and AFAP1L2
have both similar structure and similar sequence, with 44% identity (80% similarity)
between the PH1 domains and 40% identity (74% similarity) between the PH2 domains
(Figure 7). It is these similar sequences and overall domain structure that designate
AFAP1, AFAP1L1 and AFAP1L2 as related proteins. Consistent with AFAP1,
AFAP1L1 and AFAP1L2 also contain at least one SH3 binding motif in their N-terminus.
An SH3 domain is a region of approximately sixty amino acids known to bind to prolinerich regions with a core PXXP motif (Ren et al., 1993). AFAP1 contains two juxtaposed
SH3 binding motifs, PPQMPLPEIP and PPDSGPPPLP, and binds cSrc using the Nterminal PEIP sequence (Guappone and Flynn, 1997). AFAP1L2 is also known to be a
cSrc binding partner by virtue of its SH3 binding motif, PDLPPPKMIP (Xu et al., 2007).
While AFAP1L1 contains an SH3 binding motif, DLPPPLPNKP, this sequence is not
consistent with a consensus cSrc binding motif and instead resembles that of a consensus
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binding motif for cortactin, which preferentially binds to a +PPΨPXKPXWL motif
where + is a basic residue, Ψ is an aliphatic residue, and X is any amino acid (Sparks et
al., 1996). While consensus amino acid sequence designates these as SH3 binding motifs,
it is the specificity of the surrounding amino acids that can direct AFAP family members
to interact with different SH3 domain containing proteins.
Also consistent with AFAP1, AFAP1L1 and AFAP1L2 have potential sites for
phosphorylation as predicted by Scansite (Figure 9), although not all of these have been
confirmed as true phosphorylation targets or SH2 motifs (Obenauer et al., 2003). The
SH2 domain, a protein binding domain of approximately 100 amino acids, binds
preferentially to an SH2 binding motif, a short amino acid sequence containing a site of
tyrosine phosphorylation which is directly amino terminal to 1 or 2 negatively charged
amino acids followed by a hydrophobic amino acid (Songyang et al., 1993). It is these
surrounding amino acids that allow SH2 domains to display selectivity in their binding
partners (Cantley et al., 1991). The known N-terminal AFAP1 SH2 binding motif,
Y93YEEA, shares 100% identity with both AFAP1L1 and AFAP1L2 while the Cterminal SH2 binding motif, Y451DYI, shares 75% identity as both AFAP1L1 and
AFAP1L2 share a YDYV sequence. A third SH2 binding motif in AFAP1L2, Y54IYM, is
responsible for PI3K interaction and is not conserved in AFAP1 or AFAP1L1.
The leucine zipper of AFAP1 is a helical repeat of leucine residues that is
responsible for intramolecular regulation of AFAP1 by contacting the PH1 domain and
keeping AFAP1 is a closed conformation and also for contacting other AFAP1 molecules
when AFAP1 is activated by PKCα so as to aid in multimerization and bundling of actin
filaments (Qian et al., 2004). AFAP1L1 contains a similar but less conserved leucine
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zipper motif which may still allow AFAP1L1 to multimerize with other AFAP1L1
molecules or perhaps other AFAP family members. AFAP1L2 contains a coiled-coil
region corresponding to the AFAP1 leucine zipper and actin binding domain and may
instead use an N-terminal actin binding domain to localize to branched filamentous (F)actin networks in the lamellipodium (Lodyga et al., 2010; Xu et al., 2007).

VI: The AFAP Family: Cellular Function
AFAP1 was first identified as a tyrosine-phosphorylated protein that had the
ability to interact with activated forms of the non-receptor protein tyrosine kinase cSrc
(Flynn et al., 1993). This interaction was dependent upon the integrity of both the cSrc
SH2 and SH3 domains as well as their binding motifs within AFAP1 (Kanner et al.,
1991; Kmiecik and Shalloway, 1987; Reynolds et al., 1989). When cells become
transformed by cSrc, AFAP1 undergoes a change in localization from actin filaments into
podosomes (Flynn et al., 1993; Linder and Kopp, 2005). In its inactive form, cSrc is
found in the perinuclear region while activated cSrc moves to the cell periphery where
association with the plasma membrane is necessary for cell transformation (Yeatman,
2004). This movement is dependent upon the Rho family members where active cSrc can
be moved to focal adhesions by RhoA, to lamellipodia by Rac1 and to filopodia by
Cdc42 (Sandilands and Frame, 2008). With regard to AFAP1, consitutively active RhoA
was able to largely overcome actin filament rearrangement seen upon activation of
AFAP1. Therefore, the ability of AFAP to bind to and activate cSrc may be in a Rhodependent manner (Baisden et al., 2001a). To determine the temporal binding of AFAP1
and cSrc, a temperature-sensitive form of constitutively active viral Src, LA29, which
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resides on perinuclear vesicles at non-permissive temperatures (39.5°C) and induces
cellular transformation at permissive temperature (35°C), was utilized.

Upon cell

stimulation with PKCα at non-permissive temperature, AFAP1 was seen to move to
perinuclear vesicles and colocalize with cSrc. AFAP1 and cSrc, which is activated by the
binding of AFAP1, can then move to sites of actin rearrangement in transformed cells
when shifted to the permissive temperature (Walker et al., 2007).

Interestingly, a

polymorphic variant of AFAP1 exists that is an efficient cSrc activator. A
nonsynonymous single nucleotide polymorphism (SNP) in the PH2 domain resulting in a
Ser403 to Cys403 amino acid change found in approximately 21% of both tumor and
adjacent normal tissues and 28% of normal tissues is more efficient at activating cSrc
when cSrc levels are high. The PH2 domain of AFAP1 does not contain the necessary
conserved basic residues for lipid binding and is instead predicted by molecular modeling
to be in contact with a water molecule 71% of the time. This Ser403 to Cys403 change was
predicted to interrupt the PH2 domain’s ability to interact with a water molecular possibly
leading to a destabilized structure of the PH2 domain which may alter its binding
capacity and thus create a more constitutively active AFAP molecule (Clump et al.,
2010).
Stimulation of cells with PKCα induces a cell morphology like that seen with
activated cSrc. PKCα binds to the PH1 domain of AFAP1 and phosphorylates a key
serine residue in the substrate domain, Ser277 (Dorfleutner et al., 2008; Gatesman et al.,
2004). AFAP1 is normally held in an inhibitory intramolecular interaction by binding of
the leucine zipper to the PH1 domain (Qian et al., 2004). The binding of PKCα to the
PH1 domain disrupts this interaction and AFAP is able to interact with cSrc. Mutants of
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AFAP1 that contain deletions of the PH1 domain are unable to bind PKCα and cannot
associate with and activate cSrc (Gatesman et al., 2004). When cSrc is not present, PKCα
is unable to direct this change thus indicating that cSrc is necessary for actin filament
rearrangement.(Gatesman et al., 2004).
The leucine zipper of AFAP1 is located in the C-terminal portion of the AFAP1
molecule juxtaposed to an actin binding domain and holds AFAP1 into an autoinhibitory
conformation by contacting the PH1 domain. Deletion or modification of the leucine
zipper destabilizes this intramolecular interaction, resulting in a conformational change in
AFAP1 that allows cSrc activation and more efficient bundling of actin filaments (Qian
et al., 1998; Qian et al., 2004). Similarly, when this inhibition is released by binding of
PKCα, the leucine zipper may then promote increased actin filament crosslinking activity
through interactions with other AFAP1 molecules (Qian et al., 2004). This is witnessed
by the interaction of AFAP1 in cell lysates with GST proteins expressing only the
AFAP1 leucine zipper. Upon expression of AFAP1 constructs lacking the leucine zipper,
AFAP1 is shown to have an intrinsic ability to activate cSrc and localize to podosomes
because the intramolecular inhibition of AFAP1 is not present (Qian et al., 1998).
Therefore, the leucine zipper plays a key role in the ability of AFAP1 to multimerize and
subsequently cross-link actin filaments. As the neighboring actin binding domain, which
has been shown to be necessary and sufficient for the binding of AFAP1 to actin, of
AFAP1 contacts actin filaments, the leucine zipper allows multimerization of AFAP1
molecules and thus bundles the actin filaments together (Qian et al., 2000). Gel filtration
experiments have shown that AFAP1 has the ability to exist in large multimeric
complexes that are mediated by the leucine zipper. Upon deletion of the leucine zipper,
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AFAP1 complexes are smaller and predicted to exist as dimers or trimers. These smaller
complexes allow AFAP1 to more efficiently cross-link actin from a meshwork into a
bundle. Co-pelleting assays of recombinant AFAP1 showed a direct association of
AFAP1 with actin filaments, and this association was not inhibited by deletion of the
leucine zipper (Qian et al., 2002).
Knockdown of AFAP1 by short hairpin RNA (shRNA) in the MDA-MB-231
breast cancer cell line, while having no gross effect on cell morphology, resulted in a loss
of stress filament integrity and reduced cell adhesion. While cortical actin structure was
maintained in AFAP1 shRNA knockdown cells, stress fibers could not be detected by
phalloidin immunostaining, possibly due to the loss of cross-linking of actin filaments by
the lack of AFAP1. The role of AFAP1 in the integrity of stress filaments was confirmed
by an inducible shRNA system in which AFAP1 levels were rescued or knocked down
due to the absence or presence of doxycycline. When AFAP1 levels are knocked down,
phalloidin readily decorates cortical actin while stress fibers cannot be detected. Upon
rescue of AFAP1 levels by relief of doxycycline, stress fibers reappear. The ability of
AFAP1 molecules to bundle actin by virtue of their actin binding domains and leucine
zippers may be responsible for the lack of stress fiber formation in AFAP1 knockdown
cells. Stimulation of wild-type MDA-MB-231 cells with lysophosphatidic acid (LPA), a
Rho activator, induces actin filament cross-linking into stress fibers and more pronounced
focal adhesions. When MDA-MB-231 AFAP1 knockdown cells are treated with LPA,
stress fiber formation is inhibited and focal contacts do not form (Dorfleutner et al.,
2007). AFAP1 knockdown cells are slower to adhere to fibronectin, however, given
enough time, they will reach adhesion levels similar to cells expressing AFAP1 and with
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no detectable difference in cell survival. It is possible that this difference in cell adhesion
may be due to the role of AFAP1 in cellular adhesion structures. While wild-type cells
readily form adhesion structures when plated onto fibronectin, AFAP1 knockdown cells
have an impaired ability to form focal contacts and have no stress fiber formation in the
same time span that wild-type cells have matured their focal contacts. The formation of
stress fibers and their role in cell contractility is essential for the maturation of focal
adhesions and thus the loss of AFAP1 may affect the adherence ability of the cell
(Parsons et al., 2010). As cellular adhesion is a prerequisite for cell migration,
knockdown of AFAP1 in prostate cancer cell line PC3 impaired cellular motility as
witnessed by their lack of migration in a modified Boyden chamber (Zhang et al., 2007).
While the knockdown of AFAP1 in MDA-MB-231 cells did not affect the expression
levels of α5 integrin, β1 integrin, paxillin or vinculin, PC3 cells showed decreased levels
of β1 integrin when AFAP1 expression was lost (Dorfleutner et al., 2007; Zhang et al.,
2007). β1 integrin expression can be restored in PC3 AFAP1 knockdown cells by
reintroduction of wild-type AFAP1. While the AFAP1 mutant defective for binding to
cSrc, AFAP171A , also has the ability to restore β1 integrin expression, AFAP1 mutants
lacking the PH1 domain failed to restore β1 integrin expression and stress filament and
focal contact expression in PC3 AFAP1 knockdown cells. This indicates that it is not the
altered AFAP1/cSrc interaction that is affected when AFAP1 is knocked down in PC3
cells, but that the role of AFAP1 in focal contact formation through stress fiber formation
and cell contractility may be regulated by the ability of AFAP1 to bind to PKC (Zhang et
al., 2007). While AFAP1 has been shown to bind to multiple PKC family members,
α,β,γ,λ, it is the activation and binding of PKCα which phosphorylates AFAP1 on serine
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residues in the substrate domain (Dorfleutner et al., 2008; Qian et al., 2002). Mutation of
key serine residues revealed that Ser277 is phosphorylated by PKCα and this is either
independent or upstream of cSrc activation. A phospho-specific antibody created against
the AFAP1 pSer277 site showed that in resting A7r5 cells, while AFAP1 localizes to stress
filaments, there is no evidence for phosphorylation of Ser277. Stimulation of A7r5 cells
with the phorbol ester phorbol 12,13-dibutyrate (PDBu), a PKCα activator, induced
phospho-GFP-AFAP1 to localize strongly to podosomes. When GFP-AFAP1 is
overexpressed in A7r5 cells, the majority of cells display stress fibers while some display
both stress fibers and small podosomes and a very small percentage spontaneously
produced podosomes. If A7r5 cells express GFP-AFAP1S277A, a mutant of AFAP1 in
which Ser277 has been mutated to an alanine, there is in increase in the number of cells
that spontaneously form podosomes and it is reasoned that phosphorylation of AFAP1 at
Ser277 plays a role in podosome formation (Dorfleutner et al., 2008). When podosome
lifespan was calculated, A7r5 cells expressing AFAP1S277A mutants showed decreased
podosome turnover and longer average lifespan of podosomes as compared to wildtype
AFAP1 (Dorfleutner et al., 2008). Due to its ability to act as an actin bundling protein by
virtue of the leucine zipper and actin binding domain, AFAP1 may regulate the
construction/deconstruction of podosomes in response to cellular adhesion signals such as
PKC activation.
AFAP1L2 was also initially discovered as a cSrc binding partner and has been
found to be able to interact with the SH2 and SH3 domain of both cSrc and GTPase
activating protein (GAP) (Han et al., 2004). Similarly to AFAP1, AFAP1L2 has the
ability to interact with cSrc when overexpressed, activates cSrc as witnessed by an
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overall increase in tyrosine phosphorylation seen when both AFAP1L2 and cSrc are
overexpressed, and has been shown to be a phosphorylation target of cSrc. Deletions in
AFAP1L2 that remove the N-terminal SH3 and SH2 binding motifs (XB130∆N) reduce
the interaction between AFAP1L2 and cSrc and result in a decrease in cSrc
phosphorylation at Tyr416 and overall cellular phosphotyrosine when mutant AFAP1L2
and cSrc are overexpressed. Similarly, siRNA knockdown of AFAP1L2 decreases the
tyrosine phosphorylation of cSrc at Tyr416 (Xu et al., 2007).
Using a luciferase assay, it was shown that co-expression of AFAP1L2 and cSrc
had the ability to increase the activation of activating protein-1 (AP-1) and serum
response element (SRE) reporters which may indicate that the AFAP1L2 and cSrc
interaction is important in gene regulation. Expression of XB130∆N with cSrc greatly
decreased SRE activity in comparison with wild-type AFAP1L2 but there was still some
activation of SRE in comparison with cSrc expression alone. This indicates that there are
domains in AFAP1L2 other than the N-terminal SH3 and SH2 domains that can be
involved in cSrc activation and SRE activity (Xu et al., 2007). Stimulation of cells by
epidermal growth factor (EGF) showed enhanced SRE activation in cells expressing
wild-type AFAP1L2 and cSrc and this activation was blunted when cSrc was expressed
with XB130∆N, suggesting a role for AFAP1L2 in signal transduction from EGF leading
to cellular processes such as mitosis, transformation or survival. Knockdown of
AFAP1L2 by siRNA was able to blunt the effects of EGF stimulation and arrest cells in
the G1 phase, thus supporting the conclusion that AFAP1L2 plays a role in EGF
signaling. In comparison, the interleukin-8 (IL-8) promoter which contains AP-1 sites
was linked to a luciferase reporter and, similarly, showed increased activation when
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AFAP1L2 and cSrc were overexpressed. This was also blunted by the expression of
XB130∆N (Xu et al., 2007).
Unlike AFAP1, AFAP1L2 has not been shown to interact with stress fibers.
Immunofluoresence of GFP-tagged, His-tagged and endogenous AFAP1L2 in multiple
cell lines indicated that AFAP1L2 has a cytosolic distribution in resting cells but can
translocate to the lamellipodium under cell stimulation in a Rac-dependent manner.
AFAP1L2 contains a coiled-coil in its C-terminus where AFAP1 contains an actin
binding domain, and deletion of this coiled-coil domain had no effect on the translocation
of AFAP1L2 to branched F-actin networks. Instead of an actin binding domain similar to
AFAP1, AFAP1L2 may contain an actin binding domain 2 (ABD2) similar to that of the
actin binding domain of talin in its N-terminus. Deletion of the N-terminus inhibited
AFAP1L2 translocation to the lamellipodia while expression of a tagged peptide of the
first 167 amino acids of the N-terminus was sufficient for translocation (Lodyga et al.,
2010).
Tissue analysis of AFAP1L2 showed localization mainly to the thyroid and spleen
and it was noted that AFAP1L2 expression was also found in human papillary thyroid
carcinoma (PTC) at or below normal thyroid levels (Lodyga et al., 2009). Because a
central feature of PTC is dysregulation of the Rearranged in Transformation/papillary
thyroid carcinoma (RET/PTC) tyrosine kinase and AFAP1L2 is a potential substrate for
kinase activity, AFAP1L2 and RET/PTC were transiently overexpressed in human
embryonic kidney 293 (HEK) cells and an increase in tyrosine phosphorylation of
AFAP1L2 dependent on the kinase activity of RET/PTC was seen. Although AFAP1L2
has been shown to interact with and be a substrate for cSrc, the presence or absence of
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cSrc had no effect on RET/PTC phosphorylation or interaction with AFAP1L2 (Lodyga
et al., 2009). Point mutations within the predicted SH2 binding motifs of AFAP1L2
revealed that Tyr54 is a major, although not the sole, target for RET/PTC phosphorylation.
This SH2 binding motif, YIYM, resembles that of a PI3K binding motif, YXXM in
which X is any amino acid. Indeed, expression of AFAP1L2 with RET/PTC greatly
increased the association of AFAP1L2 with the p85 regulatory subunit of PI3K in
immunoprecipitation experiments and this interaction was dependent upon the
phosphorylation status of Y54 (Lodyga et al., 2009). Since the serine/threonine kinase Akt
is a well known downstream target of PI3K signaling, Akt activation was tested in
response to overexpression of AFAP1L2 and RET/PTC to see if AFAP1L2 played a role
in the Akt pathway. Akt phosphorylation was reduced by either mutation of AFAP1L2 so
that it may not be phosphorylated at Y54 or inhibiting the PI3K pathway. siRNA
knockdown of AFAP1L2 also lead to a decrease in Akt phosphorylation while it had no
effect on other PI3K targets such as extracellular signal-regulated kinase (ERK). As Akt
activation is known to lead to cell survival, AFAP1L2 was knocked down in TPC1
thyroid papillary carcinoma cells to look at the effect of AFAP1L2 on tumor cell survival
(Marte and Downward, 1997). Knockdown of AFAP1L2 in TPC1 cells showed a higher
amount of cells in the G0/G1 phase and decreased proliferation of TPC1 tumor cells. As
the proliferation of TPC1 has been attributed to the RET/PTC recombination, AFAP1L2
may be playing an important role in the progression of tumor cells by linking together the
RET/PTC and Akt pathways. Downregulation of AFAP1L2 has been shown in TPC1
cells to decrease cell migration and invasion. Therefore, it is hypothesized that AFAP1L2
may translocate to the cell periphery upon stimulation where it may interact with PI3K
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and thus link the RET/PTC kinase to the Akt pathway and subsequent migration and
invasion (Lodyga et al., 2010).
Although the function of AFAP1L1 can be hypothesized based upon its sequence
and similarity with AFAP1 and AFAP1L2, no cellular data was available to determine
the function of AFAP1L1.

VII: The AFAP Family: Pathology and Disease
As cSrc is highly active in diseases such as cancer and AFAP1 is a known cSrc
activator, it is probable that AFAP1 and possibly other AFAP family members have a
role in disease progression. Dorfleutner et al. have shown that expression of AFAP1 is
necessary for stress fiber formation and the efficient formation of focal adhesions
(Dorfleutner et al., 2007). The phosphorylation of AFAP1 at Ser277 plays a role in the
stability and lifespan of podosomes (Dorfleutner et al., 2008). In cases where AFAP1 is
overexpressed, it has been shown that increased levels of AFAP1 correlate with
progressive stages of disease. Through immunohistochemical staining, Zhang et al.
showed that normal prostate tissues have high AFAP1 levels in prostate smooth muscle
(Zhang et al., 2007). AFAP1 was low in the luminal secretory layer and the basal layer of
prostatic glands. In benign prostatic hyperplasia, the luminal secretory layer of cells again
had low AFAP1 immunoreactivity while basal layer cells had weak reactivity. In
contrast, prostate cancer tissues exhibited strong AFAP1 immunoreactivity in all prostate
tissues. Levels of AFAP1 immunostaining correlated with increasing Gleason scores for
grading the aggressiveness of tumors, and this correlation was seen in normal versus
tumorigenic cells lines as well. The downregulation of AFAP1 through RNA interference
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(RNAi) slowed the proliferation of the prostate cancer cell line PC3 in soft agar, possibly
through a decrease in anchorage-independent growth.

These same cells implanted

orthotopically into nude mice produced either no or significantly smaller tumors as
compared to parental lines, indicating that AFAP1 played an important role in the
progression of prostate tumors. The migration of PC3 cells lacking AFAP1 expression
was markedly decreased when compared to parental lines, and this was thought to be due
to a loss of focal contacts in AFAP1 knockdown cells as these cells also resulted in a loss
of β1 integrin expression. Although the reason for high expression levels of AFAP1 in
prostate cancer is still unknown, it is increased integrin signaling to the extracellular
matrix through AFAP1 that is thought to mediate prostate cancer growth and invasive
potential (Zhang et al., 2007).
In addition to prostate cancer, Clump et al. have also shown that AFAP1 levels,
although not detectable in normal ovarian tissue, are increased in ovarian cancer and also
correlate with progression of disease (Clump et al., 2010). A polymorphic variant of
AFAP1 in which a key serine residue in the PH2 domain is mutated to a cysteine,
AFAP1403C, is found in approximately 20-30% of both normal and ovarian cancer tissues.
This variant has an increased capacity for cSrc activation and again, although the reason
for increased AFAP1 expression in ovarian cancer is also unknown, overexpression of
this polymorphic variant can result in increased cSrc activation and a more aggressive
cancer (Clump et al., 2010). Through these experiments, it is plausible to assume that
AFAP1 could be used in both prostate and ovarian cancers as a marker for tumor
progression and aggressiveness.
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AFAP1L2 is also known to play role in cancer. AFAP1L2 expression is high in
normal thyroid tissue and has been shown to be expressed in high levels in human
papillary thyroid carcinoma (Lodyga et al., 2009). A genetic hallmark of PTC are various
rearrangements of the RET tyrosine kinase with portions of various other proteins, most
often coiled-coil domain containing protine 6 (CCDC6), which is a coiled-coil domain
containing protein that may act in tumor suppression through apoptosis (Leone et al.,
2010). AFAP1L2 has multiple sites for tyrosine phosphorylation and Y54 was shown to be
the major target of RET/PTC kinase. The amino acid sequence surrounding Y54 predicts a
motif that is homologous for a binding site of the p85 subunit of PI3-kinase and these
proteins are able to interact in an endogenous setting. Akt is a serine/threonine kinase
downstream of PI3k activation and the interaction of AFAP1L2 and PI3k greatly
increased the activation of Akt. Aberrant activation of this pathway can lead to cell
proliferation and survival in cancer cells such as in thyroid papillary carcinoma where
high levels of AFAP1L2 are found. Therefore, both AFAP1 and AFAP1L2 have been
shown to play a role in cancer and possible cell survival and metastasis.
As for AFAP1L1, online database screens can assess the level of AFAP1L1
expressed in normal and cancerous tissues. The National Cancer Institute Serial Analysis
of Gene Expression (SAGE) database predicts AFAP1L1 levels in normal tissues to be
high in heart, ovary, uterus, skin and vasculature. In comparison, AFAP1L1 levels are
predicted to be high in various cancers such as brain, breast, liver, prostate, skin,
stomach, and thyroid cancers. The Oncomine database predicts the highest AFAP1L1
expression levels as compared to normal to be found in esophageal cancer, glioblastoma
and neuroblastoma. With regard to various cancers, regardless of the origin, it appears
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that AFAP1L1 expression is upregulated, not downregulated, compared to levels in
normal tissues. Therefore, AFAP1L1 may play a role in the formation or progression of
different cancers by virtue of its signaling capabilities.

IX: Summary
The AFAP family represents a family of adaptor proteins with a variety of roles in
signal transduction. AFAP1 is well-known as a cSrc activator and actin cross linking
protein and its role in stress fiber formation is indispensable. AFAP1 also plays a key role
in podosome formation and turnover. As AFAP1 levels are increased in various cancers,
the inherent abilities of AFAP1 may play a role in the progression of disease. AFAP1L2,
like AFAP1, is also a known cSrc binding protein and has been shown to link the
RET/PTC kinase rearrangement to the Akt pathway by virtue of PI3K. AFAP1L2
localizes to the lamellipodium of motile cells in a Rac-dependent manner and its
expression is necessary for efficient motility and invasion. As AFAP1L2 has been shown
to be highly expressed in papillary thryroid carcinoma, it too provides an interesting
target in the progression of disease. Although the role of AFAP1L1 can be inferred by its
similarity with AFAP1 and AFAP1L2, no data is available on the role of AFAP1L1 in the
cell. The purpose of this study was to elucidate the function of AFAP1L1 by virtue of its
cellular and tissue localization and its interaction with cellular binding partners.
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Figure 1B
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Figure 1. Similarity between human AFAP family members and Ciona intestinalis
(A) The 493 amino acid sequence of a predicted AFAP homolog in Ciona intestinalis
was compared by ClustalW2 alignment (50) with the 730 amino acid sequence of
AFAP1, the 768 amino acid sequence of AFAP1L1 and the 818 amino acid sequence of
AFAP1L2. Identical amino acid sequence is shown by its one letter abbreviation in the
consensus sequence while similar amino acid sequence is represented by *.
(B) The highly conserved PH1 domains of the human AFAP family members were
compared with the amino acid sequence of the Ciona intestinalis predicted AFAP
homolog using ClustalW2 analysis (50). Identical amino acid sequence is shown by its
one letter abbreviation in the consensus sequence while similar amino acid sequence is
represented by *.
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Figure 2B
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Figure 2. Cladistic analysis of AFAP family members
(A) Full length amino acid sequences of AFAP family members were compared by ClustalW2
alignment (50) and a cladogram created so as estimate a shared ancestry between AFAP family
members.
(B) Full length amino acid sequences of all AFAP family members across species that are
deposited in the Ensembl database were used to create a detailed phylogram of all AFAP family
member sequences known. Red nodes indicate a duplication event while blue nodes indicate a
speciation event. The alignment of shared amino acid similarity between all AFAP family
member sequences is shown.
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Figure 3
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Figure 3. Phylogenetic analysis of AFAP1
Full length amino acid sequences for AFAP1 across human (Homo sapiens), chimpanzee (Pan
troglodytes), mouse (Mus musculus), Ciona intestinalis, macaque (Macaca mulatta), Xenopus
tropicalis, zebrafish (Danio rerio) and Anole lizard (Anolie carolinesis) were compared by
Clustal W2 alignment (50) and a detailed phylogram created to compare the sequential and
temporal relationship of ancestry in AFAP1 sequences.
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AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

MEELIVELRLFLELLDHEYLTSTVREKKAVITNILLRIQSSKGFDVKDHAQKQETANSLP
MEELIVELRLFLELLDHEYLTSTVREKKAVITNILLRIQSSKGFDVKDHAQKQETANSLP
MEELIVELRLFLELLDHEYLTSTVREKKAVLTNILLRLQSSKGFEVKDHAQKAEANN-LP
MEELIVELQLFLQLLDHEYLTSTVREKKAVLTNILLRIQSSKDFDLKEKVQKQEVVNSLP
MEELLAELRVFLELLDREYLTAGVREKKQQILNILHRVLATR-----EPSCKTEIHTSLP
MEEL**EL**FL*LLD*EYLT* VREKK * NIL R* ***
*
K E * LP

60
60
59
60
55

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

APPQMPLPEIPQPWLPPDSGPPPLPTSSLPEGYYEEAVPLSPGKAPEYITSNYDSDAMSS
APPQMPLPEIPQPWLPPDSGPPPLPTSSLPEGYYEEAVPLSPGKAPEYITSNYDSDAMSS
APPQMPLPEIPQPWLPPDSGPPPLPTSSLPEGYYEEAVPLSPGKAPEYITSNYDSDAMSS
APPQMPLPEIPQQWLPPDNGPPPLPSSSLPEGYYEEAVPLSPGKAPEYITSNYDSDAMSS
APPQMPLPEIPHPWMPPDNGPPPLPSSSLPEGYYEEAVPLGPGKAPEYITSNYDSDAMSS
APPQMPLPEIP* W*PPD*GPPPLP*SSLPEGYYEEAVPL*PGKAPEYITSNYDSDAMSS

120
120
119
120
115

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

SYESYDEEEEDGKGKKTRHQWPSEEASMDLVKDAKICAFLLRKKRFGQWTKLLCVIKDTK
SYESYDEEEEDGKGKKTRHQWPSEEASMDLVKDAKICAFLLRKKRFGQWTKLLCVIKDTK
SYESYDEEEEDGKGKKTRHQWPSEEASMDLVKDAKICAFLLRKKRFGQWTKLLCVIKDTK
SYESYDEEDEDGKGKKTRHQWPSEEASMDLVKDAKICAFLLRKKRFGQWTKLLCVIKENK
SYESYDEEEEDGKGQKMRHQWPSEEASMDLVKDARICAFLLRKKRFGQWTKLLCVIKDNK
SYESYDEE*EDGKG*K RHQWPSEEASMDLVKDA*ICAFLLRKKRFGQWTKLLCVIK**K

180
180
179
180
175

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

LLCYKSSKDQQPQMELPLQGCNITYIPKDSKKKKHELKITQQGTDPLVLAVQSKEQAEQW
LLCYKSSKDQQPQMELPLQGCNITYIPKDSKKKKHELKITQQGTDPLVLAVQSKEQAEQW
LLCYKSSKDQQPQMELPLQGCSITYIPRDSKKKKHELKITQQGTDPLVLAVQSKEQAEQW
LLCYKSSKDQQPQMELLLNGCSIIYIPKDSKKKKHELKITHQGQDALVLAVQSKEQADQW
LLCYKSSKDQTPQMELLLSGCSITHIPKDGKKKKHELKIVHQGADALVLAVQSKEQAEQW
LLCYKSSKDQ PQMEL L*GC*I *IP*D*KKKKHELKI**QG D*LVLAVQSKEAQ*QW

240
240
239
240
235

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

LKVIKEAYSGCSGPVDSECPPPPSS--PVHKAELEKKLSSERPSSDGEGVVENGIT-TCN
LKVIKEAYSGCSGPVDSECPPPPSS--PVHKAELEKKLSSERPSSDGEGVVENGIT-TCN
LKVIKEAYSGCSGPVDPECSPPPSTSAPVNKAELEKKLSSERPSSDGEGGVENGVT-TCN
LKIIKEVCSNCVGTTDSDG---PSSNSPVHKTELEKKLSSERPSSDGEGTVENGIASICN
LKVMKEVCSNGNGVVDCDG---AGSGSTVHKAELEKKLSCDRPSSDGEPCHENGIS---D
LK**KE* S* G *D *
*** *V*K*ELEKKLS**RPSSDGE
ENG**
*

297
297
298
297
289

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

GKEQVKRKKSSKSEAKGTVSKVTGKKITKIISLGKKKPSTDEQTSSAEEDVPTCGYLNVL
GKEQVKRKKSSKSEAKGTVSKVTGKKITKIISLGKKKPSTDEQTSSAEEDVPTCGYLNVL
GKEQAKRKKPSKSEAKGTVSKVTGKKITKIIGLGKKKPSTDEQTSSAEEDVPTCGYLNVL
GKEQVKRKKSSKTDSKSTVSKVTGKKITKIIGLGKKKPSTDEQTSSAEEDIPTCGYLNVL
GKDPAKGKKNSKSEQKGTVGRVTGKKITKIISLGKKKPSTDEQTSSAEEDVPTCGYLNVL
GK* *K KK SK** K*TV**VTGKITTKII*LGKKKPSTDEQTSSAEE* PTCGYNNVL

357
357
358
357
349

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

SNSRWRERWCRVKDNKLIFHKDRTDLKTHIVSIPLRGCEVIPGLDSKHPLTFRLLRNGQE
SNSRWRERWCRVKDNKLIFHKDRTDLKTHIVSIPLRGCEVIPGLDCKHPLTFRLLRNGQE
SNSRWRERWCRVKDSKLILHKDRADLKTHLVSIPLRGCEVIPGLDSKHPLTFRLLRNGQE
SNNRWRERWCRVKDNKLIFHKDRTDLKTHIVSIPLRGCEVIPGLDSKHPLTFRLLRNAQE
SNNRWRERWCQLKDNQLFLHKDRADLKTHMASLPLRGCEVIPGLDSKHPFAFRLLRNGQE
SN*RWRERWV**KD**L**HKDR*DLKTH**S*PLRGCEVIPGLD*KHP**FRLLRN*QE

417
417
418
417
409

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

VAVLEASSSEDMGRWIGILLAETGSSTDPEALHYDYIDVEMSASVIQTAKQTFCFMNRRV
VAVLEASSSEDMGRWIGILLAETGSSTDPEALHYDYIDVEMSASVIQTAKQTFCFMNRRV
VAVLEASSSEDMGRWIGILLAETGSSTDPGALHYDYIDVEMSANVIQTAKQTFCFMNRRA
VAVLEASSSEDMGRWIGILLAESGSSADPGTLHYDYIDVDITASVIQAAKQTFCFMNRRV
VAVLEASSSESMGRWLGVLLAETGSTTDPAALHYDYIDVETTANVIQLAKQSFCFTSKRA
VAVLEASSSE*MGRW*G*LLAE*GS**DP *LHYDYIDV* *A*NIQ AKQ*FCF **R*

477
477
478
477
469

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

ISANPYLGGTSNGYAHPSGTALHYDDVPCINGSLKGKKPPVASNGVTGKGKTLSSQPKKISANPYLGGTSNGYAHPSGTALHYDDVPCINGSLKGKKPPVASNGVTGKGKTLSSQPKKVSTSPYLGSLSNGYAHPSGTALHYDDVPCVNGSLKNKKPPASSNGVPVKGKAPSSQQKKLSTNPYRGNPTNGYACPSGMALHYDDVPCINGSFKGKKVSTATNGVVGKGRTLNNPQKKVSPNPYLDNPVNGYACPTGVALHYDDVPCINGTMKGKK-GLITNGFGAKKLDKNQPKKAN
*S**PY ** NGYA P*G ALHYDDVPC*NG**K*KK
*NG* K
** K

536
536
537
536
528

46

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Conensus

-ADPAAVVKRTGSNAAQYKYGKNRVEADAKRLQTKEEELLKRKEALRNRLAQLRKERKDL
-ADPAAVVKRMGSNAAQYKYGKNRVEADAKRLQTKEEELLKRKEALRNRLAQLRKERKDL
-VETAGGVKRTASNAEQYKYGKNRVEADAKRLQSKEEELLKRKEALRNRLAQLRKERKDL
-SEFSSNVKRSTSSAEQYRYGKNRVEADAKKLQTKEEELLKKKEALRNRLAQLRKERKDL
GISSTLPVKRNNSSVDQYKYGKNRVEADAKKLQAKEEELMRKKQEIRNRLTQLKKDRKDL
* * VKR S** QY*YGKNRVEADAK*LQ*KEEEL***K* *RNRL*QL*K*RKDL

595
595
596
595
588

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

RAAIEVNAGRKPQAILEEKLKQLEEECRQKEAERVSLELELTEVKESLKKALAGGVTLGL
RAAIEVNAGRKPQAILEEKLKQLEEECRQKEAERVSLELELTEVKESLKKALAGGVTLGL
RAAIEVNAGRKTQAALEDKLKRLEEECKQREAERVSLELELTEVKESLKKALAGGVTLGL
RAALEANVGRKPLIILEDKLKKLEEECKLKESERVSLELELTEVKENLKKALAGGITLGL
RTALENNTAKRSQASLTERLKKVEDECKLKEEERVSLELELTEVKESLKKALNGGVTLGL
R*A*E N*****
L **LK**E*EC* *E ERVSLELELTEVKE*LKKAL GG*TLGL

655
655
656
655
648

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

AIEPKSGTSSPQSPVFRHRTLENSPISSCDTSDTEG-PVPVNSAAVLKKSQAAPGSSPCR
AIEPKSGTSSPQSPVFRHRTLENSPISSCDTSDTEG-PVPVNSAAVLKKSQAAPGSSPCR
AIEPRSGTSSPQSPVFRHRTLENSPISSCDTSDAEG-PLPVNSAAVLKKSQPSSGSSPCR
AIEPKSGTSTAQSPVLKHQTLENSPISSCDTSDTET-SVPVNSAVVMKR-HSSSSSSPCR
TIEPKTGSSSPQSPVLMRRTVDNSPISSCNTSDTETCSLPVNSASLLRR-QTQQKASPVR
*IEP**G*S**QSPV* **T**NSPISSC*TSD*E **PVNSA **** **
*SP R

714
714
715
713
707

AFAP1.human
AFAP1.chimpanzee
AFAP1.mouse
AFAP1.lizard
AFAP1.zebrafish
Consensus

GHVLRKAKEWELKNGT
GHVLRKAKEWELKNGT
GHVLQKAKEWELKNGT
GHVLQKAKEWELKNGT
GHVLRKAKEWEMKSGT
GHVL*KAKEWE*K*GT

730
730
731
729
723

Figure 4. Comparison of AFAP1 sequences across species
The 730 amino acid sequence of human AFAP1 was compared by ClustalW2 alignment
(50) with the 730 amino acid sequence of chimpanzee AFAP1, the 731 amino acid
sequence of mouse AFAP1, the 729 amino acid sequence of Anole lizard AFAP1 and the
723 amino acid sequence of zebrafish AFAP1. Identical amino acid sequence is shown
by its one letter abbreviation in the consensus sequence while similar amino acid
sequence is represented by *.
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Figure 5
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Figure 5. Comparison of AFAP1L1 sequences across species
The 768 amino acid human AFAP1L1 sequence was compared using ClustalW2
alignment (50) with the 768 amino acid sequence of chimpanzee AFAP1L1, the 768
amino acid sequence of mouse AFAP1L1, the 760 amino acid sequence of Anole lizard
AFAP1L1 and the 747 amino acid sequence of zebrafish AFAP1L1. Identical amino acid
sequence is shown by its one letter abbreviation in the consensus sequence while similar
amino acid sequence is represented by *.
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Figure 6
AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

MERYKALEQLLTELDDFLKILDQENLSSTALVKKSCLAELLRLYTKSSSSDEEYIYMNKV
MERYKALEQLLTELDDFLKILDQENLSSTALVKKSCLAELLRLYTKSSSSDEEYIYMNKV
--------------------------------------------------------MNKV
-----ALEQLLTELEDFLKILDKENLSSTAIVKKSFLADLLRLCTKSNGGDEEYIYMNKV
MDKHKVLEQLLEQLQKFLKILDVEKLSGNAKVQKGLLMELLQSYKSSNGGDEEYIYMNKV
MNLV

60
60
4
55
60

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

TINKQQNAESQGKAPEEQGLLPNGEPSQHSSAPQKSLPDLPPPKMIPERKQLAIPKTESP
TINKQQNAESQGKAPEEQGLLPNGEPSQHSSAPQKSLPDLPPPKMIPERKQLAIPKTESP
SVNGEQNSASPDKVPEEQGPLTNGEPSQHSSAPQKSLPDLPPPKMIPERKQPTVPKIESP
SIN-KQHGELEKSDKGHRDSLTNGDAEQHLSPPQKSLPDLPPSKIIPETKPYSGSKTESP
IVT----CQTQDKTNRDHRPEANGDPSKHIS--VKNPPEPPPPRPVSKQKRAPAPASMEN
**
*
**
*NG****H S
K* P* PP** *** K * *
*

120
120
64
114
114

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

EGYYEEAEPYD-TSLNEDGEAVSSSYESYDEEDGSKGKS-APYQWPSPEAGIELMRDARI
EGYYEEAEPYD-TSLNEDGEAVSSSYESYDEEDGSKGKS-APYQWPSPEAGIELMRDARI
EGYYEEAEPFD-RSINEDGEAVSSSYESYDEDENSKGKA-APYQWPSPEASIELMRDARI
EGYYEEAEPYG-ISLNDDGEAVSSSYESYDEEENTKGKS-APHQWPSPEASIELMKDARI
ESYYEDPQPYDPISINEDTEQLSSSYESYDEEEVTKGKSTAQHQWPSPEASIELMKDARI
E*YYE***P** S*N*D E *SSSYESYDE** *KGK* A *QWPSPEA*IELM*DARI

178
178
122
172
174

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

CAFLWRKKWLGQWAKQLCVIKDNRLLCYKSSKDHSPQLDVNLLGSSVIHKEKQVRKKEHK
CAFLWRKKWLGQWAKQLCVIKDNRLMCYKSSKDHSPQLDVNLLGSSVIHKEKQVRKKEHK
CAFLWRKKWLGQWAKQLCVIRDTRLLCYKSSKDHSPQLDVNLRGSSVVHKEKQVRKKGHK
CAFLWRKKWLGQWAKQLCVIKDNRLLCYKTSKDHNPQLDVNLLGCSVIHKEKNVRKQEHK
CAFLWRKKWLGQWAKQLCVVREHRLLCYKSSKDQTPLLDISLLGCSVVYKEKQTKRKEHK
CAFLWRKKWLGQWAKQLCV*** RL*CYK*SKD**P LD**L G*SV**KEK***** HK

238
238
182
232
234

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

LKITPMNADVIVLGLQSKDQAEQWLRVIQEVSGLPSEGASEGNQYTPDAQRFNCQKPDIA
LKITPMNADVIVLGLQSKDQAEQWLRVIQEVSGLPSEGASEGNQYTPDAQRFNCQKPDIA
LKITPMNADVIVLGLQSKDQAEQWLRVIQEVSGLPSEGASEGNQYTPDAQRLNCQKPDIA
LKIIPMNADVIVLGLQSKDQAEQWLRVIQETSGLYPDGWGEGNQYVPDSQRLSYPKVEAT
LKISPLGAEAIVLGLQSKEQAEQWLKVIQEISPKNTTGSD-----VTDSPTLICTKGEQS
LKI P**A**IVLGLQSK*QAEQWL*VIQE S
* G *
**D* *
K * *

298
298
242
292
289

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

EKYLSASEYGSSVDGHPEVPETKDVKKKCSAGLKLSNLMNLGRKKSTSLEPVERSLETSS
EKYLSASEYGSSVDGHSEVPETKDVKKKCSAGLKLSNLMNLGRKKSTSLEPVERSLETSS
EKYLSAAEYGITINGHPEIPETKDVKKKCSAGLKLSNLMNLGRKKSTSLEPPERSLETSS
ERYSVASESGSSTDGHPELMETKDAKKKGTSGLKLSNLMNLGRKKSASLDSPERSLDTCT
ERYSVASESGSSTDSHAENMENKDVKKKYG---KFSNLMNIGKKKVCSLESPEKSVDTSG
E*Y A*E G * **H*E E*KD*KKK
K*SNLMN*G*KK SL** E*S**T*

358
358
302
352
346

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

YLNVLVNSQWKSRWCSVRDNHLHFYQDRNRSKVAQQPLSLVGCEVVPDPSPDHLYSFRIL
YLNVLVNSQWKSRWCSVRDNHLHFYQDRNRSKVAQQPLSLVGCEVVPDPSPDHLYSFRIL
YLNVLVNSQWKSRWCFVRDSHLHFYQDRNRSKVAQQPLSLVGCDVLPDPSPDHLYSFRIL
YLNVLVNSQWKSRWCYVKDGQLHFYQDKNKTKTAQQPLNLIGCEIFPDPSPDHLYSFRIL
YLNVLVNTQWRSRWCSVKDRQLWIYSDKSKGKVAQQPLSLEGCMVLPDPSPEHLYSFRIQ
YLNVLVN*QW*SRWC V*D *L *Y*D*** K*VAQQP*L GC **PDPSP*HLYSFRI

418
418
362
412
406

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

HKGEELAKLEAKSSEEMGHWLGLLLSESGSKTDPEEFTYDYVDADRVSCIVSAAKNSLLL
HKGEELAKLEAKSSEEMGHWLGLLLSESGSKTDPEEFTYDYVDADRVSCIVSAAKNSLLL
HNGEELAKLEAKSSEEMGHWLGLLLSESGSKTDPEELTYDYVDAERVSCIVSAAKTSLLL
HNGEERAMLEAKTCEEMGHWLGLLLSESGSKTDPEELTYDYVDADRVSCIVSAAKNSLLL
MDGEELAILEAKSSADMGHWLGLILSQTGTKTDPEDLSYDYVNSERISSIVNAAKTSMYL
*GEE A LEAK** *MGHWLGL*LS**G*KTDPE***YDYV***R*S*IV*AAK*S* L

478
478
422
472
466

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

MQRKFSEPNTYIDGLP-SQDRQEELYDDVDLSELTA-AVEPTEEATP--VADDPNERESD
MQRKFSEPNTYIDGLP-SQDRQEELYDDVELSELTA-AVEPTEEATP--VADDPNERESD
MQRKFSEPNTYIDGLP-SRDCQDDLYDDVEVSELIA-VVEPAEEAAP--AVDANSGSEPD
MQRKYSEPNTYIDNLPKEKEEQEELYDDVDVPESTMNKFNISHQEIP--LIESKSAGEQD
MQRRYSEPNTYTDSPPSDPQTCDDIYDDVPSTENEQEEVQEVQNGSEEGTVNAEEENGKD
MQR**SEPNTY D* P * * ***YDDV *E
** **
* *
D

534
534
478
530
526

50

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

RVYLDLTPVKSFLHGPSSAQAQASSPTLSCLDNATEALPADSGPGPTPDEPCIKCPENLG
RVYLDLTPVKSFLHGPSSAQAQASSPTLSCLDNATEALPADPGPGPTPDEPCIKCPENLG
RVYLDLTPVKSFLHSSSEAQAQASLPAVPHQDDVAETLTVDPKPGTTPEEPHTESPGDPE
RVYLDLTPVQSFVYSAGRKHGQLTPSVSPSLQRSVHKNSTDSDK----DLFTLYKEGELN
RVYLDLIPLRSFLHTSSAKTLGQNLPGDPHLPPAATLISP-PPPGPQLFGTVYNTPGLPT
RVYLDL P**SF** **
* * *
*
* *

594
594
538
586
585

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

EQQ-----LESLEPEDPSLRITTVKIQTEQQRISFPPSCPDAVVATPPGASPPVK-DRLR
EQQ-----LESLEPEDPSLRITTVKIQTEQQRISFPPSCPDAVVATPPGASPPVK-DRLR
VQQRQPEVQESSEPIEPTPRITMVKLQAEQQRISFPANCPDTMASAPIAASPPVK-EKLR
RQS-----VEATDQLLP-LRTTTVKIQAQQQQIAFPQSAFEMKNATTIVAAPKEKGERPK
MIKYPIAADRTRNPEIQKKASPLPKTQSLPQTSAQTPQSPPTSRAR--AASTDRLLDRLK
*
** *
* K Q* Q * * **
*
A**
** *

648
648
597
640
643

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

VT-----SAEIKLGKNRTEAEVKRYTEEKERLEKKKEEIRGHLAQLRKEKRELKETLLKC
VT-----SAEIKLGKNRTEAEVKRYTEEKERLEKKKEEIRGHLAQLRKEKRELKETLLKC
VT-----SAEIKLGKNRTEAEVKRYTEEKERLERSKEEIRGHLAQLRREKRELKETLLRC
VA-----PVETKLGKNRTEAEVKRYSEERDRLEKEKEEIRSQLAQLRKDKRELKELLTNC
FSPAGPGSVEVKLGKNRTEADVRRYTDDRDRLEREREEVKNTLATLRKDRREVKDELSSC
**
**E KLGKNRTEA*V*RY*****RLE***EE*** LA LR***RE*K* L C

703
703
652
695
703

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

TDKEVLASLEQKLKEIDEECRGEESRRVDLELSIMEVKDNLKKAEAGPVTLGTTVDTTHL
TDKEVLASLEQKLKEIDEECRGEESRRVDLELSIMEVKDNLKKAEAGPVTLGTTVDTTHL
TDKGVLAKLEQTLKKIDEECRMEESRRVDLELSIMEVKDNLKKAEAGPVTLGTTVDTTHL
TDKSILSTLEQNLKEIEEECKRKEDQRVDLELNLVEVKENLRKAESGPVTLGTAVDTTHL
QVQTELASLEARLKQMEETCREAERRRVEVELSLMEVKENLRKVESGPFTLGTTVDSSLL
* L**LE LK***E C* E *RV**EL***EVK*NL*K*E*GP*TLGT*VD** L

763
763
712
755
763

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

ENVSPRP--KAVTPASAP--------------DCTPVNSATTLKNRPLSVVVTGKGTVLQ
ENVSPRP--KAVTPASAP--------------DCTPVNSATTLKNRPLSVMVTGKGTVLQ
DNMSPRPQPKAATPNPPP--------------DSTPVNSASVLKNRPLSVMVTGKGTVLQ
ENSSPKM--KVANPMNST--------------ESSPVNSAMALKNRPLSIMVTGKGTVLQ
DISVPKP-AAVSSPAPNTPNNTNINTPACTNNEDSPVNSATALKNRPPSVMAASKGNVLQ
*
P*
* *P
*
* *PVNSA *LKNRP S*****KG*VLQ

807
807
758
799
822

AFAP1L2.human
AFAP1L2.chimpanzee
AFAP1L2.mouse
AFAP1L2.lizard
AFAP1L2.zebrafish
Consensus

KAKEWEKKGAS
KAKEWEKKGAS
KAKEWEKKGAS
KAKEWEKKGAS
KAKEWEKKNTT
KAKEWEKK***

818
818
769
810
833

Figure 6. Comparison of AFAP1L2 sequences across species
The 818 amino acid sequence of AFAP1L2 was compared by ClustalW2 alignment (50)
with the 818 amino acid sequence of chimpanzee AFAP1L2, the 769 amino acid
sequence of mouse AFAP1L2, the 810 amino acid sequence of Anole lizard AFAP1L2
and the 833 amino acid sequence of zebrafish AFAP1L2. Identical amino acid sequence
is shown by its one letter abbreviation in the consensus sequence while similar amino
acid sequence is represented by *.
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Figure 7
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Figure 7. Identity and similarity between human AFAP family members
The 730 amino acid sequence of AFAP1 was compared to the 768 amino acid sequence
of AFAP1L1 and the 818 amino acid sequence of AFAP1L2 using ClustalW2 alignment
(50). Identical amino acid sequence is shown by its one letter abbreviation in the
consensus sequence while similar amino acid sequence is represented by *.
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Figure 8A
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Figure 8B
AFAP1.PH1
AFAP1L1.PH1
AFAP1L2.PH1
Consensus

DAKICAFLLRKKRFGQWTKLLCVIKDTKLLCYKSSKDQQPQMELPLQGCNITYIPKDSKK 60
ECRICAFLLRKKRFGQWAKQLTVIREDQLLCYKSSKDRQPHLRLALDTCSIIYVPKDSRH 60
DARICAFLWRKKWLGQWAKQLCVIKDNRLLCYKSSKDHSPQLDVNLLGSSVIHKEKQVRK 60
***ICAFL RKK *GQW*K L VI** *LLCYKSSKD**P** * L *** * K* **

AFAP1.PH1
AFAP1L1.PH1
AFAP1L2.PH1
Consensus

KKHELKITQQGTDPLVLAVQSKEQAEQWLKVIKEAYS 97
KRHELRFTQGATEVLVLALQSREQAEEWLKVIREVSK 97
KEHKLKITPMNADVIVLGLQSKDQAEQWLRVIQEVSG 97
K*H*L**T
** *VL**QS**QAE*WL*VI*E*

AFAP1.PH2
AFAP1L1.PH2
AFAP1L2.PH2
Consensus

DVPTCGYLNVLSNSRWRERWCRVKDNKLIFHKDRTDLKTHIVSIPLRGCEVIPGLDSKHP 60
EVPCCGYLNVLVNQGWKERWCRLKCNTLYFHKDHMDLRTHVNAIALQGCEVAPGFGPRHP 60
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YSFRILHKGEELAKLEAKSSEEMGHWLGLLLSE------ 93
*FR*L** *E*A LEA**SE*MG*W*G*LL E

Figure 8. Comparison of AFAP family members
(A) Modular domain organization of AFAP family members was compared. SH3bm =
SH3 binding motif, SH2bm = SH2 binding motif, PH1 = pleckstrin homology domain 1,
PH2 = pleckstrin homology domain 2, SD = serine/threonine rich substrate domain, Lzip
= leucine zipper, ABD = actin binding domain. Sequences that do not correlate with an
identified type of modular domain or motif are labeled “A, B, C, D or E”.
(B) The PH1 domains of AFAP family members were compared by ClustalW2 analysis
(50). Identical amino acid sequence is shown by its one letter abbreviation in the
consensus sequence while similar amino acid sequence is represented by *.
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Figure 9. A Scansite scan determined potential sites for phosphorylation
The Scansite motif scanning progam (59) determined possible sites of protein interaction in
AFAP family members. Predicted sites include Src homology 3 groups (SH3), Src homology 2
groups (SH2), tyrosine kinase groups (Y_kin), lipid binding groups (Lip_bind) and basophilic
serine/threonine kinase groups (Baso_ST_kin).
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ABSTRACT
The actin-filament associated protein (AFAP) family of adaptor proteins consists
of three members: AFAP1, AFAP1L1, and AFAP1L2/XB130 with AFAP1 being the best
described as a cSrc binding partner and actin cross-linking protein. A homology search of
AFAP1 recently identified AFAP1L1 which has a similar sequence, domain structure and
cellular localization; however, based upon sequence variations, AFAP1L1 is
hypothesized to have unique functions that are distinct from AFAP1. While AFAP1 has
the ability to bind to the SH3 domain of the nonreceptor tyrosine kinase cSrc via an Nterminal SH3 binding motif, it was unable to bind cortactin. However, the SH3 binding
motif of AFAP1L1 was more efficient at interacting with the SH3 domain of cortactin
and not cSrc. AFAP1L1 was shown by fluorescence microscopy to decorate actin
filaments and move to punctate actin structures and colocalize with cortactin, consistent
with localization to invadosomes. Upon overexpression in A7r5 cells, AFAP1L1 had the
ability to induce podosome formation and move to podosomes without stimulation.
Immunohistochemical analysis of AFAP1L1 in human tissues shows differential
expression when contrasted with AFAP1 with localization of AFAP1L1 to unique sites in
muscle and the dentate nucleus of the brain where AFAP1 was not detectable. We
hypothesize AFAP1L1 may play a similar role to AFAP1 in affecting changes in actin
filaments and bridging interactions with binding partners, but we hypothesize that
AFAP1L1 may forge unique protein interactions in which AFAP1 is less efficient, and
these interactions may allow AFAP1L1 to affect invadosome formation.
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INTRODUCTION
Adaptor proteins are non-enzymatic proteins that have the ability to link together
different components of cellular signaling complexes through protein-binding motifs.
Actin Filament-Associated Protein of 110 ki lodaltons (kDa) (AFAP-110/AFAP1) is an
adaptor protein with multiple protein binding motifs that is known to function as both an
actin binding protein and a cSrc activating protein (Flynn et al., 1993; Qian et al., 2000).
The AFAP1 protein binding motifs include two juxtaposed poly-proline rich Src
homology 3 ( SH3) binding motifs of approximately 10 amino acids with essential
prolines at the amino acid number seven and ten positions within the motif (Mayer,
2001), two Src homology 2 (SH2) binding motifs containing a phosphotyrosine residue
amino terminal to 1 or 2 ne gatively charged amino acids followed by a hydrophobic
amino acid (Songyang et al., 1993), two pleckstrin homology (PH) domains, a substrate
domain (SD) rich in serine and threonine residues that is a substrate for serine/threonine
kinases, a h elical leucine zipper (Lzip) with a heptad repeat of leucine residues
(Kouzarides and Ziff, 1988) for intra- and inter-molecular interactions within itself and
other AFAP1 molecules and an actin binding domain (ABD) which is both necessary and
sufficient for AFAP1 to interact with actin filaments (Baisden et al., 2001a; Qian et al.,
1998; Qian et al., 2000; Qian et al., 2004). AFAP1 is known to bind actin filaments
through its carboxy terminal actin filament-binding domain and will multimerize through
its leucine zipper, thus enabling it to crosslink actin filaments (Qian et al., 2002).
Activation by the serine/threonine kinase PKCα directs AFAP1 to colocalize with cSrc in
the perinuclear region of the cell and activate cSrc by binding to the SH3 domain via its
N-terminal SH3 binding motif (Gatesman et al., 2004; Walker et al., 2007).
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Subsequently, cSrc then has the ability to activate downstream cellular signals that affect
cell adhesion, invasion and motility (Fincham et al., 1996; Frame and Brunton, 2002).
Upon cSrc binding and activation, AFAP1 and cSrc move to podosomes,
adhesion structures found on the ventral membrane of cells which contain an F-actin rich
core (Gatesman et al., 2004; Linder and Kopp, 2005). Podosomes also secrete proteases
which enable cells to degrade the extracellular matrix, cross tissue barriers and invade.
As cSrc activation is known to switch cells from a normal to an invasive phenotype, the
activation and movement of cSrc and AFAP1 may be important steps toward promoting
cellular changes in adhesion and invasive potential. Also involved in this process is the
ability of a cell to assemble, disassemble and remodel its actin cytoskeleton (Yilmaz and
Christofori, 2009). As AFAP1 has been shown to affect dynamic changes in actin
filament cross-linking (Qian et al., 2004), AFAP1 may also play a r ole in actin
cytoskeleton remodeling in addition to cSrc activation.
AFAP1 represents a f amily of three proteins that also include Actin Filament
Associated Protein 1 Like 1 (AFAP1L1) and Actin Filament Associated Protein 1 Like 2
(AFAP1L2/XB130) so named as a family by t he Human Genome Project due to
similarity in modular domain structure and amino acid sequence, most notably within
their PH domains. There are 250 know n PH domain-containing proteins in the human
genome and while the amino acid sequences of these PH domains are not well conserved,
they are predicted to have a similar structure with a β-barrel with four β strands on one
side and three β strands on the other connected by three variable loops connecting β1/β2,
β3/β4 and β6/β7 (DiNitto and Lambright, 2006). However, within the AFAP family, the
amino acid sequence, as well as st ructure and placement within the protein, are well
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conserved between the PH domains, designating them as a related family of proteins.
Overall, AFAP1L2/XB130 consists of 818 a mino acids and is 35% identical (64%
similar) to AFAP1. AFAP1L2/XB130 was also discovered as a cSrc binding protein and
contains a shared functional domain structure to AFAP1 including one SH3 motif, three
SH2 motifs, 2 P H domains, a coiled-coil region corresponding to the AFAP1 leucine
zipper and a sequence similar to the AFAP1 actin binding domain (Xu et al., 2007).
However, unlike AFAP1, AFAP1L2/XB130 did not appear to bind efficiently to actin
filaments. AFAP1L2/XB130 does appear to have functions distinct from AFAP1 in that
it acts as an intermediary between the RET/PTC kinase and PI-3kinase pathway in the
thyroid (Lodyga et al., 2009).
In this report we characterize the third AFAP family member, AFAP1L1, which
also contains a shared domain structure with AFAP1 and AFAP1L2/XB130. Cladistic
analysis of the three AFAP family members (data not shown) indicated that AFAP1 and
AFAP1L1 are more closely related to each other than to AFAP1L2/XB130, therefore we
sought to compare and contrast AFAP1L1 to AFAP1 so as to characterize AFAP1L1 and
determine whether it has functions that are shared or distinct relative to AFAP1.
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MATERIALS AND METHODS
Cell Culture and Reagents
A7r5, rat aortic smooth muscle cells, were purchased from American Type
Culture Collection and grown in Dulbecco’s modified Eagle’s medium (DMEM,
Mediatech) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals), 2mM
L-Glutamine (Gibco) and penicillin/streptomycin (Mediatech) at 37°C with 5% CO2.
MDA-MB-435, MDA-MB-231, B1A (Dorfleutner et al., 2007), and Cos-1 cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM, Mediatech), 10% fetal bovine
serum

(FBS,

Atlanta

Biologicals),

2mM

L-Glutamine

(Gibco)

and

penicillin/streptomycin (Mediatech) at 37°C with 5% CO2. MCF-10A cells were grown
in complete Mammary Epithelium Basal Medium supplemented with MEGM
SingleQuots (Lonza) and MCF-7 cells were cultured in Modified Eagle’s medium
containing 10% FBS and 10 µg/ml bovine insulin (Sigma).
Antibodies used for western blotting and immunofluorescence are as follows:
anti-AFAP1 (F1) (Flynn et al., 1993), anti-AFAP1 (BD Transduction Labs), anticortactin (Millipore), and βactin (Sigma). Tetramethylrodamine-isothiocyanate (TRITC)conjugated phalloidin was from Sigma and Alexa Fluor conjugated phalloidin and
secondary antibodies were from Invitrogen. The antibody against AFAP1L1, 1L1-CT,
was generated by ProSci Incorporated. Rabbits were immunized with AFAP1L1 peptide
corresponding to amino acids 714-727. 1L1-CT antibody was affinity-purified by affinity
absorption against the AFAP1L1 peptide attached to an Ultralink Iodoacetyl column
(Pierce) according to manufacturer’s protocol. Two additional antibodies against
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AFAP1L1, Ab1 and Ab2, targeting either the C-terminus (amino acid 525- 659) or the Nterminus (amino acids 21-159) of 1L1, respectively, were from Sigma.

Constructs
The afap1l1 cDNA sequence was purchased in two vectors from OpenBioSource.
The coding sequence for AFAP1L1 amino acids 1 t hrough 340 w as identified in a
pCMV-SPORT6 vector. The coding sequence for AFAP1L1 amino acids 273 t hrough
768 was identified in a pINCY vector. A BstYI restriction site, GATCC, in the overlap
region was mutated to a BglII restriction site, GATCT, to create a unique restriction site
using the Stratagene QuikChange Site-Directed Mutagenesis Kit according to
manufacturer’s protocol. AFAP1L1 N-terminal coding sequence was subcloned into
pBluescript II K S (Stratagene) using HindIII and an engineered EcoRI restriction site.
AFAP1L1 C-terminal coding sequence was subcloned into pBluescript II KS using
engineered HindIII and EcoRI restriction sites. F ull length afa1l1 was created by
restriction digest of pBluescript containing each afap1l1 coding sequence with the unique
BglII site in the overlap region and a unique Sca1 site found in the vector followed by
fusion of the two halves of pBluescript. The afap1l1 full length sequence was confirmed
by DNA sequencing.
Full length afap1l1 was subcloned into pEGFP (Clonetech) using HindIII and
EcoRI. Full length afap1l1 was subcloned from pEGFP into pcDNA3.1(+) hygro
(Invitrogen) using HindIII and Kpn1. GFP-AFAP1 was previously described by (Qian et
al., 2000).
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Transfection
For antibody characterization and GST pull down overexpression studies
respectively, Cos-1 and 293T cells were transiently transfected with 5µg of either GFPAFAP1 or GFP-AFAP1L1 using Lipofectamine and Plus reagent according to
manufacturer’s protocol. For confocal overexpression studies, mouse embryo fibroblasts
(MEF) were transfected with 5µg of either GFP-AFAP1L1 or untagged AFAP1L1 (in
pcDNA3.1) using Lipofectamine and Plus reagent.
To determine endogenous AFAP1L1 localization to invadopodia, MDA-MB-435
cells were transfected with cSrc527F plasmid using Lipofectamine and Plus reagent
(Invitrogen) according to the manufacturer’s instructions. A7r5 cells were transfected
with GFP-AFAP1 or GFP-AFAP1L1 in increasing amounts from 0.1 µg to 1.0 µg using
Lipofectamine and Plus reagent per well of a 6 well plate. Total DNA concentration for
dose response transfections was kept constant using an empty pcDNA3.1 vector to keep
the total DNA transfected at 1.0 µg to maintain equal transfection efficiency.

Immmunoblotting
Cos-1 cells transiently expressing GFP-AFAP1 or GFP-AFAP1L1 were lysed in
2X SDS buffer (125mM Tris-HCl pH6.8, 20% glycerol, 4% SDS). Cell lines MCF-10A,
MCF-7, MDA-MB-231, MDA-MB-435, B1A, and Cos-1 were lysed in 2X SDS buffer.
Protein concentration was determined using a BCA Protein Assay Kit (Pierce) according
to manufacturer’s protocol. 50µg of total lysate was resolved by 8 % SDS-PAGE.
Proteins were transferred to polyvinylidene fluoride (PVDF) membrane (Immobilon-P,
Millipore) using semi-dry electroblotting. Proteins were detected by incubation with
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either anti-1L1-CT (ProSci) 1:250, anti-1L1-Ab1 (Sigma) 1:1000, anti-1L1-Ab2 (Sigma)
1:500, anti-AFAP1 (BD Transduction Labs) 1:10000, anti-AFAP1 (F1) 1:20000, antiGFP (Zymed) 1:1000 or anti-β-actin (Sigma) 1:10000 in 5% powdered milk (TBS, 0.05%
Tween-20) followed by incubation with 1:3000 dilution of donkey anti-mouse or donkey
anti-rabbit horseradish peroxidase conjugated antibodies (GE Healthcare Bio-Sciences).
Chemiluminescence was visualized with Pierce ECL Western Blotting Substrate.

Immunofluorescence
MDA-MB-435, MEF and A7r5 cells were grown on fibronectin-coated coverslips
(50µg/ml) overnight at 37°C. For GFP-AFAP1L1 overexpression and overexpressed
untagged AFAP1L1, MEF and A7r5 cells were fixed with 3.7% formaldehyde,
permeabilized with 0.2% triton X-100 and incubated with or without anti-cortactin
antibody (1:200). Actin filaments were decorated with TRITC-phalloidin (1:600) or
Alexa Flour conjugated phalloidin (1:100). For endogenous AFAP1L1 staining, MDAMB-435 were fixed and permeabilized in 3.7% formaldehyde containing 0.1% triton X100, incubated with Alexa Flour conjugated phalloidin (1:100) in 3% BSA, and then
stained with anti-AFAP1L1 antibodies Ab1 or Ab2 (Sigma, 2 µg/ml) and anti-cortactin
antibodies. Fluorescence conjugated secondary antibodies (Invitrogen) were used at a
1:200 dilution. Coverslips were mounted on slides using Prolong Gold (Invitrogen) and
imaged with a Zeiss LSM 150 microscope or Nikon eclipse Ti inverted epi-fluorescence
microscope. Podosomes were confirmed by anti-cortactin localization along the
basolateral membrane via confocal microscopy (0.5 µm scanning thickness). Images
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were further processed with Zeiss LSM Image Browser (Zeiss), CorelDRAW12, Nikon
NIS element software (Nikon) and Adobe Photoshop.

Immunoprecipitation
Cos-1 cells were lysed in RIPA buffer (50mM Tris pH7.5, 150mM NaCl, 2mM
EDTA, 1% Igepal, 0.25% sodium deoxycholate, 10mM β-glycerol, 1mM sodium
vanadate, 5µg/µl aprotinin, 5µg/µl leupeptin, 1mM PMSF). 1 mg of Cos-1 lysate was
used for each control IgG, anti-1L1-CT and AFAP1 (F1) pull down. Lysates were precleared with agarose A beads for one hour. The precleared lysates were incubated on ice
for one hour with 2µg IgG, 1L1-CT or F1 antibodies, and then 50% slurry agarose A
beads were added and incubated for one hour. Proteins were eluted from beads using 2X
Laemmli sample buffer (LSB) with 200mM dithiothreitol (DTT), separated by 8% SDSPAGE and processed for western blot analysis. 293T cells were transfected with human
cortactin cDNA with either EGFP AFAP1 or AFAP1L1 construct using Polyfect
(Qiagen) according to the manufacturer’s specification. Forty-eight hours post
transfection, cells were lysed in RIPA buffer and 2 mg of cell lysates were used for
immunoprecipitation with either GFP antibodies (Polyclonal Av antibodies, Clonetech)
or cortactin antibodies (clone 4F11, Millipore) as described above.

Immunohistochemical methods
Immunohistochemistry was performed on de -identified human brain, breast and
colon tissue slices obtained from the West Virginia University Department of Pathology
Tissue Bank. Tissues were paraffin-embedded and cut into 5 μm-thick sections and
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mounted on positive-charge coated slides. Tissue sections were dried overnight in a 45ºC
oven, deparaffinized, rehydrated, and subjected to heat-induced epitope retrieval for two
hours in 1 mM citrate buffer (pH 6.00) in an 80º C water bath. Endogenous peroxide
activity was blocked with 3% hydrogen peroxide and was followed by treatment with a
serum-free protein blocker to block non-specific binding. Following each step of the
immunoreaction except the protein blocker, sections were rinsed in Tris-buffered saline
with Tween-20. Tissues were incubated for two hours with either anti-AFAP1 antibody
(F1) at a dilution of 1:50 or with anti-1L1-CT diluted 1:50 in 10% normal horse serum.
Negative controls (i.e., preimmune serum or normal rabbit IgG) were incubated in 10%
normal horse serum. Sections were incubated with biotinylated-linked secondary
antibody, followed by t reatment with streptavidin peroxidase and stained with
diaminobenzidine substrate-chromogen solution. Counterstaining was performed with
hematoxylin, followed by a water rinse and bluing solution. Tissues were then dehydrated
and mounted with coverslips.

Affinity precipitation with GST fusion proteins
293T cells transiently expressing GFP-AFAP1 or GFP-AFAP1L1 were lysed in
Modified RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 2mM EDTA, 1% Igepal,
0.25% sodium deoxycholate, 10 m M β-glycerol, 1 m M sodium vanadate, 5µg/µl
aprotinin, 5µg/µl leupeptin and 1µM PMSF). GFP-AFAP1 and GFP-AFAP1L1 lysates
were pre-cleared using 50 µg of GST protein bound to Glutathione Sepharose 4B coated
beads (GE Healthcare) and 1mg of each pre-cleared lysate was incubated at 4°C for 1
hour with either 50 µg control GST, 50 µg GST-Src SH3 domain or 50 µg GST-cortactin
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SH3 domain bound t o GST beads. Proteins were eluted from beads by boi ling for 5
minutes in 2X Laemmli sample buffer with 200mM DTT and further processed with
PAGE and western blot analysis. Western blot results were examined with ImageJ
densitometry analysis so as to provide a ratio between the amount of AFAP1 and
AFAP1L1 pulled down with each GST or GST fusion protein.
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RESULTS
Identification of AFAP1L1
AFAP1L1 was discovered during a homology search of the human genome using
sequences of the AFAP1 PH domains and was subsequently referred to as t he third
member of the AFAP family by the Human Genome Project. The afap1l1 gene is located
on chromosome 5q33.1 and consists of 19 exons that are predicted to encode 768 amino
acids in the open reading frame (Figure 1). All AFAP family members contain at least
one predicted N-terminal SH3 binding motif, at least one predicted N-terminal SH2
binding motif, two PH domains separated by a region rich in serine and threonine
residues and a C-terminal SH2 binding motif (Figure 2A). One major difference is found
in the C-terminus where AFAP1 and AFAP1L1 contain a leucine zipper and actin
binding domain while AFAP1L2/XB130 contains a related coiled-coil in this respective
region (Figure 2B) (Baisden et al., 2001b; Xu et al., 2007).
There appear to be differences in the SH3 binding motif of AFAP1L1 compared
to AFAP1. A FAP1 contains two juxtaposed SH3 binding motifs, PPQMPLPEIP and
PPDSGPPPLP, beginning at amino acids 65 and 76 respectively (Guappone and Flynn,
1997). AFAP1 will bind cSrc using the N-terminal P71EIP of the first SH3 binding motif
(Guappone and Flynn, 1997), while AFAP1L2/XB130 has been reported to also bind
cSrc through its SH3 binding motif, identified as PDLPPPKMIP (Xu et al., 2007).
However, the AFAP1L1 coding sequence contains only one predicted SH3 binding motif
in its amino terminus, DLPPPLPNKP, which is not consistent with a consensus cSrc SH3
binding motif but may have the ability to bind to other SH3 domains.
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AFAP1 contains two SH2 binding motifs that interact with cSrc, YYEEA in the
N-terminal portion of the protein and YDYI in the C-terminal portion, which are both
sites for tyrosine phosphorylation (Guappone et al., 1998). AFAP1L1 shares 100%
sequence identity with both AFAP1 and AFAP1L2/XB130 in its predicted N-terminal
SH2 binding motif, YYEEA, and is highly similar in its C-terminal SH2 binding motif
YDYV (Guappone et al., 1998; Xu et al., 2007). Thus, these may be potential sites for
tyrosine phosphorylation.
The N-terminal and C-terminal PH domains of the AFAP family share sequence
similarity and, thus, can be predicted to share structural similarity. The amino acid
sequence intervening between the PH domains of AFAP1 (substrate domain, SD, Figure
2B) is rich in serine and threonine residues (Qian et al., 2002). Serine277 in AFAP1 is a
known target of phosphorylation by PKCα and plays a role in the ability of AFAP1 to
regulate podosome formation and lifespan (Dorfleutner et al., 2008). A FAP1L1 and
AFAP1L2/XB130 also have multiple serine and threonine residues in the sequence
flanked by t heir PH domains, although these sequences have not been confirmed to be
phosphorylated by serine/threonine protein kinases.
The leucine zipper of AFAP1 is essential for intra-molecular regulation of AFAP1
and interaction with other AFAP1 molecules and is directly adjacent to the actin binding
domain (Qian et al., 2004). AFAP1L1 contains a si milar sequence that may have the
ability to act as a leucine zipper or coiled-coil motif as well as a putative actin binding
domain which is similar to the known actin filament binding domain found in AFAP1
(Qian et al., 2000). AFAP1L2/XB130 contains a coiled-coil motif in its C-terminus and a
sequence that is similar to the AFAP1 actin binding domain, but AFAP1L2/XB130 has
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not been demonstrated to bind actin filaments (Xu et al., 2007). An amino acid sequence
alignment of the three family members found that AFAP1 and AFAP1L1 overall share
44% identity and 71% similarity while AFAP1L1 and AFAP1L2/XB130 share 31%
identity and 61% similarity and their sequences predict conserved functional domains
within the proteins (Figure 2B).

A novel antibody is specific for AFAP1L1
A rabbit polyclonal antibody was generated against the carboxy terminal amino
acids 714-727 of human AFAP1L1. We refer to this antibody as 1L1-CT. We also
utilized two commercially available AFAP1L1 antibodies, called Ab1 (epitope defined as
amino acids 525-659) and Ab2 (epitope defined as amino acids 21-159). The ability of
these antibodies to detect AFAP1L1 was studied using lysates of human breast lines
MCF-10A, MCF-7, MDA-MB-231, B1A (a variant of MDA-MB-231 cells that had
AFAP1 knocked down using shRNA (Dorfleutner et al., 2007)), MDA-MB-435 as well
as monkey kidney cell line Cos-1. All three AFAP1L1 antibodies detected a distinct
protein band by western blot analysis with a Mr of 115 kDa (Figure 3A, result from Ab2
as a r epresentative example) with MDA-MB-435 having the highest endogenous
expression levels of AFAP1L1 among the tested cell lines. The Mr of AFAP1L1 was
further confirmed by s iRNA knockdown against AFAP1L1 (data not shown). The
expression pattern of AFAP1L1 across breast cancer cell lines was further confirmed in
messenger RNA levels through quantitative RT-PCR analysis (data not shown). To test
the ability of the 1L1-CT antibody to immunoprecipitate endogenous AFAP1L1, Cos-1
cells were lysed and 1mg of lysate (1µg/µl) was incubated with either 5µg 1L1-CT, 5µg
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AFAP1 antibody F1 or 5µg control rabbit IgG and the immunoprecipitate resolved by
SDS-PAGE (Figure 3B).

Upon western blot analysis with 1L1-CT, it was apparent

that the 1L1-CT antibody specifically immunoprecipitated a protein with a Mr of 115kDa,
consistent with the predicted Mr for AFAP1L1 (Figure 3B, left panel, middle lane); while
the AFAP1 antibody F1 did not immunoprecipitate a protein of this Mr (Figure 3B, left
panel, right lane) that could be detected by the 1L1-CT antibody. To test the specificity
of F1 antibody for endogenous AFAP1, Cos-1 cells were lysed and 1.5mg (1µg/µl) of
lysate was incubated with rabbit IgG, F1 or 1L1-CT. F1 antibody specifically
immunoprecipitated the expected AFAP1 protein with an Mr of 110 kD a (Figure 3B,
right panel, right lane) and did not immunoprecipitate AFAP1L1 (Figure 3B, right panel,
middle lane), indicating that these two antibodies are specific for endogenous protein. To
determine if 1L1-CT and F1 antibodies can specifically recognize overexpressed protein,
plasmids encoding GFP-AFAP1L1 and GFP-AFAP1 were transfected into Cos-1 cells.
Western blot analysis of these cells (Figure 3C) showed that 1L1-CT antibody detected
overexpressed GFP-AFAP1L1 but not overexpressed GFP-AFAP1 (Figure 3C, left
panel). AFAP1 antibody F1 detected GFP-AFAP1 but not GFP-AFAP1L1 (Figure 3C,
middle panel). T hese data indicate that the AFAP1L1 antibody 1L1-CT and AFAP1
antibody F1 have specificity for AFAP1L1 and AFAP1, respectively. These data also
indicated that 1L1-CT antibody is specific to the AFAP1L1 of human and monkey
species. 1L1-CT antibody did not recognize any distinct band in murine cell lysates (data
not shown), because the epitope is not conserved in murine AFAP1L1 (Figure 3D).
Sigma antibodies Ab1 and Ab2 also failed to recognize AFAP1L1 in murine cell lysates.
An alignment of the peptide sequence used to create 1L1-CT against the amino acid
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sequence of human, chimpanzee, mouse and rat AFAP1L1 was shown to illustrate the
similarity of the 1L1-CT binding site across species (Figure 3D).

Immunohistochemical analysis of AFAP1L1
The ability of the 1L1-CT antibody to specifically recognize endogenous
AFAP1L1 in its native conformation by immunoprecipitation and to recognize AFAP1L1
by immunofluorescence (Supplemental Figure 1) demonstrated its usefulness for
immunohistochemistry.

To

determine

the

tissue

localization

of

AFAP1L1,

immunohistochemistry was performed on hu man breast, colon and brain tissues using
1L1-CT antibody (Figure 4). AFAP1 or AFAP1L1 tissue localizations were compared
using sequential sections of tissue immunolabeled with F1 or 1L1-CT antibodies,
respectively, in order to contrast expression patterns. In the breast, AFAP1 was found to
strongly associate with the ductal cells and also the breast microvasculature (Figure 4A
panels a, c and e). AFAP1L1 was found in the contractile myoepithelial cell layer which
surrounds the breast ducts and in the microvasculature (Figure 4A panels b, d a nd f),
similar to AFAP1. In the colon (Figure 4B), AFAP1 was found in the epithelial mucous
membrane as well as in the colonic crypts (Figure 4B panels a and g) which aid in
mucous production and production of new epithelial cells for the intestinal surface
(Sherwood, 2003). AFAP1L1 was also found in the mucous membrane and colonic
crypts (Figure 4B panels b a nd h). Both AFAP1 and AFAP1L1 are found in the
microvasculature (Figure 4B panels a-d) while AFAP1 can also be found in nerves that
pass through the lamina propria (Figure 4B panel g). T he lamina propria lies directly
beneath the epithelial cell layer and consists of connective tissue, blood vessels, nerve
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fibers and lymphatic ducts (Widmaier, 2003). The muscularis, layers of smooth muscle
which provide movement of the colon, expresses both AFAP1 and AFAP1L1 (Figure 4B
panels c-f) while AFAP1 is solely found in Auberbach’s plexus (Figure 4B panel e), the
nerves that innervate the muscle of the gut (Sherwood, 2003). While AFAP1 and
AFAP1L1 have overlapping localization in human breast and colon tissue, human brain
showed examples of differential expression patterns for these two proteins (Figure 4C).
The cerebellum is located at the base of the skull and is an important part of the motor
system. Divided into three layers, the cerebellar cortex is composed of a g ranular cell
layer consisting of small granule cells which receive input from mossy fibers and extend
into the molecular layer, the outermost portion of the cerebellar cortex which houses
stellate and basket cells. Purkinje cells are large neurons acting as t he sole output of
motor coordination from the cerebellar cortex and are found in a single layer between the
molecular and granular layers (Squire, 2008). AFAP1 is found in the microvasculature of
the brain, in the molecular layer and meningeal vessels and to a slight level around the
granule cells of the granular layer (Figure 4C panels a, c, e and g). AFAP1L1 is again
found in low levels in the microvasculature of the brain but is localized around the
Purkinje neurons and the granule cells of the granular layer (Figure 4C panels b, d, f and
h). This immunolabeling is not inside of either the Purkinje neurons or the granule cell
bodies but instead extends away from the cell body. A lthough the source of this
immunolabeling is unknown, mossy fibers and climbing fibers extend into the granule
cell layer and Purkinje cell layer respectively, synapsing onto granule and Purkinje cells
(Squire, 2008). This may provide the source of immunolabeling for AFAP1L1 away from
the granule and Purkinje cell body. Outside of the cerebellar cortex, AFAP1 and
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AFAP1L1 are both found in glial cells (Figure 4C panels o-p) but have a differential
expression pattern in the dentate nucleus (Figure 4C k-n), one of four deep cerebellar
nuclei responsible for voluntary movements of the extremities (Squire, 2008). Again,
AFAP1L1 is highly expressed away from the cell bodies within the dentate nucleus,
while

AFAP1

was

not

detected

in

this

structure.

Relative

intensities

of

immunohistochemical signal for AFAP1 and AFAP1L1 are presented in Table 1.

AFAP1L1 subcellular localization
AFAP1 is known to bind actin filaments, move to actin rich structures called
podosomes upon stimulation with the phorbol ester PDBu and also to be localized in
podosome-like

structures

termed

invadopodia

in

MDA-MB-231

cells,

while

AFAP1L2/XB130 is not known to bind actin filaments (Flynn et al., 1993; Gatesman et
al., 2004; Xu et al., 2007). Thus, we sought to determine if AFAP1L1 had the potential
to be localized with actin filaments and podosomes, similar to AFAP1 (Gatesman et al.,
2004). For this analysis, we used the rat-derived A7r5 cell line, a well established cell
model system for podosome formation (Hai et al., 2002). O verexpression of GFPAFAP1L1 alone in A7r5 cells produced two distinct phenotypes (Figure 5A). G FPAFAP1L1 expressing cells either have GFP-AFAP1L1 decorating actin stress fibers
while cortactin is found in the cytoplasm and around the cell periphery (Figure 5A panels
a-d) or both GFP-AFAP1L1 and cortactin colocalizing in punctate actin dots along the
ventral membrane (Figure 5A and Supplemental Figure 2). The adaptor protein cortactin
was used as a marker for podosome formation. Podosome formation was observed either
around the cell periphery (5A panels e-h) or scattered across the ventral membrane (5A
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panels i-l). Thus, AFAP1L1 decorates actin stress fibers and co-localizes with cortactin in
podosomes. Overexpression of AFAP1L1 induced the formation of podosomes in a small
percentage of cells.
Next, we utilized MDA-MB-435 cells to determine the subcellular localization of
endogenous AFAP1L1 based on t he high level of expression of AFAP1L1 in this cell
line. Immunolabeling of MDA-MB-435 with Sigma Ab2 (Figure 5B, panel a-c) and Ab1
(data not shown) showed a population of AFAP1L1 decorating actin stress filaments
while the rest of AFAP1L1 was detected diffusely across the cytoplasm. A similar pattern
of expression was observed for the 1L1-CT antibody in MEF cells overexpressing
untagged AFAP1L1 (Supplemental Figure 1).
To determine whether endogenous AFAP1L1 could co-localize to invadopodia,
we transiently transfected a constitutively active Src construct (Src527F) into MDA-MB435 to induce invadopodia, podosome-like structures found in cancer cells. The
overexpression of Src527F induced punctate actin- and cortactin-rich structures in these
cells (Figure 5C, b-c, f-g) accompanied by the loss of stress filaments, which were
consistent with the appearance of typical invadopodia. T he immunolabeling of
endogenous AFAP1L1 (Figure 5C, a) showed discernable association with invadopodia,
co-localizing with cortactin and actin (Figure 5C, a-d, marked with white arrow as an
example of colocalization). These data indicate that AFAP1L1, like AFAP1, is associated
with actin stress filaments and localizes to invadosomes (the collective term for
podosomes and invadopodia) at both overexpressed and endogenous levels (also see
Supplemental Figure 3) (Linder, 2009; Saltel et al., 2010).
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Quantification of podosome formation in A7r5 expressing AFAP1 or AFAP1L1
In a previous study of AFAP1, expression of GFP-AFAP1 was sufficient to
induce podosomes in a portion of the A7r5 cells in which it was expressed (Dorfleutner et
al., 2008). Therefore, we sought to compare the potency of the GFP-AFAP1 and GFPAFAP1L1 constructs to induce podosomes using a dose response analysis. A7r5 cells
were transfected with equal amounts of total plasmid cDNA containing the indicated
amount of GFP-AFAP1 or GFP-AFAP1L1 plasmid (Figure 6). Transfection of equal
amounts of plasmid (combination of empty vector and GFP-AFAP) ensured that
transfection efficiencies were identical for each dose of plasmid. Forty eight hours after
transfection, the cells expressing either GFP-AFAP1 or GFP-AFAP1L1 were assessed for
podosome formation. Reduction of plasmid DNA resulted in a corresponding reduction
of GFP-AFAP1 and GFP-AFAP1L1 expression (Figure 6A). The reduction of expression
was also reflected in a r eduction in the percent of cells exhibiting podosomes (Figure
6B). When 1µg and 0.35 µg of plasmid DNA was used, the percentage of GFP-AFAP1
expressing cells exhibiting podosomes dropped from 11.4% to 7.1% while in
GFPAFAP1L1 expressers the change was more modest, 9.2% to 8.0%. At 0.1 µg of DNA
the number of podosome cells appeared to increase. This increase resulted from the
variability in expression levels among cells and the dimness of the low expressers which
made these cells difficult to detect by immunofluorescence. O verall, this experiment
demonstrated that under identical conditions of transfection, expression, processing and
immunofluorescence analysis, expression of GFP-AFAP1 and GFP-AFAP1L1 induce
podosome formation in A7r5 cells.
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Interaction of AFAP1L1 and cortactin
To determine if AFAP1L1 might have a differential ability to interact with
proteins relative to AFAP1, we screened SH3 domains from various proteins for the
binding to AFAP1L1. A Panomics array screening of SH3 domains showed that the SH3
domain of cortactin and the SH3 binding motif of AFAP1L1 had a strong potential to
interact (data not shown). To confirm these screening results, GST fusion proteins
containing the cortactin SH3 domain and the Src SH3 domain were incubated with 1mg
of cell lysate containing either overexpressed GFP-AFAP1L1 or GFP-AFAP1.

As

expected from the known binding of AFAP1 to Src, AFAP1 showed a strong interaction
with the Src SH3 domain with a 14-fold increase in the ratio of AFAP1 pulled down by
GST-Src SH3 as compared to GST control while precipitation by the cortactin SH3
domain was undetectable (Figure 7A). However, AFAP1L1 was more efficiently
precipitated by GST-SH3-cortactin than GST-SH3-Src with an approximately 9-fold
increase in the ratio of AFAP1L1 pulled down by GST-cortactin SH3 compared to GST
control (Figure 7B). These data indicate that the SH3 binding motifs of AFAP1 and
AFAP1L1 have the ability to interact with different affinities toward different SH3
binding partners. To further examine the potential binding of AFAP1L1 with cortactin,
we transiently overexpressed either GFP-AFAP1 or GFP-AFAP1L1 with cortactin in
293T cells. G FP-AFAP1L1 co-immunoprecipitated with cortactin (Figure 7C, upper
panel) more efficiently than did GFP-AFAP1 (the amounts of immunoprecipitated GFP
proteins were relatively equal Figure 7C, lower panel). Conversely, cortactin specifically
co-immunoprecipitated GFP-AFAP1L1, but not GFP-AFAP1 (Figure 7D, upper panel).
These data suggest that cortactin can form a complex with AFAP1L1, but is either unable
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to form a complex with AFAP1 or its ability to bind in a complex with AFAP1 is below
detection limits. This interaction is hypothesized to occur through SH3 interactions based
on our affinity precipitations with the SH3 domains and suggests a unique function for
AFAP1L1 that is distinct from AFAP1.
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DISCUSSION
AFAP family amino acid sequence
AFAP1 is a well-studied cSrc binding partner and actin filament cross-linking
protein that is the prototype member of what is predicted to be a family of three proteins
which also includes AFAP1L1 and AFAP1L2/XB130. There are no published reports on
AFAP1L1 and the goal of this study was to analyze some of the similarities and
differences between AFAP1 and AFAP1L1 in order to understand what functions
AFAP1L1 may have relative to AFAP1. The AFAP family consists of three family
members that share similarity in protein binding motifs including both PH domains.
Analysis of the overall amino acid structure of previously described AFAP1 and newly
presented AFAP1L1 show 44% identity and 71% similarity between the two proteins.
AFAP1 contains two juxtaposed SH3 binding motifs in its N-terminus, PPQMPLPEIP
and PPDSGPPPLP, of which the first is necessary for efficient cSrc binding. Mutation of
a necessary proline, Pro71, to an alanine, Ala71, in the AFAP1 SH3 binding motif
prevented cSrc binding (Guappone and Flynn, 1997). While AFAP1L1 only contains one
putative SH3 binding motif, DLPPPLPNKP, this sequence is not consistent with the
conserved consensus cSrc SH3 binding motif. Rather, the AFAP1L1 SH3 binding motif
more closely resembles that of a cortactin SH3 domain binding site, which preferentially
binds a +PPΨPXKPXWL motif where + is a basic residue, Ψ is an aliphatic residue, and
X is any amino acid (Sparks et al., 1996).
In addition to the SH3 binding motif, cSrc also has the ability to phosphorylate
and bind two SH2 binding motifs in AFAP1. In AFAP1, an N-terminal YYEEA sequence
adjacent to the SH3 binding motifs and a C-terminal YDYI sequence have been shown to
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be phosphorylated by c Src (Guappone et al., 1998). A FAP1L1 contains the conserved
YYEEA sequence in its N-terminus adjacent to the SH3 binding motif and a similar
YDYV sequence in its C-terminus. Although we did not analyze AFAP1L1 as a possible
target for phosphorylation by tyrosine kinases, these similar SH2 binding motifs may be
potential targets for tyrosine phosphorylation. A ScanSite motif scan comparison between
AFAP1 and AFAP1L1 predicts these sites for tyrosine phosphorylation and also predicts
similar sites for serine/threonine phosphorylation as well (data not shown). The amino
acid sequences between the PH1 and PH2 domains of AFAP1 and AFAP1L1 are rich in
serine and threonine residues that are predicted to be sites of serine and threonine
phosphorylation. In particular, AFAP1 is known to be phosphorylated on serine 277 by
PKCα and this phosphorylation is important for podosome turnover (Dorfleutner et al.,
2008). Although we have not validated AFAP1L1 as a PKC substrate, AFAP1L1 also
contains a similar PKCα phosphorylation site.
The conservation of domain structure, overall sequence similarity and high
similarity of sequence between the two PH domains indicates that AFAP1, AFAP1L1
and AFAP1L2/XB130 are members of a family of proteins, referred to here and in
genome databases as the AFAP family. The amino terminal PH1 domain of AFAP1 has
been known to function in intra-molecular regulation of AFAP1 (Qian et al., 2004). In
addition, the PH1 domain is a binding partner for PKCα and phospholipids (Cunnick and
Flynn, manuscript in preparation) (Qian et al., 2002).
The actin binding domain within AFAP1 is necessary and sufficient for the
binding of AFAP1 to actin filaments (Qian et al., 2000). Comparison of the AFAP1 actin
binding domain sequence to the corresponding sequence in AFAP1L1 does not indicate a
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high level of similarity although our data indicates that AFAP1L1 also has the ability to
associate with actin filaments. We predict that the sequences within the C-terminus of
AFAP1L1 that are similar to the known actin filament binding domain in AFAP1 may
promote actin filament association, however, as the binding affinity of AFAP1 for actin is
relatively low, we predict that the putative actin binding domain of AFAP1L1 may have a
lower affinity for actin. S tudies are underway to determine the mechanism of actin
filament binding and if the leucine zipper/coiled-coil motif adjacent to the putative actin
filament binding domain can regulate self-association and actin filament cross-linking,
similar to AFAP1 (Qian et al., 2004).

AFAP1L1 western blot analysis
AFAP1L1 can be found in human breast and breast cancer cell lines, as well as
the Cos-1 monkey cell line. The predicted molecular weight of AFAP1L1 is 85kDa, but it
is detected as a single protein band by w estern blot analysis with a Mr of 115 kD a,
Similarly, AFAP1 has a molecular weight of 82 kDa but is detected on western blot as a
110 kDa protein.. F or AFAP1, it was hypothesized that the difference in molecular
weight and Mr might be due to overall charge and the shape of the protein, which may
also apply to AFAP1L1. T he AFAP1L1 specific antibodies, 1L1-CT, Ab1 and Ab2
antibodies (latter two from Sigma), have the ability to specifically detect AFAP1L1 but
not AFAP1 by western blot. In our hands, all three antibodies could detect AFAP1L1 by
immunoprecipitation, immunofluorescence and western blot; however, the 1L1-CT
antibody was determined to be less efficient in detecting denatured AFAP1L1 by western
blot, indicating that this antibody may preferentially recognize a conformational epitope
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and be less efficient in detecting denatured AFAP1L1, relative to Ab1 and Ab2, which
appear to detect denatured AFAP1L1 efficiently. Conversely, the anti-AFAP1 antibody
F1 is able to specifically immunoprecipitate AFAP1 but does not immunoprecipitate
AFAP1L1.

AFAP1L1 tissue expression pattern
AFAP1 and AFAP1L1 have similar distribution in breast and colon tissue with
the exception that AFAP1 can be found in the nerves that innervate the gut while
AFAP1L1 was not detected there. While immunolabeling of the brain shows similarities
between AFAP1 and AFAP1L1 in the granule cell layer and glial cells, differences occur
in the brain where AFAP1L1 is found in the Purkinje cell layer and the dentate nucleus,
while AFAP1 was not detected here. The dentate nucleus is known to be involved in
motor coordination; alterations in the neuronal composition of signaling to and from the
dentate have been implicated in diseases with motor dysfunction such as A lzheimer’s
disease, autism spectrum disorders and Pick’s disease (Braak et al., 1999; Fukutani et al.,
1999; Lotspeich and Ciaranello, 1993). Consistent immunolabeling of AFAP1L1
between the granule cell layer, Purkinje layer and dentate nucleus indicates that the
AFAP1L1 immunohistochemical signal is not in the cell bodies of the granule cells,
Purkinje neurons or cells of the dentate nucleus, but is instead found extending away
from the cell body. Thus, we hypothesize that AFAP1L1 may be playing a role in either
the axon terminals of afferent neurons or the dendritic spines of efferent neurons in these
areas, both of which have a dynamic actin cytoskeleton and are rich in proteins involved
in cytoskeletal remodeling, such as cortactin (Hering and Sheng, 2003). As we see t he
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most marked difference between AFAP1 and AFAP1L1 expression in the dentate
nucleus, we speculate that AFAP1L1 may play a role in the association of proteins
involving signaling to or from the dentate nucleus. Notably, podosomes have recently
been shown to be involved in maturation of the neuromuscular junction and a similar
mechanism may be involved in neuron-neuron interactions (Proszynski et al., 2009).

AFAP1L1 subcellular localization and podosome formation
GFP-AFAP1L1 and endogenous AFAP1L1 colocalized with actin filaments and
invadosomes similar to the subcellular localization pattern of AFAP1. Overexpression of
GFP-AFAP1L1 induced podosome formation in the absence of extracellular signals (e.g.,
phorbol ester). A direct comparison of the ability of GFP-AFAP1 and GFP-AFAP1L1 to
induce podosomes demonstrated that both proteins had similar capacities to induce these
structures. Thus, like AFAP1, AFAP1L1 may have the ability to interact with proteins
involved in podosome formation such as f-actin, cSrc or possibly cortactin. A panomics
array of various SH3 domains was scanned for the ability to bind the AFAP1L1 SH3
binding motif, and these data indicated that the AFAP1L1 SH3 binding motif and the
cortactin SH3 domain showed the strongest interaction among those SH3 domains
surveyed (data not shown). GST fusion proteins containing either the cortactin SH3
domain or Src SH3 domain show that AFAP1 interacted with GST-Src SH3 much better
than with GST-cortactin SH3. However, with AFAP1L1 the reverse was true. AFAP1L1
interacted with GST-cortactin-SH3 better than GST-Src SH3. T hese data indicate that
the SH3 binding motifs of AFAP1 and AFAP1L1 likely have different affinities for
different SH3 binding partners. The co-immunoprecipitation of cortactin with full length
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AFAP1L1 and not with AFAP1 further supports the possibility of differential
characteristics of these two proteins and also suggests the interaction of AFAP1L1 with
cortactin as a p ossible mechanism of AFAP1L1 localization to invadosomes.
Investigations are underway to determine if the SH3 binding motif of AFAP1L1 mediates
the binding of AFAP1L1 to cortactin and to determine the functional relevance of this
interaction.

Conclusion
The goal of this study was to characterize the AFAP family member AFAP1L1
and to determine if it had functions common and distinct to AFAP1. Our data indicate
that AFAP1L1 has strong similarity and conservation of domain structure with AFAP1.
Also similar to AFAP1, it has an ability to associate with actin filaments, can be found in
actin-rich structures such as invadosomes, and is capable of independently inducing
podosomes upon ove rexpression. AFAP1L1 shares expression patterns with AFAP1 in
several tissues. However, AFAP1L1 did display some unique properties. For example,
unlike AFAP1, AFAP1L1 was found in the dentate nucleus and its expression appeared
to occur along neuronal processes. Interestingly, it is in these processes that podosomes
are hypothesized to be associated with synaptic connections (Proszynski et al., 2009), and
these same connections in the dentate nucleus contain cortactin binding proteins (Hering
and Sheng, 2003). As podosomes play a role in enabling cells to traverse and cross tissue
barriers, we hypothesize that AFAP1L1 may play a unique role in the innervation of the
dentate nucleus. Although it may have a weak affinity, AFAP1L1 is not predicted to be a
strong binding partner for cSrc through SH3 interactions; however, it does interact with
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cortactin. As a potential binding partner for actin filaments and cortactin, AFAP1L1 may
associate with podosomes via interactions with these proteins and regulate podosome
formation in cells, including neurons within the dentate nucleus.
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Table 1
AFAP1 and AFAP1L1 immunohistochemical signal in human tissue
AFAP1

AFAP1L1

Breast Lobule

++++

+

Breast Duct

++++

+

Breast

+++

+

Colon Muscularis

++

+++

Colon Mucosa

+++

+++

Colon Lamina Propria

-

-

Cerebellar Cortex

+

+

Cerebellar Granule Cell

++

++++

+

++++

Meningeal Vessels

++++

+

Dentate Nucleus

-

++++

Glial Cells

++

+++

Microvasculature

Layer
Cerebellar Purkinje
Layer

Table 1: AFAP1 and AFAP1L1 immunohistochemical signal intensity in human tissue
The intensity of AFAP1 staining in human breast, colon and brain tissues was analyzed. Staining
in breast ducts was scored as ++++ for highest level of intensity. Staining in the dentate nucleus
was scored as – for no level of staining. Other tissues labeled for AFAP1 were compared using
this scale. AFAP1L1 staining intensity was analyzed in a similar manner, designating AFAP1L1
staining in the dentate nucleus as ++++ and lamina propria as – for no level of staining. Other
tissues labeled for AFAP1L1 were compared using this scale.
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Figure 1: AFAP1L1 sequence
AFAP1L1 coding sequence was divided into codons with corresponding amino acid sequence.
Start and stop codons are indicated in bold type.
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Figure 2B
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Figure 2: AFAP family members share both sequence and domain similarity
(A) AFAP1, AFAP1L1 and AFAP1L2 amino acid sequences were compared using ClustalW2
alignment (Larkin et al., 2007). Consensus sequence between all three family members is labeled
as consensus. Intron/exon boundaries are marked by red letters. Predicted SH3 binding motifs
are highlighted in green, predicted SH2 binding motifs in pink, predicted PH domains in light
blue, predicted Substrate Domain (SD) in yellow, predicted leucine zipper (AFAP1, AFAP1L1)
and coiled coil (AFAP1L2) in red and predicted actin binding domain in dark blue. The
AFAP1L1 peptide sequence used to create 1L1-CT antibody is underlined.
(B) Modular domain organization of AFAP family members was compared. SH3bm = SH3
binding motif, SH2bm = SH2 binding motif, PH1 = pleckstrin homology domain 1, PH2 =
pleckstrin homology domain 2, SD = serine/threonine rich substrate domain, Lzip = leucine
zipper, ABD = actin binding domain. Sequences that do not correlate with an identified type of
modular domain or motif are labeled “A, B, C, D or E”.
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Figure 3: A novel antibody specifically recognizes AFAP1L1
(A) Cell lines were lysed in 2X SDS buffer, resolved by 8% SDS-PAGE and transferred to
PVDF. The Sigma antibody Ab2 specifically recognized a protein band of 115 kDa. Bands
identified as AFAP1L1 and recognized by the Ab2 antibody (top panel) are indicated by an
arrow. Gamma tubulin was used as a loading control. Not shown, but in an adjacent lane, was a
lysate prepared from 293T cells transfected with untagged AFAP1L1 which was used in
identifying the band corresponding to AFAP1L1.
(B) Endogenous AFAP1L1 and AFAP1 were specifically immunoprecipitated from Cos-1 cells
using 5µg 1L1-CT and F1 polyclonal antibodies respectively and the resolved proteins detected
with 1L1-CT (left panel) or AFAP1 monoclonal antibodies (BD Transduction, right panel).
Rabbit IgG antibody was used as a control. Note the differences in the molecular weight markers
for each western.
(C) GFP-AFAP1L1 and GFP-AFAP1 were overexpressed in Cos-1 cells and lysed in 2X SDS
buffer. Lysates were resolved by 8% SDS-PAGE, transferred to PVDF membrane and
immunoblotted with either AFAP1L1 (1L1-CT) or AFAP1 (F1) antibody.

GFP (top right

western) and β-actin (bottom westerns) were used as loading controls.
(D) The peptide sequence used to create antibody 1L1-CT was compared to analogous sequences
in human, chimpanzee, mouse and rat to show similarity between antibody binding sites.

98

Figure 4
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M

Figure 4: Immunohistochemical analysis of AFAP1L1 shows differential expression from
AFAP1 in human tissue
Paraffin-embedded human breast (A), colon (B) and brain (C) tissues were analyzed for AFAP1
and AFAP1L1 localization using F1 and 1L1-CT antibodies respectively. Breast regions include
breast ducts (4A panels a-d), breast lobules (4A panels a,b) and microvasculature (4A panels e,f).
Colon regions include the mucosa (4B panels a,b,g,h), lamina propria (4B panels a-d, g,h) and
muscularis (4B panels a-f). Brain regions include the cerebellar cortex (4C panels a-j), dentate
nucleus (4C panels k-n) and glial cells (4C panels o,p). AFAP1L1 is designated by long thin
arrows while AFAP1 is designated by arrowheads.
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Figure 5
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Figure 5: Subcellular localization of GFP-AFAP1L1 shows association with actin and
invadosomes
(A) A7r5 cells transiently expressing GFP-AFAP1L1 were plated onto fibronectin-coated
coverslips and immunolabeled for cortactin (Millipore). Actin was visualized with TRITCphalloidin (Sigma). Representative images of cells with well-formed stress fibers or podosome
formation are shown.
(B) MDA-MB-435 cells were plated on fibronectin coated coverslips and immunolabeled for
endogenous AFAP1L1 (Sigma Ab2, panel a-c). Rabbit IgG was used as a control (panel d-f) and
actin was visualized with AlexaFluor labeled phalloidin. Epifluorescence images of
representative cells are shown.
(C) MDA-MB-435 cells were transfected with Src 527F construct, plated onto fibronectin coated
coverslips and immunolabeled for AFAP1L1 (Sigma Ab1, panel a-d). Rabbit IgG was used as
control antisera for AFAP1L1 antibody (panel e-h). Cortactin was immunolabeled with
monoclonal anti-cortactin antibodies (4F11, Millipore) and actin was visualized by AlexaFluor
labeled phalloidin (panel c, g). Examples of AFAP1L1 co-localizing to invadopodia, actin and
cortactin rich punctate structures are marked with white arrows.
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Figure 6

Figure 6: Podosome formation in A7r5 transfected with GFP-AFAP1 or GFPAFAP1L1 plasmids.
A7r5 cells were transfected with the indicated amounts of plasmids encoding either GFPAFAP1 or GFP-AFAP1L1 (in combination with pcDNA3.1) to bring the total amount of
plasmid DNA to 1 µg for each transfection. Twenty four hours post-transfection, the cells
were transferred to fibronectin-coated coverslips. Forty-eight hours after transfection,
cells were processed for immunofluorescence analysis or used to prepare whole cell SDS
lysates. (A) Equal amounts of SDS lysates were resolved by 8% SDS-PAGE and then
transferred to PVDF membranes and subsequently probed with an antiserum that
recognizes GFP. (B) Cells expressing GFP-AFAP1 or GFP-AFAP1L1 were assessed for
podosome formation and the percentage of cells exhibiting podosomes for each
transfection was calculated. 150 to 300 cells were counted for each transfection. Panel A
and B represents one experiment out of two independently performed experiments.
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Figure 7: AFAP1L1 interacts with cortactin SH3 domain
(A) 1mg of lysate from 293T cells transiently expressing GFP-AFAP1 was incubated with 50µg
of GST, GST-Src-SH3 domain or GST-cortactin-SH3 domain bound fusion protein to
glutathione Sepharose 4B beads and probed for GFP through western blot analysis (upper panel).
The lower panel represents a GelCode Blue Stain (ThermoScientific) of GST or GST fusion
protein. A graph representing the ratio of AFAP1 pulled down by each GST fusion protein
compared to GST control using scanning densitometry is shown.
(B) 1mg of lysate from 293T cells transiently expressing GFP-AFAP1L1 was incubated with
50µg of GST, GST-Src-SH3 domain or GST-cortactin-SH3 domain bound to glutathione
Sepharose 4B beads and probed for GFP through western blot analysis (upper panel). The lower
panel represents a GelCode Blue Stain (ThermoScientific) of GST or GST fusion protein. A
graph representing the ratio of AFAP1L1 pulled down by each GST fusion protein compared to
GST control using scanning densitometry is shown.
(C) 293T transiently expressing cortactin with either GFP-AFAP1 or GFP-AFAP1L1 were
immunoprecipitated with anti-GFP antibody, probed for cortactin through western blot analysis
(upper panel) and then re-probed for GFP tagged proteins (lower panel).
(D) 293T transiently expressing cortactin with either GFP-AFAP1 or GFP-AFAP1L1 were
immunoprecipitated with anti-cortactin antibody, probed for GFP tagged proteins through
western blot analysis (upper panel) and then re-probed for cortactin (lower panel).

105

Supplemental Figure 1

Supplemental Figure 1: AFAP1L1 overexpression in MEF cells
Mouse embryo fibroblast cells were transfected with 5 µg of either GFP-AFAP1L1 or
untagged AFAP1L1 (in pcDNA3.1). Untagged AFAP1L1 was probed using 1L1-CT
antibody (1:200). GFP-AFAP1L1 localized to stress filaments and cortical actin (panels
a-c). Untagged AFAP1L1 also localized to stress filaments and showed some diffuse
cytoplasmic staining (panels d-f). Actin was visualized by TRITC-phalloidin
(Invitrogen). Rabbit IgG was used as a control (panels g-i).
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Supplemental Figure 2

Supplemental Figure 2: Colocalization of GFP-AFAP1L1 and cortactin
A7r5 cells transiently expressing GFP-AFAP1L1 were plated onto fibronectin-coated
coverslips and immunolabeled for cortactin (Millipore). Representative images of cells
with well-formed stress fibers (panels a-c), podosomes around the periphery of the cell
(panels d-f) or podosomes throughout the cell (panels g-i) are presented showing
colocalization of GFP-AFAP1L1 and cortactin in podosomes.
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Supplemental Figure 3

Supplemental Figure 3: Overexpression of dsRed-AFAP1 and GFP-AFAP1L1 in
A7r5 cells
A7r5 cells transiently expressing dsRed-AFAP1 and GFP-AFAP1L1 were plated onto
fibronectin coated coverslips. Actin was visualized by BODIPY-650/665 (Invitrogen).
Representative cells with well formed stress fibers (panels a-d) and podosome formation
(panels e-h) show colocalization of dsRed-AFAP1 and GFP-AFAP1L1 on both stress
fibers and in podosomes.
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I. A panomics screen using the AFAP1L1 SH3 binding motif identified potential
AFAP1L1 binding partners
A TranSignal SH3 Domain Array 1 of recombinant binding sites of SH3 domain
containing proteins spotted onto a membrane was obtained from Panomics (Affymetrix)
to probe for potential SH3 domain binding partners of the AFAP1L1 SH3 binding motif
(Figure 1A). A biotinylated peptide of the AFAP1L1 binding motif (biotinADLPPPLPNKPPE) was synthesized by EZBiolab Custom Peptide Service so as to
probe the TranSignal SH3 Domain Array 1 for binding partners. 1mg of biotinconjugated peptide was brought up in 1ml of sterile water so as to produce a peptide
solution of 1mg/ml. Peptide solution was diluted to 0.1µg/µl and 15µl (1.5µg total) was
incubated with 15µl of 1.25µg/µl streptavidin-horseradish peroxidase (HRP) conjugate
for 30 minutes by rocking at 4°C. Streptavidin was used to bind to the biotin linker of the
AFAP1L1 peptide so as to create an HRP-linked AFAP1L1 binding motif peptide. The
peptide solution was then placed into 5ml of 3% bovine serum albumin (BSA) in TBST
and kept at 4°C.
The SH3 Domain Array membranes were incubated in 5% powdered milk
dissolved in TBST to block overnight at 4°C, washed for 30 minutes with TBST and
incubated for two hours in 3% BSA/TBST. The membranes were then incubated with
either 10µg or 15µg of peptide solution overnight at 4°C. After washing for 30 minutes in
TBST, the membranes were developed using Pierce ECL Western Blotting Substrate.
Five duplicate SH3 domain spots giving the strongest signal with biotinylated
AFAP1L1 SH3 binding motif were considered for potential AFAP1L1 binding (Figure
1B).

110

Spectrin alpha chain (non-erythrocytic)
Spectrin alpha chain (alpha-II spectrin/SPTAN1) is a member of a family of
scaffolding proteins that stabilize the plasma membrane and is involved in various cell
processes such as cell growth and differentiation, vesicular trafficking and
neurotransmitter release, among others. It has also been shown to be involved in DNA
repair (McMahon et al., 2009). Alpha-II spectrin is a rod-like protein of 2,472 amino
acids that heterodimerizes with beta-spectrin subunits and contains 23 spectrin repeats,
three EF-hand domains and two potential calcium binding domains (2010; Jain et al.,
2009). The SH3 domain is located in the central portion of the protein and has been
shown to bind both cSrc and low molecular weight protein-tyrosine phosphatase isoform
A (Nedrelow et al., 2003; Nicolas et al., 2002).

Spectrin alpha chain (erythrocytic)
Spectrin alpha chain erythrocyte (SPTA1) is a 2,419 amino acid protein that
contains 21 spectrin repeats, three EF-hand domains, two potential calcium binding
domain and a central SH3 domain (2010; Jain et al., 2009). Like SPTAN1 in nonerythrocytic cells, SPTA1 provides structural support to the plasma membrane of the
erythrocyte by heterodimerizing with beta-spectrin subunits and providing a scaffold for
other cytoskeletal proteins (Chakrabarti et al., 2006). The SH3 domain of SPTA1 has
been shown to have a possible interaction with Fas ligand (Voss et al., 2009).
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Avian sarcoma virus CT10 oncogene homolog, domain #2
Avian sarcoma virus CT-10 oncogene homolog (Crk) is a 304 amino acid protein
that acts as an adaptor molecule. Crk exists in two isoforms, Crk-I and Crk-II which have
distinct roles in the cell. Crk-I contains an SH2 domain and one SH3 domain while Crk-II
contains one SH2 domain, two SH3 domains and multiple sites for tyrosine, serine and
threonine phosphorylation (2010; Gelkop et al., 2003; Jain et al., 2009). Biotinylated
AFAP1L1 binding motif had the ability to interact with the C-terminal SH3 domain of
Crk-II. While the N-terminal SH3 domain of Crk-II has multiple known binding partners,
the exact binding function of the N-terminal SH3 domain is still unknown although it has
been shown to be involved in the activation of Abl kinase (Gelkop et al., 2003; Reichman
et al., 2005). The N-terminal SH3 domain of Crk-II was not available on the TranSignal
SH3 Domain Array 1.

Cortactin
Cortactin (CTTN) is a 550 amino acid rod-shaped protein involved in signaling
processes such as cell adhesion, migration and invasion and plays an important role by
stabilizing branching points of the actin cytoskeleton. Cortactin consists of an N-terminal
acidic domain, six and one half tandem cortactin repeats of which the fourth repeat is
necessary for actin binding, an α-helical domain, a region rich in prolines, tyrosines and
serines and a C-terminal SH3 domain. The SH3 domain of cortactin is known to interact
with WASp interacting protein (WIP), neural Wiskott-Aldrich syndrome protein (NWASp), myosin light chain kinase (MLCK), and dynamin-2 (Ammer and Weed, 2008).
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Post-synaptic density protein 95
Post-synaptic density protein 95 (PSD-95) is a 724 amino acid scaffolding protein
found in the post-synaptic density, a dense area in the postsynaptic region of a neuron
rich in proteins involved with the cytoskeleton and cell adhesion such as adaptor proteins,
signaling kinases, phosphatases, membrane-bound receptors and G-proteins (Boeckers,
2006). PSD-95 consists of three PDZ domains, an SH3 domain, a guanylate kinase-like
domain and multiple sites for serine and tyrosine phosphorylation (2010; Jain et al.,
2009). PSD-95 is a major component of the post synaptic density and has multiple roles
such as stabilizing membrane protein localization and mediating synaptic plasticity (Han
and Kim, 2008). PSD-95 has been shown to interact with the Src family kinases Src, Lyn
and Yes, however the SH3 domain of PSD-95 does not appear to have typical SH3
binding ability and it remains to be seen if it is the SH3 domain of PSD-95 that allows
interaction with SFK (Kalia and Salter, 2003).
While the exact function of AFAP1L1 is unknown, due to its similarity with
family member AFAP1, we hypothesized that AFAP1L1 would also have a role in actin
dynamics. It is interesting that the results of the panomics screen resulted in proteins that
have direct roles in the regulation of the actin cytoskeleton and this may strengthen the
hypothesis of a role for AFAP1L1 with the actin cytoskeleton. Two SH3 binding domains
had the strongest reaction with the AFAP1L1 binding motif: cortactin and PSD-95.
Although the results from a panomics array can suggest possible protein-protein
interactions, the interaction of SH3 domain peptides with the AFAP1L1 SH3 binding
motif peptide could produce artificial results due to such forced interactions. Due to its
accessibility and previous data results showing colocalization of AFAP1L1 and cortactin

113

in cells, we chose to determine if AFAP1L1 and cortactin were true binding partners in
our AFAP1L1 characterization studies.

II. Postsynaptic Density Protein 95
The postsynaptic density (PSD) is an electron-dense portion of a neuronal synapse
in which multiple classes of proteins such as cell-adhesion proteins, cytoskeletal proteins,
scaffolding and adaptor proteins, membrane-bound receptors and channels, G-proteins
and modulators and signaling molecules can be found. PSDs can be found on the
dendritic shaft or at the tip of a dendritic spine and lie just below the membrane of
glutamatergic synapses (Boeckers, 2006). Glutamatergic synapses are excitatory synapses
that can contain any of five glutamate transporters, GLAST, GLT-1, EAAC1, EAAT4
and EAAT5, which are differentially expressed throughout the central nervous system
(Tanaka, 2000). As an example of a glutamatergic synapse, Purkinje cells are the largest
neurons in the brain and are found in a single layer between the molecular and granular
layers of the cerebellum. While the output from Purkinje cells is inhibitory, the major
input to a Purkinje neuron is excitatory. It is thought that a Purkinje cell refines the
multitude of excitatory pulses it receives into one major inhibitory stimulus sent to the
deep cerebellar nuclei which can control motor output. Purkinje cells are contacted in two
ways by excitatory synapses. Parallel fibers are projections of mossy fibers from the brain
stem and spinal cord which pass through the granular cell layer and create thousands of
weak excitatory synapses onto Purkinje cells. The major input of excitatory stimulus
applied to a Purkinje cell is through projections from the brain stem called climbing
fibers. Each Purkinje cell is innervated by a single climbing fiber which wraps itself
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around the body of the Purkinje cell and thus creates multiple signaling sites. Basket and
stellate cells of the molecular layer which surround the Purkinje cell are thought to relay
weak inhibitory signals; however the major input into a Purkinje cell is through
excitatory synapses. It is at these excitatory glutamatergic synapses on Purkinje cells that
four of the five glutamate transporters are found with EAAT4 being found in the highest
concentration in dendritic spines (Takayasu et al., 2009).
Correct regulation of glutamate receptors and subsequent signaling in the PSD is
essential and is highly regulated by PSD-95/DLG/ZO-1 (PDZ) domain containing
proteins. PSD-95 (SAP90) is a member of the membrane-associated guanylate kinase
(MAGUK) family and is considered to be the best characterized and prototype MAGUK
family member in the PSD (Boeckers, 2006). PSD-95 is an adaptor protein that consists
of three PDZ domains, an SH3 domain and a guanylate kinase-like domain (Han and
Kim, 2008). It is through these domains that PSD-95 has the ability to bind to other PSD95 proteins to form a scaffold, traffic proteins and receptors to the synapse and link
receptors at the excitatory synapse to the underlying actin cytoskeleton of the dendritic
spine so as to regulate synaptic plasticity and signaling (Boeckers, 2006). While some
MAGUK proteins are expressed in early development, PSD-95 is expressed
predominantly in later stages (Kim and Sheng, 2004).
PSD-95 is positioned at the synaptic membrane and functions to tether N-methyl
D-aspartate (NMDA) receptors and other transmembrane receptors such as ADAM22,
neuroligin 1 and synaptic-like adhesion molecule (SALM) to the cellular membrane by
interaction with their cytoplasmic tails (Boeckers, 2006; Han and Kim, 2008). It
additionally interacts with other intracellular PSD proteins such as A-kinase anchor
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protein 79 (AKAP79), spine associated Rap-Gap (SPAR) and synaptic Ras GTPaseactivating protein (SynGAP) by virtue of its adaptor domains to regulate their localization
to the synaptic membrane (Boeckers, 2006). These proteins link PSD-95 into a signaling
complex that ties it to the underlying actin cytoskeleton. PSD-95 has been shown to
directly bind the Src family kinases Src, Lyn and Yes which are found in the PSD (Kalia
and Salter, 2003). As signaling to NMDA receptors has been shown to play a role in
synaptic plasticity, it is possible that PSD-95 may link together signals from the NMDA
receptor to Src family kinases and thus result in alterations of the underlying cytoskeleton
to affect dendritic spine morphogenesis. The alteration in morphology of dendritic spines
regulated by the actin cytoskeleton is crucial for higher brain functions such as learning
and memory (Sekino et al., 2007).
While there are many other important proteins in the postsynaptic density,
cortactin in particular for its role in actin rearrangement and dendritic spine
morphogenesis, PSD-95 plays a central role in linking synaptic signaling to cell
morphology (Sekino et al., 2007). Due to the high level of actin dynamics in the
postsynaptic density, it is conceivable that AFAP1L1 could play a role in the
postsynaptic density as it is a cortactin binding partner and is hypothesized to play a role
in actin rearrangement.

III. Differential immunohistochemical staining of AFAP1L1 in human brain
The dentate nucleus is one of four grey matter structures (dentate nucleus,
vestibular nucleus, fastigial nucleus and globose/emboliform nucleus) found deep within
the white matter of the cerebellum (Squire, 2008). Very little data exists on the functions
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of these nuclei due to their small size and inability to be rigorously tested by imaging
techniques. The dentate nucleus is the most easily identifiable deep cerebellar nuclei. A
recent study determined that activation in the dentate nucleus mainly occurs during times
of complex motor, sensorimotor and cognitive tasks such as exploratory movements,
procedural memory, emotional and cognitive functions and cognitive tasks. Notably, the
dentate nucleus was highly active in puzzle solving, planning tasks and verbal memory
(Habas, 2010).
To determine differences in tissue localization between AFAP1 and AFAP1L1,
tissues with known expression of AFAP1 were chosen for analysis. AFAP1 and a brain
specific isoform, AFAP-120, are both expressed in the embryonic brain of mouse pups
while proteins levels are decreased in adult mice except in the olfactory bulb (Clump et
al., 2003). While AFAP1 and AFAP1L1 had similar staining patterns in the cerebellum
with staining in microvasculature and around granule cells, AFAP1L1 had a distinct
pattern of staining that was found extending from the molecular layer, surrounding the
Purkinje neurons of the cerebellar cortex, in distinct locations around the granule cells
(Figure 2A) and also surrounding the neurons of the dentate nucleus (Figure 2B). This
was in contrast to AFAP1 which was not detected in these regions.
Work done by Tabakoff et al. in HXB/BXH recombinant inbred rats showed an
association of AFAP1L1 with alcohol preference and consumption (Tabakoff et al.,
2009). Rats were first exposed to 10% ethanol and then given a choice between water and
10% ethanol for seven weeks followed by removal of the brain and RNA extraction for
microarray analysis. AFAP1L1 showed a significant increase in expression in the brains
of two different strains of mice that preferred alcohol over water using two separate array

117

platforms. Tabakoff et al. hypothesized that AFAP1L1 is associated with the trafficking
of the GABAA receptor by virtue of its association with actin organization, and that
AFAP1L1 is located in the postsynaptic density in association with actin filaments and
dynamin which supports our hypothesis that AFAP1L1 may be found in this area.
The postsynaptic density, as previously described, is found just below the
membrane of the dendritic spine or dendritic shaft. Distinct from AFAP1, AFAP1L1 is
found surrounding the Purkinje neurons and neurons of the dentate nucleus while staining
appears to be excluded from the cell body. Due to its localization, it can be hypothesized
that AFAP1L1 could be found in the postsynaptic densities of these cells. Postsynaptic
densities can by isolated from brain tissue of multiple species through isolation with
Triton X-100 and surveyed by Coomassie stain and mass spectrometry or western blot
(Carlin et al., 1980; Walikonis et al., 2000). Isolation of the postsynaptic density fraction
from cerebellar tissue samples followed by SDS-PAGE analysis with AFAP1L1 specific
antibodies could provide a means to determine if AFAP1L1 is found in the postsynaptic
density.

IV. Mutating the SH3 binding motif of AFAP1L1 so as to determine specific residues
necessary for cortactin binding
A Src homology 3 (SH3) domain is a conserved protein domain of approximately
50-70 amino acids that preferentially binds to an SH3 binding motif, a poly-proline rich
region of a peptide in which there is a conserved PXXP motif. The amino acids
surrounding the PXXP motif confer specificity for the binding of particular SH3
domains. Cortactin contains an SH3 domain in the C-terminus of the protein that
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resembles that of the Src family kinases and has been shown to bind a variety of proteins
including dynamin-2, N-WASp and MLCK among others (Ammer and Weed, 2008;
Sparks et al., 1996; Weed and Parsons, 2001). AFAP1L1 has also been shown to interact
with a GST fusion protein of the cortactin SH3 domain. We have shown previously with
prototype AFAP family member AFAP1 that mutation of a key proline at amino acid 71
to an alanine (P71A) in the N-terminal SH3 binding motif decreases the ability of AFAP1
to interact with and activate cSrc (Guappone and Flynn, 1997). AFAP1L1 contains one
SH3 binding motif with an amino acid sequence of DLPP115PLP118NKP121. Prolines at
amino acids 115, 118 and 121 fall into the PXXP motif and may affect the binding ability
of AFAP1L1 to cortactin. Thus, we sought to determine if mutation of key proline
residues in the AFAP1L1 binding motif could abrogate cortactin binding.
The proline residue at amino acid 115 is encoded by a CCA codon. Mutation of
the first cytosine in the codon to a guanine (CCAàGCA) allows for only a single
nucleotide alteration which changes the encoded amino acid from a proline to an alanine.
This results in a similar non-polar amino acid so as to limit major modifications that
would affect the binding and folding of the protein. Primers used to mutate P115A are as
follows with the nucleotide mutation highlighted in yellow:
Forward 5’ CC GAC CTG CCT GCA CCG CTC CCC 3’
Reverse 3’ GGG GAG CGG TGC AGG CAG GTC GG 5’
The proline residue at amino acid 118 is encoded by a CCC codon. Mutation of
the first cytosine to a guanine results in a single amino acid from proline to alanine.
Primers used to mutate P118A are as follows with the nucleotide mutation highlighted in
yellow:
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Forward 5’ CCT CCA CCG CTC GCC AAC AAG CCT C 3’
Reverse 3’ G AGG CTT GTT GGC GAG CGG TGG AGG 5’
The proline residue at amino acid 121 is encoded by a CCT codon. Mutation of
the first cytosine to a guanine results in a single amino acid change from proline to
alanine. Primers used to mutate P121A are as follows with the nucleotide mutation
highlighted in yellow:
Forward 5’ CTC CCC AAC AAG GCT CCC CCT GAG G 3’
Reverse 3’ C CTC AGG GGG AGC CTT GTT GGG GAG 5’
Mutagenesis of P115A, P118A, and P121A, was accomplished by use of the
QuikChange Site-Directed Mutagenesis Kit from Agilent (Stratagene). GFP-tagged
AFAP1L1 was mutated so as to contain each separate P à A mutation using the
following reaction methods:
10X
Reaction
Buffer
GFP-AFAP1L1
plasmid
dNTP mix

5µl

Forward primer

125ng

Reverse primer

125ng

Pfu Ultra DNA
Polymerase
Water

1µl

10ng
1µl

To 50µl

Reaction mixtures were subjected to polymerase chain reaction in the following manner:
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Segment
1
2

Cycles
1
16

Temperature
95°C
95°C
55°C
68°C

Time
30 seconds
30 seconds
1 minute
7
minutes
(1min per kb)

PCR products were incubated at 37°C for one hour with 1µl of restriction enzyme
Dpn1 so as to digest parental DNA. Mutated PCR products were then transformed into
dH5α bacterial cells by incubation of 5µl of PCR product with 50µl of bacteria on ice for
30 minutes. Bacteria were heat shocked at 42°C for 30 seconds followed by 2 minutes on
ice. 1ml of SOC media was added and bacteria were placed on a 37°C shaker for one
hour. Bacteria were spun down, 900µl of media were removed and the bacterial pellet
was brought up in the remaining 100µl. Bacteria were plated onto LB-agar plates
containing kanamycin and grown at 37°C overnight. Resultant colonies were picked and
grown overnight in 3ml of LB media containing kanamycin while shaking at 37°C. 1.5ml
of bacterial culture was subjected to EasyPrep lysis so as to recover DNA. DNA
concentrations were read using a NanoDrop spectrophotometer (ThermoScientific) and
800ng of DNA product was sent to GeneWiz for sequencing. The primers used for
sequencing were as follows:
Forward: 5’ GTG AAC ACA GCA GAC CTC CAC 3’
Reverse: 3’ GCT CAT TGC GTC AGA GTC ATT 5’
Of the three P115A colonies chosen, two had the correct mutation and P115A #1 was
chosen for larger DNA prep (Figure 3A). Four P118A colonies were chosen of which two
had the correct mutation and P118A #1 was chosen for larger DNA prep (Figure 3B). Four
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P121A colonies were chosen for sequencing and two had the correct mutation with P121A
#2 being chosen for larger DNA prep (Figure 3C).
GFP-AFAP1L1 SH3 binding motif mutants were tested for their ability to interact
with FLAG tagged cortactin. While equal amounts of cortactin and GFP constructs were
expressed

(Figure

4,

top

panel),

immunoprecipitation

against

cortactin

and

immunoblotting against GFP showed that all AFAP1L1 SH3 binding motif mutants were
able to interact with cortactin (Figure 4, bottom panel). GFP-AFAP1 was used as a
control and, as previously shown, did not immunoprecipitate with cortactin. Reprobing
for cortactin showed that equal amounts of cortactin were pulled down in all AFAP1 and
AFAP1L1

immunoprecipitations.

The

SH3

binding

motif

of

AFAP1L1

is

DLPP115PLP118NKP121. While P115, P118 and P121 were chosen due to their localization
within a PXXP motif, it is possible that other prolines in the SH3 binding motif may play
a role in binding. To further elucidate what amino acids in the SH3 binding motif, if any,
are responsible for cortactin binding, amino acids P114, P116 or L117 could be mutated and
tested for their ability to immunoprecipitate cortactin. Also, the entire AFAP1L1 binding
motif could be deleted to determine if another region in AFAP1L1 is responsible for
cortactin binding.

V. Antibody epitopes and binding
There are currently a limited number of antibodies available for the study of
AFAP1L1. A polyclonal antibody created by ProSci Incorporated (1L1-CT) detects an
epitope in the C-terminus of AFAP1L1 that corresponds to amino acids 714-727. Two
additional polyclonal antibodies from Sigma Aldrich, Ab1 and Ab2, also recognize
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AFAP1L1. Ab1 (Sigma C-term) was created using an immunogen corresponding to
amino acids 525-659 near the N-terminal portion of AFAP1L1. Ab2 (Sigma N-term) was
created using an immunogen corresponding to amino acids 21-159 in the N-terminal
portion of AFAP1L1 (Figure 5) (Larkin et al., 2007). The immunogen used to create
Sigma N-term encompasses a unique region in the N-terminus of AFAP1L1, a proposed
SH2 binding motif and a proposed SH3 binding motif while the immunogen used for
Sigma C-term encompasses a unique region in AFAP1L1 after the PH2 domain, the
putative leucine zipper and the putative actin binding domain. The epitope recognized by
1L1-CT corresponds to a unique region in the C-terminus of AFAP1L1.
All three antibodies recognize AFAP1L1 at an approximate Mr of 115kDa via
western blot in a similar manner in a panel of cell lines with the band corresponding to
AFAP1L1 being confirmed through siRNA knockdown. However, each antibody also
picks up additional background bands. Antibody 1L1-CT detects a band corresponding to
AFAP1L1 and also detects a strong band directly above AFAP1L1 with a Mr of
approximately 120kDa in all cell lines tested. 1L1-CT also detects two lower bands with
approximate Mr of 90kDa and 75kDa. Sigma C-term detects AFAP1L1, a band directly
below with an approximate Mr of 110kDa, a doublet with an approximate Mr of 120kDa
and a single band with an approximate Mr of 60kDa. Sigma N-term detects a single band
directly above the band corresponding to AFAP1L1 and various lower bands with
approximate Mr of 75kDa and 65kDa (Figure 6).
Due to similarity in the AFAP family, it is possible that commercial AFAP1L1
antibodies could cross-react between other AFAP family members . Antibody 1L1-CT
was specifically chosen to be created by ProSci Incorporated because of its unique
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epitope found in AFAP1L1. At the time of antibody creation, amino acids 714-727 of
AFAP1L1 did not show any other possible protein interactions by virtue of a BLAST
search against the epitope. 1L1-CT shows some identity and strong similarity to AFAP1
although the epitope is not fully conserved. The epitope is less conserved in AFAP1L2
and therefore is predicted to specifically identify AFAP1L1. Interestingly, the epitope for
antibody 1L1-CT is more similar with an N-terminal sequence rather than a C-terminal
sequence in AFAP1L2 (Figure 7). A BLAST search identified that Sigma N-term may
have the ability to detect all three AFAP family members due to the immunogen covering
a conserved SH2 binding motif and SH3 binding motif area in these proteins (Figure 8).
Additionally, a BLAST search determined that Sigma C-term antibody may also have the
ability to detect all three AFAP family members, again due to the high level of similarity
in the protein sequence used to create the antibody (Figure 9).
There are various splice variants of the AFAP family members that may also
contribute to the banding pattern seen with AFAP1L1 antibodies. AFAP1 has a similar
neural-specific isoform in which an additional 258 base pairs are inserted between amino
acids 510 and 511 which is detected at an approximate Mr of 120kDa (Flynn et al., 1995)
(Figure 10). AFAP1L1 has a smaller isoform of 725 amino acids predicted by the
Ensembl database in which exon 18 has been deleted. While the canonical sequence of
AFAP1L1 is predicted to have a molecular weight of approximately 82kDa, the band
corresponding to AFAP1L1 is detected at an approximate Mr of 115kDa, most likely due
to overall charge on the protein. This is similar to AFAP1 which is predicted to have a
molecular weight of 81kDa and is detected at an approximate Mr of 110kDa and
AFAP1L2 which is predicted to have a molecular weight of 91kDa and is detected at an
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approximate Mr of 130kDa. Exon 18 of AFAP1L1 encodes 43 amino acids; therefore it
can be hypothesized that this isoform of AFAP1L1 will run lower than AFAP1L1
although its exact location cannot be identified based solely upon sequence due to the
change in overall charge on the protein. Two additional isoforms of each transcript are
also predicted by the Ensembl dataset in which the sequence of Exon 1 appears to be
altered (Figure 11). AFAP1L2 has four predicted isoforms by the Ensembl database.
Canonical AFAP1L2 contains 818 amino acids while a predicted isoform of 814 amino
acids lacks four amino acids in the C-terminal unique region of AFAP1L2. A predicted
protein coding isoform of 841 amino acid lacks a canonical start codon and contains an
additional 28 amino acids inserted between Exons 5 and 6 while lacking the four amino
acids in the C-terminal unique region that are also missing in the 814 amino acid isoform.
A short 312 amino acid form of AFAP1L2 is predicted by the Ensembl database that
contains 18 additional amino acids in Exon 2 and ends at Exon 5 of canonical AFAP1L2,
thus encoding only the predicted SH2 and SH3 binding motifs with their surrounding
unique sequences (Figure 12).
In addition to other members and splice variants of the AFAP family, AFAP1L1
antibodies may have the ability to interact with other proteins. When created, the epitope
for 1L1-CT antibody was run through a human protein BLAST search and returned only
AFAP1L1 as an exact protein sequence match. Since the creation of antibody 1L1-CT, an
additional human protein which is identical to AFAP1L1 in the C-terminal 444 amino
acids and therefore shares the 1L1-CT epitope was discovered. This unnamed protein
(Accession BAG64383) contains 625 amino acids and mRNA was isolated from human
thymus tissue (Maruyama et al., 2009). This protein is identical to human lysosomal
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protein transmembrane 5 in the N-terminal portion of the protein and identical to
AFAP1L1 in the C-terminal portion (Figure 13). Apart from protein sequence, there is
currently no known functional data for this protein.
Due to the large sequence used to create Sigma N-term and Sigma C-term
antibodies, the exact epitope to which the antibodies bind is unknown. It is conceivable
that Sigma N- and C-term antibodies may have the ability to bind other proteins outside
of the AFAP family.
Although 1L1-CT antibody detects multiple bands in western blot, it specifically
identified one single band during immunoprecipitation. Due to the denaturing
characteristics of SDS-PAGE, 1L1-CT antibody may have the ability to detect other
proteins in their denatured state when looking at whole cell lysates when in fact these
epitopes may not be accessible in an intact cell. Immunoprecipitation by 1L1-CT
antibody would detect proteins in their native conformation before denaturing conditions
and therefore can provide validity to the fact that 1L1-CT antibody can specifically detect
AFAP1L1. Currently, immunoprecipitation with Sigma antibodies has not been carried
out.

VI. siRNA knockdown of AFAP1L1
Short interfering RNA (siRNA) is a useful tool to transiently decrease the
expression of a specific protein through posttranscriptional gene silencing by specific
degradation of messenger RNA (mRNA). As a cellular process, long dsRNA is processed
through the protein Dicer into duplexes of short nucleotide sequences of approximately
21 base pairs and loaded as single antisense RNA strands into RNA-induced silencing
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(RISC) complexes.

The single stranded antisense strand of RNA then binds to its

complementary sequence in mRNA and causes degradation through cleavage, thus
regulating protein expression within the cell. siRNA can be synthetically produced and
introduced so as to exploit the cell’s machinery and decrease the expression of a protein
of choice (Dorsett and Tuschl, 2004; Whitehead et al., 2009).
siRNA knockdown of AFAP1L1 has many benefits. Knockdown of AFAP1L1
expression is useful in western blotting to determine the Mr of AFAP1L1 as siRNA
knockdown should deplete AFAP1L1 expression and thus remove the AFAP1L1 signal.
Expression of untagged pcDNA3.1-AFAP1L1 in 293T cells resulted in a strong band at
an approximate Mr of 115kDa which corresponds to a band seen endogenously in
multiple cell lysates. This Mr 115kDa band was not seen after treatment with siRNA
specific to AFAP1L1 and was thus confirmed as the Mr of AFAP1L1.
As AFAP1L1 expression has also been shown to play a role in motility structures,
siRNA against AFAP1L1 has implications for determining the role of AFAP1L1 in
invadosome formation. Preliminary studies show decreased podosome formation in cells
lacking AFAP1L1 and further studies are underway to confirm these results.
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Figure 1A
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Figure 1. A Panomics TranSignal SH3 Domain Array I predicted AFAP1L1 SH3
domain binding partners
(A) The SH3 domain layout of a TranSignal SH3 Domain Array I from Panomics, Inc.
was shown as a guide to determine possible SH3 domain binding partners of a
biotinylated AFAP1L1 SH3 binding motif peptide.
(B) Five duplicate SH3 domain spots were chosen as potential sites for AFAP1L1
binding based upon their chemiluminescence. 1 = Spectrin alpha chain (nonerythrocytic), 2 = Cortactin, 3 = Spectrin alpha chain (erythrocytic), 4 = Avian sarcoma
virus CT10 oncogene homolog domain #2, and 5 = Post synaptic density protein 95.
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Figure 2. Immunohistochemical staining of AFAP1L1 in human cerebellum and
dentate nucleus
(A) AFAP1L1 immunohistochemical signal in human cerebellum shows distinct staining
extending from the molecular layer (panels e-f), surrounding the Purkinje neurons (panels
a-h) and in distinct locations around the granule cells of the granular layer (panels g-h).
(B) AFAP1L1 immunohistochemical signal in the human dentate nucleus shows distinct
signal around the cells of the dentate nucleus.
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Figure 3

A.
AFAP1L1
P115A.1

CTAGCCAAGAGCCCACGCCTGAGAAACGCGGCCGACCTGCCTCCACCGCTCCCCAACAAG 360
CTAGCCAAGAGCCCACGCCTGAGAAACGCGGCCGACCTGCCTGCACCGCTCCCCAACAAG 162
****************************************** *****************

B.
AFAP1L1
P118A.1

CTAGCCAAGAGCCCACGCCTGAGAAACGCGGCCGACCTGCCTCCACCGCTCCCCAACAAG 360
CTAGCCAAGAGCCCACGCCTGAGAAACGCGGCCGACCTGCCTCCACCGCTCGCCAACAAG 163
*************************************************** ********

C.
AFAP1L1
P121A.2

CCTCCCCCTGAGGACTACTATGAAGAGGCCCTTCCTCTGGGACCCGGCAAGTCGCCTGAG 420
GCTCCCCCTGAGGACTACTATGAAGAGGCCCTTCCTCTGGGACCCGGCAAGTCGCCTGAG 224
***********************************************************

Figure 3. Mutation of the SH3 binding motif of AFAP1L1
Key prolines in the SH3 binding motif of AFAP1L1 were mutated to alanines so as to test
the ability of the alanine mutation to abrogate AFAP1L1 binding to cortactin. (A) P115A,
(B) P118A, and (C) P121A, were mutated to alanine by site-directed mutagenesis.
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Figure 4. Immunoprecipitation of cortactin with AFAP1L1 SH3 binding motif
mutants
GFP-AFAP1 and GFP-AFAP1L1, as well as three AFAP1L1 SH3 binding motif mutants
GFP-AFAP1L1P115A, GFP-AFAP1L1P118A and GFP-AFAP1L1P121A, were overexpressed
with FLAG-cortactin and immunoprecipitated against cortactin. Lysates were resolved by
SDS-PAGE and immunoblotted for GFP. Reprobe against the GFP tag confirmed equal
immunoprecipitation of all constructs (bottom panel). 5µg of each lysate was resolved by
SDS-PAGE and immunoblotted for both GFP and cortactin to confirm that equal
amounts of constructs were expressed in each lysate (top panel).
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Figure 5
AFAP1L1
SigmaNterm

MDRGQVLEQLLPELTGLLSLLDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTA 60
--------------------LDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTA 40
****************************************

AFAP1L1
SigmaNterm

DLHSGPSFVESLFEEFDCDLSDLRDMPEDDGEPSKGASPELAKSPRLRNAADLPPPLPNK 120
DLHSGPSFVESLFEEFDCDLSDLRDMPEDDGEPSKGASPELAKSPRLRNAADLPPPLPNK 100
************************************************************

AFAP1L1
SigmaNterm

PPPEDYYEEALPLGPGKSPEYISSHNGCSPSHSIVDGYYEDADSSYPATRVNGELKSSYN 180
PPPEDYYEEALPLGPGKSPEYISSHNGCSPSHSIVDGYY--------------------- 139
***************************************

AFAP1L1

DSDAMSSSYESYDEEEEEGKSPQPRHQWPSEEASMHLVRECRICAFLLRKKRFGQWAKQL 240

AFAP1L1

TVIREDQLLCYKSSKDRQPHLRLALDTCSIIYVPKDSRHKRHELRFTQGATEVLVLALQS 300

AFAP1L1

REQAEEWLKVIREVSKPVGGAEGVEVPRSPVLLCKLDLDKRLSQEKQTSDSDSVGVGDNC 360

AFAP1L1

STLGRRETCDHGKGKKSSLAELKGSMSRAAGRKITRIIGFSKKKTLADDLQTSSTEEEVP 420

AFAP1L1

CCGYLNVLVNQGWKERWCRLKCNTLYFHKDHMDLRTHVNAIALQGCEVAPGFGPRHPFAF 480

AFAP1L1
SigmaCterm

RILRNRQEVAILEASCSEDMGRWLGLLLVEMGSRVTPEALHYDYVDVETLTSIVSAGRNS 540
--------------------------------------------VDVETLTSIVSAGRNS 16
****************

AFAP1L1
SigmaCterm

FLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCSEKSHRVDPQVKVKR 600
FLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCSEKSHRVDPQVKVKR 76
************************************************************

AFAP1L1
SigmaCterm

HASSANQYKYGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPGA 660
HASSANQYKYGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPG- 135
***********************************************************

AFAP1L1
1L1-CT

KLKALEEAVATLEAQCRAKEERRIDLELKLVAVKERLQQSLAGGPALGLSVSSKPKSGET 720
-----------------------------------------------------KPKSGET 7
*******
ANKPQNSVPEQPLPVNCVSELRKRSPSIVASNQGRVLQKAKEWEMKKT 768
ANKPQNS----------------------------------------- 14
*******

AFAP1L1
1L1-CT

Figure 5. AFAP1L1 antibodies aligned with AFAP1L1 amino acid sequence
Sigma N-term, Sigma C-term and 1L1-CT antibodies were aligned to full length
AFAP1L1 amino acid sequence using ClustalW2 analysis (27) so as to determine where
in the sequence antibodies bound and what conserved binding motifs these antibodies
may cover. The proposed SH3 domain is highlighted in green, proposed SH2 domains are
highlighted in pink, the PH1 and PH2 domains are highlighted in light blue, the substrate
domain is highlighted in yellow, the proposed leucine zipper is highlighted in red and the
proposed actin binding domain in highlighted in dark blue.
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Figure 6. AFAP1L1 antibody specificity
A panel of cell lines was tested against all three AFAP1L1 antibodies to test for
specificity. 293T cells overexpressing an untagged pcDNA3.1 afap1l1 construct were
used as a control to determine AFAP1L1 Mr. Cell lines tested were breast lines MCF10a,
MCF7, MDA-MB-231, MDA-MB-435, B1A ( a knockdown of AFAP1 in MDA-MB231 cells), and CaOv3, an ovarian cancer cell line. Sigma N-term (A), Sigma C-term (B)
and 1L1-CT (C) all recognize AFAP1L1 to differing extents and detect various
background bands.
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Figure 7

AFAP1L1
1L1-CT
Consensus

KPKSGETANKPQNS 727
KPKSGETANKPQNS 14
KPKSGETANKPQNS

AFAP1
1L1-CT
Consensus

EPKSGTSSPQSPVFRHRTLENSPISSCDTSDTEGPVPVNSAA 683
KPKSGETA------------NKPQNS---------------- 14
*KPKS **
N*P *S

AFAP1L2
1L1-CT
Consensus

APEEQGLLPNGEPSQHSSAPQKSLPDLPPPKMIPERKQLAIPKTESP 120
KPK------SGETANK---PQNS------------------------ 14
P*
*GE****
PQ*S

Figure 7. 1L1-CT binding across AFAP family members
The amino acid sequence against which antibody 1L1-CT was raised was compared
across AFAP family members. Identical amino acid sequence is shown by its one letter
abbreviation in the consensus sequence while similar amino acid sequence is represented
by *.
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Figure 8
AFAP1L1
Sigma.N-term
Consensus

MDRGQVLEQLLPELTGLLSLLDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTA 60
--------------------LDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTA 40
LDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTA

AFAP1L1
Sigma.N-term
Consensus

DLHSGPSFVESLFEEFDCDLSDLRDMPEDDGEPSKGASPELAKSPRLRNAADLPPPLPNK 120
DLHSGPSFVESLFEEFDCDLSDLRDMPEDDGEPSKGASPELAKSPRLRNAADLPPPLPNK 100
DLHSGPSFVESLFEEFDCDLSDLRDMPEDDGEPSKGASPELAKSPRLRNAADLPPPLPNK

AFAP1L1
Sigma.N-term
Consensus

PPPEDYYEEALPLGPGKSPEYISSHNGCSPSHSIVDGYYEDADSSYPATRVNGELKSSYN 180
PPPEDYYEEALPLGPGKSPEYISSHNGCSPSHSIVDGYY--------------------- 139
PPPEDYYEEALPLGPGKSPEYISSHNGCSPSHSIVDGYY

AFAP1
Sigma.N-term
Consensus

MEELIVELRLFLELLDHEYLTSTVREKKAVITNILLRIQSSKGFDVKDHAQKQETANSLP 60
--------------LDHEYLSDTTLEKKMAVASILQSLQ--------------------- 25
LDHEYL**T* EKK ****IL *Q

AFAP1
Sigma.N-term
Consensus

APPQMPLPEIPQPWLPPDSGPPPLPTSSLPEGYYEEAVPLSPGKAPEYITSNYDSDAMSS 120
----------------------PLPAKEVSYLYVNTADLHSGPSFVESLFEEFDCDLS-- 61
PLP***** Y * A
S * E * ***D*D

AFAP1
Sigma.N-term
Consensus

SYESYDEEEEDGKGKKTRHQWPSEEASMDLVKDAKICAFLLRKKRFGQWTKLLCVIKDTK 180
--DLRDMPEDDGE--------PSKGASPELAKSPRLR----------------------- 88
* D E*DG*
PS* AS *L*K****

AFAP1
Sigma.N-term
Conensus

LLCYKSSKDQQPQMELPLQGCNITYIPKDSKKKKHELKITQQGTDPLVLAVQSKEQAEQW 240
------NAADLP------------------------------------------------ 94
* * P

AFAP1
Sigma.N-term
Consensus

LKVIKEAYSGCSGPVDSECPPPPSSPVHKAELEKKLSSERPSSDGEGVVENGITTCNGKE 300
-------------------PPLPNKPPPEDYYEEALP------LGPGKSPEYISSHNG-- 127
PP P**P *
E* L*
G G
* I** NG

AFAP1
Sigma.N-term
Consensus

QVKRKKSSKSEAKGTVSKVTGKKITKIISLGKKKPSTDEQTSSAEEDVPTCGYLNVLSNS 360
----CSPSHSIVDGYY-------------------------------------------- 139
**S*S **G

AFAP1L2
Sigma.N-term
Consensus

MERYKALEQLLTELDDFLKILDQENLSSTALVKKSCLAELLRLYTKSSSSDEEYIYMNKV 60
--------------------LDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTA 40
LD*E LS*T*L KK **A**L*
**** *Y*Y*N**

AFAP1L2
Sigma.N-term
Consensus

TINKQQNAESQGKAPEEQGLLPNGEPSQHSSAPQKSLPDLPPPKMIPERKQLAIPKTESP 120
DLHS-------------------------------------------------------- 44
***

AFAP1L2
Sigma.N-term
Consensus

EGYYEEAEPYDTSLNEDGEAVSSSYESYDEEDGSKGKSAPYQWPSPEAGIELMRDARICA 180
------GPSFVESLFEEFDCDLSDLRDMPEDDGE---------PSKGASPELAKSPRLR- 88
* ** SL E* ** S* ** E*EG*
PS A* EL ***R*

AFAP1L2
Sigma.N-term
Consensus

FLWRKKWLGQWAKQLCVIKDNRLLCYKSSKDHSPQLDVNLLGSSVIHKEKQVRKKEHKLK 240
------------------------------------------------------------

AFAP1L2
Sigma.N-term
Consensus

ITPMNADVIVLGLQSKDQAEQWLRVIQEVSGLPSEGASEGNQYTPDAQRFNCQKPDIAEK 300
----NAADLPPPLPNKPPPEDYYEEALPLG--------------------PGKSPEYISS 124
NA *
L *K *E** *
**
**P* **

AFAP1L2
Sigma.N-term
Consensus

YLSASEYGSSVDGHPEVPETKDVKKKCSAGLKLSNLMNLGRKKSTSLEPVERSLETSSYL 360
HNGCSPSHSIVDGYY--------------------------------------------- 139
* **S
S VDG*
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Figure 8. Sigma N-term binding across AFAP family members
The amino acid sequence against which Sigma N-term antibody was raised was
compared across AFAP family members. Identical amino acid sequence is shown by its
one letter abbreviation in the consensus sequence while similar amino acid sequence is
represented by *.
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Figure 9
AFAP1L1
Sigma.C-term
Consensus

RILRNRQEVAILEASCSEDMGRWLGLLLVEMGSRVTPEALHYDYVDVETLTSIVSAGRNS 540
--------------------------------------------VDVETLTSIVSAGRNS 16
VDVETLTSIVSAGRNS

AFAP1L1
Sigma.C-term
Consensus

FLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCSEKSHRVDPQVKVKR 600
FLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCSEKSHRVDPQVKVKR 76
FLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCDEKSHRVDPQVKVKR

AFAP1L1
Sigma.C-term
Consensus

HASSANQYKYGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPGA 660
HASSANQYKYGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPG- 135
HASSANQPKQGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPG

AFAP1
Sigma.C-term
Consensus

LEASSSEDMGRWIGILLAETGSSTDPEALHYDYIDVEMSASVIQTAKQTFCFMNRRVISA 480
---------------------------------VDVETLTSIVSAGRNSFLYAR------ 21
*DVE *S********F * *

AFAP1
Sigma.C-term
Consensus

NPYLGGTSNGYAHPSGTALHYDDVPCINGSLKGKKPPVASNGVTGKGKTLSSQPKKADPA 540
-----SCQNQWPEPR----VYDDVPYEKMQDEEPERPTGAQ-VKRHASSCSEKSHRVDPQ 71
* *N ***P
YDDVP * * * * P**** V* **** S******DP

AFAP1
Sigma.C-term
Consensus

AVVKRTGSNAAQYKYGKNRVEADAKRLQTKEEELLKRKEALRNRLAQLRKERKDLRAAIE 600
VKVKRHASSANQYKYGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIR 131
* VKR *S*A QYLYGKNR*E DA*R ***E*L K*KE**R**L LR*E***L* AI*

AFAP1
Sigma.C-term
Consensus

VNAGRKPQAILEEKLKQLEEECRQKEAERVSLELELTEVKESLKKALAGGVTLGLAIEPK 660
SSPG-------------------------------------------------------- 135
**G

AFAP1L2
Sigma.C-term
Consensus

GEELAKLEAKSSEEMGHWLGLLLSESGSKTDPEEFTYDYVDADRVSCIVSAAKNSLLLMQ 480
---------------------------------------VDVETLTSIVSAGRNSFLYAR 21
VD** ***IVSA**NS*L *

AFAP1L2
Sigma.C-term
Consensus

RKFSEPNTYIDGLPSQDRQEELYDDVDLSELTAAVEPTEEATPVADDPNERESDRVYLDL 540
---SCQNQWPE--------PRVYDDVPYEKMQ-------------DEEPER--------- 48
S N * *
**YDDV ***
D* ER

AFAP1L2
Sigma.C-term
Consensus

TPVKSFLHGPSSAQAQASSPTLSCLDNATEALPADSGPGPTPDEPCIKCPENLGEQQLES 600
---------PTGAQVKRHAS--SCSEKS------------------------------HR 67
P**AQ** ** SC ***
*

AFAP1L2
Sigma.C-term
Consensus

LEPEDPSLRITTVKIQTEQQRISFPPSCPDAVVATPPGASPPVKDRLRVTSAEIKLGKNR 660
VDP--------QVKVKRHAS-----------------------------SANQYKYGKNR 90
**P
VK** * *
** * K GKNR

AFAP1L2
Sigma.C-term
Consensus

TEAEVKRYTEEKERLEKKKEEIRGHLAQLRKEKRELKETLLKCTDKEVLASLEQKLKEID 720
AEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPG--------------- 135
*E ***RY EKE*LEK*KE IR *L LR*EKRELKE** ****
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Figure 9. Sigma C-term binding across AFAP family members
The amino acid sequence against which Sigma C-term antibody was raised was compared
across AFAP family members. Identical amino acid sequence is shown by its one letter
abbreviation in the consensus sequence while similar amino acid sequence is represented
by *.
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Figure 10
AFAP1
AFAP120

MEELIVELRLFLELLDHEYLTSTVREKKAVITNILLRIQSSKGFDVKDHAQKQETANSLP 60
MEELIVELRLFLELLDHEYLTSTVREKKAVITNILLRIQSSKGFDVKDHAQKQETANSLP 60
************************************************************

AFAP1
AFAP120

APPQMPLPEIPQPWLPPDSGPPPLPTSSLPEGYYEEAVPLSPGKAPEYITSNYDSDAMSS 120
APPQMPLPEIPQPWLPPDSGPPPLPTSSLPEGYYEEAVPLSPGKAPEYITSNYDSDAMSS 120
************************************************************

AFAP1
AFAP120

SYESYDEEEEDGKGKKTRHQWPSEEASMDLVKDAKICAFLLRKKRFGQWTKLLCVIKDTK 180
SYESYDEEEEDGKGKKTRHQWPSEEASMDLVKDAKICAFLLRKKRFGQWTKLLCVIKDTK 180
************************************************************

AFAP1
AFAP120

LLCYKSSKDQQPQMELPLQGCNITYIPKDSKKKKHELKITQQGTDPLVLAVQSKEQAEQW 240
LLCYKSSKDQQPQMELPLQGCNITYIPKDSKKKKHELKITQQGTDPLVLAVQSKEQAEQW 240
************************************************************

AFAP1
AFAP120

LKVIKEAYSGCSGPVDSECPPPPSSPVHKAELEKKLSSERPSSDGEGVVENGITTCNGKE 300
LKVIKEAYSGCSGPVDSECPPPPSSPVHKAELEKKLSSERPSSDGEGVVENGITTCNGKE 300
************************************************************

AFAP1
AFAP120

QVKRKKSSKSEAKGTVSKVTGKKITKIISLGKKKPSTDEQTSSAEEDVPTCGYLNVLSNS 360
QVKRKKSSKSEAKGTVSKVTGKKITKIISLGKKKPSTDEQTSSAEEDVPTCGYLNVLSNS 360
************************************************************

AFAP1
AFAP120

RWRERWCRVKDNKLIFHKDRTDLKTHIVSIPLRGCEVIPGLDSKHPLTFRLLRNGQEVAV 420
RWRERWCRVKDNKLIFHKDRTDLKTHIVSIPLRGCEVIPGLDSKHPLTFRLLRNGQEVAV 420
************************************************************

AFAP1
AFAP120

LEASSSEDMGRWIGILLAETGSSTDPEALHYDYIDVEMSASVIQTAKQTFCFMNRRVISA 480
LEASSSEDMGRWIGILLAETGSSTDPEALHYDYIDVEMSASVIQTAKQTFCFMNRRVISA 480
************************************************************

AFAP1
AFAP120

NPYLGGTSNGYAHPSGTALHYDDVPCING------------------------------- 509
NPYLGGTSNGYAHPSGTALHYDDVPCINGSWEPEDGFPASCSRGLGEEVLYDNAGLYDNL 540
*****************************

AFAP1
AFAP120

-----------------------------------------------------SLKGKKP 516
PPPHIFARYSPADRKASRLSADKLSSNHYKYPASAQSVTNTSSVGRASLGLNSQLKGKKP 600
:******

AFAP1
AFAP120

PVASNGVTGKGKTLSSQPKKADPAAVVKRTGSNAAQYKYGKNRVEADAKRLQTKEEELLK 576
PVASNGVTGKGKTLSSQPKKADPAAVVKRTGSNAAQYKYGKNRVEADAKRLQTKEEELLK 660
************************************************************

AFAP1
AFAP120

RKEALRNRLAQLRKERKDLRAAIEVNAGRKPQAILEEKLKQLEEECRQKEAERVSLELEL 636
RKEALRNRLAQLRKERKDLRAAIEVNAGRKPQAILEEKLKQLEEECRQKEAERVSLELEL 720
************************************************************

AFAP1
AFAP120

TEVKESLKKALAGGVTLGLAIEPKSGTSSPQSPVFRHRTLENSPISSCDTSDTEGPVPVN 696
TEVKESLKKALAGGVTLGLAIEPKSGTSSPQSPVFRHRTLENSPISSCDTSDTEGPVPVN 780
************************************************************

AFAP1
AFAP120

SAAVLKKSQAAPGSSPCRGHVLRKAKEWELKNGT 730
SAAVLKKSQAAPGSSPCRGHVLRKAKEWELKNGT 814
**********************************
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Figure 10. AFAP1 isoforms
AFAP1 canonical sequence was compared to a second neural specific AFAP1 isoform,
AFAP120 using ClustalW2 analysis (27). Identical sequence is represented by * while
similar sequence is represented by : .
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Figure 11
AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

MDRGQVLEQLLPELTGLLSLLDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTA
-ERGKMLEQLLPELTGLLSLLDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTA
MDRGQVLEQLLPELTGLLSLLDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTA
-ERGKMLEQLLPELTGLLSLLDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTA
:**::******************************************************

60
59
60
59

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

DLHSGPSFVESLFEEFDCDLSDLRDMPEDDGEPSKGASPELAKSPRLRNAADLPPPLPNK
DLHSGPSFVESLFEEFDCDLSDLRDMPEDDGEPSKGASPELAKSPRLRNAADLPPPLPNK
DLHSGPSFVESLFEEFDCDLSDLRDMPEDDGEPSKGASPELAKSPRLRNAADLPPPLPNK
DLHSGPSFVESLFEEFDCDLSDLRDMPEDDGEPSKGASPELAKSPRLRNAADLPPPLPNK
************************************************************

120
119
120
119

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

PPPEDYYEEALPLGPGKSPEYISSHNGCSPSHSIVDGYYEDADSSYPATRVNGELKSSYN
PPPEDYYEEALPLGPGKSPEYISSHNGCSPSHSIVDGYYEDADSSYPATRVNGELKSSYN
PPPEDYYEEALPLGPGKSPEYISSHNGCSPSHSIVDGYYEDADSSYPATRVNGELKSSYN
PPPEDYYEEALPLGPGKSPEYISSHNGCSPSHSIVDGYYEDADSSYPATRVNGELKSSYN
************************************************************

180
179
180
179

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

DSDAMSSSYESYDEEEEEGKSPQPRHQWPSEEASMHLVRECRICAFLLRKKRFGQWAKQL
DSDAMSSSYESYDEEEEEGKSPQPRHQWPSEEASMHLVRECRICAFLLRKKRFGQWAKQL
DSDAMSSSYESYDEEEEEGKSPQPRHQWPSEEASMHLVRECRICAFLLRKKRFGQWAKQL
DSDAMSSSYESYDEEEEEGKSPQPRHQWPSEEASMHLVRECRICAFLLRKKRFGQWAKQL
************************************************************

240
239
240
239

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

TVIREDQLLCYKSSKDRQPHLRLALDTCSIIYVPKDSRHKRHELRFTQGATEVLVLALQS
TVIREDQLLCYKSSKDRQPHLRLALDTCSIIYVPKDSRHKRHELRFTQGATEVLVLALQS
TVIREDQLLCYKSSKDRQPHLRLALDTCSIIYVPKDSRHKRHELRFTQGATEVLVLALQS
TVIREDQLLCYKSSKDRQPHLRLALDTCSIIYVPKDSRHKRHELRFTQGATEVLVLALQS
************************************************************

300
299
300
299

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

REQAEEWLKVIREVSKPVGGAEGVEVPRSPVLLCKLDLDKRLSQEKQTSDSDSVGVGDNC
REQAEEWLKVIREVSKPVGGAEGVEVPRSPVLLCKLDLDKRLSQEKQTSDSDSVGVGDNC
REQAEEWLKVIREVSKPVGGAEGVEVPRSPVLLCKLDLDKRLSQEKQTSDSDSVGVGDNC
REQAEEWLKVIREVSKPVGGAEGVEVPRSPVLLCKLDLDKRLSQEKQTSDSDSVGVGDNC
************************************************************

360
359
360
359

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

STLGRRETCDHGKGKKSSLAELKGSMSRAAGRKITRIIGFSKKKTLADDLQTSSTEEEVP
STLGRRETCDHGKGKKSSLAELKGSMSRAAGRKITRIIGFSKKKTLADDLQTSSTEEEVP
STLGRRETCDHGKGKKSSLAELKGSMSRAAGRKITRIIGFSKKKTLADDLQTSSTEEEVP
STLGRRETCDHGKGKKSSLAELKGSMSRAAGRKITRIIGFSKKKTLADDLQTSSTEEEVP
************************************************************

420
419
420
419

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

CCGYLNVLVNQGWKERWCRLKCNTLYFHKDHMDLRTHVNAIALQGCEVAPGFGPRHPFAF
CCGYLNVLVNQGWKERWCRLKCNTLYFHKDHMDLRTHVNAIALQGCEVAPGFGPRHPFAF
CCGYLNVLVNQGWKERWCRLKCNTLYFHKDHMDLRTHVNAIALQGCEVAPGFGPRHPFAF
CCGYLNVLVNQGWKERWCRLKCNTLYFHKDHMDLRTHVNAIALQGCEVAPGFGPRHPFAF
************************************************************

480
479
480
479

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

RILRNRQEVAILEASCSEDMGRWLGLLLVEMGSRVTPEALHYDYVDVETLTSIVSAGRNS
RILRNRQEVAILEASCSEDMGRWLGLLLVEMGSRVTPEALHYDYVDVETLTSIVSAGRNS
RILRNRQEVAILEASCSEDMGRWLGLLLVEMGSRVTPEALHYDYVDVETLTSIVSAGRNS
RILRNRQEVAILEASCSEDMGRWLGLLLVEMGSRVTPEALHYDYVDVETLTSIVSAGRNS
************************************************************

540
539
540
539

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

FLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCSEKSHRVDPQVKVKR
FLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCSEKSHRVDPQVKVKR
FLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCSEKSHRVDPQVKVKR
FLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCSEKSHRVDPQVKVKR
************************************************************

600
599
600
599
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AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

HASSANQYKYGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPGA
HASSANQYKYGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPGA
HASSANQYKYGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPGA
HASSANQYKYGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPGA
************************************************************

660
659
660
659

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

KLKALEEAVATLEAQCRAKEERRIDLELKLVAVKERLQQSLAGGPALGLSVSSKPKSGET
KLKALEEAVATLEAQCRAKEERRIDLELKLVAVKERLQQSLAGGPALGLSVSSKPKSGET
KLKALEEAVATLEAQCRAKEERRIDLELKLVAVKERLQQSLAGGPALGLSVSSKPKSG-KLKALEEAVATLEAQCRAKEERRIDLELKLVAVKERLQQSLAGGPALGLSVSSKPKSG-**********************************************************

720
719
718
717

AFAP1L1
AFAP1L1.767
AFAP1L1.725
AFAP1L1.724

ANKPQNSVPEQPLPVNCVSELRKRSPSIVASNQGRVLQKAKEWEMKKT
ANKPQNSVPEQPLPVNCVSELRKRSPSIVASNQGRVLQKAKEWEMKKT
-----------------------------------------EWEMKKT
-----------------------------------------EWEMKKT
*******

768
767
725
724

Figure 11. AFAP1L1 isoforms
Canonical AFAP1L1 amino acid sequence was compared using ClustalW2 analysis (27)
to three other AFAP1L1 isoforms. AFAP1L1 containing 767 amino acids has an altered
Exon 1, AFAP1L1 containing 725 amino acids does not contain Exon 18 and AFAP1L1
containing 724 amino acids does not contain Exon 18 and has an altered Exon 1. Identical
sequence is represented by * while similar sequence is represented by :.
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Figure 12
AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

MERYKA------------------LEQLLTELDDFLKILDQENLSSTALVKKSCLAELLR
MERYKA------------------LEQLLTELDDFLKILDQENLSSTALVKKSCLAELLR
-QRVRA------------------LEQLLTELDDFLKILDQENLSSTALVKKSCLAELLR
MERYKAQGCCCLVVQRRIRQVSASLEQLLTELDDFLKILDQENLSSTALVKKSCLAELLR
:* :*
************************************

42
42
41
60

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

LYTKSSSSDEEYIYMNKVTINKQQNAESQGKAPEEQGLLPNGEPSQHSSAPQKSLPDLPP
LYTKSSSSDEEYIYMNKVTINKQQNAESQGKAPEEQGLLPNGEPSQHSSAPQKSLPDLPP
LYTKSSSSDEEYIYMNKVTINKQQNAESQGKAPEEQGLLPNGEPSQHSSAPQKSLPDLPP
LYTKSSSSDEEYIYMNKVTINKQQNAESQGKAPEEQGLLPNGEPSQHSSAPQKSLPDLPP
************************************************************

102
102
101
120

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

PKMIPERKQLAIPKTESPEGYYEEAEPYDTSLN--------------------------PKMIPERKQLAIPKTESPEGYYEEAEPYDTSLN--------------------------PKMIPERKQLAIPKTESPEGYYEEAEPYDTSLNGHSGGFLPTGVPRWVQVPEGVIYATIT
PKMIPERKQLAIPKTESPEGYYEEAEPYDTSLN--------------------------*********************************

135
135
161
153

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

-EDGEAVSSSYESYDEEDGSKGKSAPYQWPSPEAGIELMRDARICAFLWRKKWLGQWAKQ
-EDGEAVSSSYESYDEEDGSKGKSAPYQWPSPEAGIELMRDARICAFLWRKKWLGQWAKQ
LEDGEAVSSSYESYDEEDGSKGKSAPYQWPSPEAGIELMRDARICAFLWRKKWLGQWAKQ
-EDGEAVSSSYESYDEEDGSKGKSAPYQWPSPEAGIELMRDARICAFLWRKKWLGQWAKQ
***********************************************************

194
194
221
212

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

LCVIKDNRLLCYKSSKDHSPQLDVNLLGSSVIHKEKQVRKKEHKLKITPMNADVIVLGLQ
LCVIKDNRLLCYKSSKDHSPQLDVNLLGSSVIHKEKQVRKKEHKLKITPMNADVIVLGLQ
LCVIKDNRLLCYKSSKDHSPQLDVNLLGSSVIHKEKQVRKKEHKLKITPMNADVIVLGLQ
LCVIKDNRLLCYKSSKDHSPQLDVNLLGSSVIHKEKQVRKKEHKLKITPMNADVIVLGLQ
************************************************************

254
254
281
272

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

SKDQAEQWLRVIQEVSGLPSEGASEGNQYTPDAQRFNCQKPDIAEKYLSASEYGSSVDGH
SKDQAEQWLRVIQEVSGLPSEGASEGNQYTPDAQRFNCQKPDIAEKYLSASEYGSSVDGH
SKDQAEQWLRVIQEVSGLPSEGASEGNQYTPDAQRFNCQKPDIAEKYLSASEYGSSVDGH
SKDQAEQWLRVIQEVSGLPSEGASEGNQYTPDAQRFNCQK-------------------****************************************

314
314
341
312

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

PEVPETKDVKKKCSAGLKLSNLMNLGRKKSTSLEPVERSLETSSYLNVLVNSQWKSRWCS 374
PEVPETKDVKKKCSAGLKLSNLMNLGRKKSTSLEPVERSLETSSYLNVLVNSQWKSRWCS 374
PEVPETKDVKKKCSAGLKLSNLMNLGRKKSTSLEPVERSLETSSYLNVLVNSQWKSRWCS 401
------------------------------------------------------------

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

VRDNHLHFYQDRNRSKVAQQPLSLVGCEVVPDPSPDHLYSFRILHKGEELAKLEAKSSEE 434
VRDNHLHFYQDRNRSKVAQQPLSLVGCEVVPDPSPDHLYSFRILHKGEELAKLEAKSSEE 434
VRDNHLHFYQDRNRSKVAQQPLSLVGCEVVPDPSPDHLYSFRILHKGEELAKLEAKSSEE 461
------------------------------------------------------------

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

MGHWLGLLLSESGSKTDPEEFTYDYVDADRVSCIVSAAKNSLLLMQRKFSEPNTYIDGLP 494
MGHWLGLLLSESGSKTDPEEFTYDYVDADRVSCIVSAAKNSLLLMQRKFSEPNTYIDGLP 494
MGHWLGLLLSESGSKTDPEEFTYDYVDADRVSCIVSAAKNSLLLMQRKFSEPNTYIDGLP 521
------------------------------------------------------------

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

SQDRQEELYDDVDLSELTAAVEPTEEATPVADDPNERESDRVYLDLTPVKSFLHGPSSAQ 554
SQDRQEELYDDVDLSELTAAVEPTEEATPVADDPNERESDRVYLDLTPVKSFLHGPSSAQ 554
SQDRQEELYDDVDLSELTAAVEPTEEATPVADDPNERESDRVYLDLTPVKSFLHGPSSAQ 581
------------------------------------------------------------
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AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

AQASSPTLSCLDNATEALPADSGPGPTPDEPCIKCPENLGEQQLESLEPEDPSLRITTVK 614
AQASSPTLSCLDNATEALPADSGPGPTPDEPCIKCPENLGEQQLESLEPEDPSLRITTVK 614
AQASSPTLSCLDNATEALPADSGPGPTPDEPCIKCPENLGEQQLESLEPEDPSLRITTVK 641
------------------------------------------------------------

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

IQTEQQRISFPPSCPDAVVATPPGASPPVKDRLRVTSAEIKLGKNRTEAEVKRYTEEKER 674
IQTEQQRISFPPSCPDAVVATPPGASPPVKDRLRVTSAEIKLGKNRTEAEVKRYTEEKER 674
IQTEQQRISFPPSCPDAVVATPPGASPPVKDRLRVTSAEIKLGKNRTEAEVKRYTEEKER 701
------------------------------------------------------------

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

LEKKKEEIRGHLAQLRKEKRELKETLLKCTDKEVLASLEQKLKEIDEECRGEESRRVDLE 734
LEKKKEEIRGHLAQLRKEKRELKETLLKCTDKEVLASLEQKLKEIDEECRGEESRRVDLE 734
LEKKKEEIRGHLAQLRKEKRELKETLLKCTDKEVLASLEQKLKEIDEECRGEESRRVDLE 761
------------------------------------------------------------

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

LSIMEVKDNLKKAEAGPVTLGTTVDTTHLENVSPRPKAVTPASAPDCTPVNSATTLKNRP 794
LSIMEVKDNLKKAEAGPVTLGTTVDTTHLEN----PKAVTPASAPDCTPVNSATTLKNRP 790
LSIMEVKDNLKKAEAGPVTLGTTVDTTHLEN----PKAVTPASAPDCTPVNSATTLKNRP 817
------------------------------------------------------------

AFAP1L2
AFAP1L2.814
AFAP1L2.841
AFAP1L2.312

LSVVVTGKGTVLQKAKEWEKKGAS 818
LSVVVTGKGTVLQKAKEWEKKGAS 814
LSVVVTGKGTVLQKAKEWEKKGAS 841
------------------------

Figure 12. AFAP1L2 isoforms
Canonical AFAP1L2 amino acid sequence was compared by ClustalW2 analysis (27) to
three other AFAP1L2 predicted isoforms. AFAP1L2 containing 814 amino acids lacks
four amino acids in the C-terminal region. AFAP1L2 containing 841 amino acids has a
undefined start codon, lacks the four amino acids in the C-terminal region as in
AFAP1L2 containing 814 amino acids and has an additional 28 amino acids inserted
between Exons 5 and 6. AFAP1L2 containing 312 amino acids contains 18 additional
amino acids in Exon 2 and ends at Exon 5 of canonical AFAP1L2. Identical amino acids
are represented by * while similar amino acids are represented by :.
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Figure 13
BAG64383
AFAP1L1
LAPTM5

-------------------------------------------------------------------------------MDRGQVLEQLLPELTGLLSLLDHEYLSDTTLEKKMAVASILQSLQPLPAKEVSYLYVNTADLHSGPSFVESLFEEFDCDL
--------------------------------------------------------------------------------

80

BAG64383 ----------MDPRLSTVRQTCCCFNVRIATTALAIYHVIMSVLLFIEHSVEVAHGKA--------SCKLSQM---GYLR
AFAP1L1 SDLRDMPEDDGEPSKGASPELAKSPRLRNAADLPPPLPNKPPPEDYYEEALPLGPGKSPEYISSHNGCSPSHSIVDGYYE
LAPTM5
----------MDPRLSTVRQTCCCFNVRIATTALAIYHVIMSVLLFIEHSVEVAHGKA--------SCKLSQM---GYLR

59
160
59

BAG64383 IADLISSFLLITMLFIISLSLLIGVVKNREKY-------LLPFLSLQ----------IMDYLLCLLTL----L------AFAP1L1 DADSSYPATRVNGELKSSYNDSDAMSSSYESYDEEEEEGKSPQPRHQWPSEEASMHLVRECRICAFLLRKKRF------LAPTM5
IADLISSFLLITMLFIISLSLLIGVVKNREKY-------LLPFLSLQ----------IMDYLLCLLTLLGSYIELPAYLK

111
233
122

BAG64383 ------------------------------GSYIELPTYLNFKSMNHMNYLPSQEDMPH----------------NQFIK
AFAP1L1 ------------------------------GQWAKQLTVIREDQL--LCYKSSKDRQPHLRLALDTCSIIYVPKDSRHKR
LAPTM5
LASRSRASSSKFPLMTLQLLDFCLSILTLCSSYMEVPTYLNFKSMNHMNYLPSQEDMPH----------------NQFIK

145
281
186

BAG64383 MMIIFSIAFITVLIFKVYMFKCVWRCYRLIKCM-------NSVEVPRSPVLLCKLDLDKRLSQEKQTSDSDSVGVGDNCS
AFAP1L1 HELRFTQGATEVLVLALQSREQAEEWLKVIREVSKPVGGAEGVEVPRSPVLLCKLDLDKRLSQEKQTSDSDSVGVGDNCS
LAPTM5
MMIIFSIAFITVLIFKVYMFKCVWRCYRLIKCM-------NSVEEKRNSKMLQKVVLP---SYEEALSPAGPV----SCS

218
361
252

BAG64383 TLGRRETCDHGKGKKSSLAELKGSMSRAAGRKITRIIGFSKKKTLADDLQTSSTEEEVPCCGYLNVLVNQGWKERWCRLK
AFAP1L1 TLGRRETCDHGKGKKSSLAELKGSMSRAAGRKITRIIGFSKKKTLADDLQTSSTEEEVPCCGYLNVLVNQGWKERWCRLK
LAPTM5
QLGQRFRLSHSSGL--SIIQPNNAW----------FISISSD-TCLDDWPF-----------------------------

298
441
290

BAG64383 CNTLYFHKDHMDLRTHVNAIALQGCEVAPGFGPRHPFAFRILRNRQEVAILEASCSEDMGRWLGLLLVGMGSRVTPEALH
AFAP1L1 CNTLYFHKDHMDLRTHVNAIALQGCEVAPGFGPRHPFAFRILRNRQEVAILEASCSEDMGRWLGLLLVEMGSRVTPEALH
LAPTM5
--------------------------------------------------------------------------------

378
521

BAG64383 YDYVDVETLTSIVSAGRNSFLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCSEKSHRVDPQVKVKRH
AFAP1L1 YDYVDVETLTSIVSAGRNSFLYARSCQNQWPEPRVYDDVPYEKMQDEEPERPTGAQVKRHASSCSEKSHRVDPQVKVKRH
LAPTM5
--------------------------------------------------------------------------------

458
601

BAG64383 ASSANQYKYGKNRAEEDARKYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPGAKLKALEEAVATLEAQCRAKEE
AFAP1L1 ASSANQYKYGKNRAEEDARRYLVEKEKLEKEKETIRTELIALRQEKRELKEAIRSSPGAKLKALEEAVATLEAQCRAKEE
LAPTM5
--------------------------------------------------------------------------------

538
681

BAG64383 RRIDLELKLVAVKERLQQSLAGGPALGLSVSSKPKSGETANKPQNSVPEQPLPVNCVSELRKRSPSIVASNQGRVLQKAK
AFAP1L1 RRIDLELKLVAVKERLQQSLAGGPALGLSVSSKPKSGETANKPQNSVPEQPLPVNCVSELRKRSPSIVASNQGRVLQKAK
LAPTM5
--------------------------------------------------------------------------------

618
761

BAG64383 EWEMKKT
AFAP1L1 EWEMKKT
LAPTM5
-------

625
768

Figure 13. AFAP1L1 and BAG64383
A protein identical to lysosomal protein transmembrane 5 (LAPTM5) in its N-terminal
181 amino acids and identical to AFAP1L1 in its C-terminal 444 amino acids was aligned
to each protein by ClustalW2 analysis (27). BAG64383 sequence identical to LAPTM5 is
highlighted in yellow, sequence identical to AFAP1L1 is highlighted in green, sequence
shared between all three proteins is highlighted in pink and sequence unique to
BAG64383 is highlighted in light blue.
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CHAPTER 4

UNIQUE METHODS
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I. Mutation and formation of full length AFAP1L1 from separate plasmids
For purposes of creating a plasmid to express tagged and untagged full length
nucleotide sequence of AFAP1L1, two vectors were purchased from Thermo Scientific
OpenBiosystems, Huntsville, Alabama. The first, a pCMV-SPORT6 vector, contained
coding sequence for the first 340 amino acids of afap1l1. The second, a pINCY vector,
contained coding sequence for amino acids 274 to 768. An overlap region of 67 amino
acids existed between the two sequences, encompassing amino acids 274 to 340 (Figure
1). To piece together the 5’ and 3’ halves of afap1l1, we identified a restriction enzyme
site in the overlap region that could be used to digest afap1l1 part 1 from pCMVSPORT6 and afap1l1 part 2 from pINCY which would create sticky ends which could be
ligated together to form full length afap1l1. Using the New England BioLabs NEBcutter
program to find restriction enzyme sites, we determined that a BstYI restriction enzyme
site (AGATCC) in the overlap region could be mutated to a BglII restriction enzyme site
(AGATCT) by mutating one base pair of amino acid 329, TCC to TCT. This would
create a restriction site unique to each plasmid so that multiple cut sites would not be
found and also would not change the amino acid encoded as TCC and TCT both code for
the amino acid serine.
Mutagenesis of amino acid 329 was accomplished by using the QuikChange
Multi-Site Directed Mutagenesis Kit from Stratagene. Forward and reverse primers were
synthesized (Forward 5’GAGGTCCCCAGATCTCCAGTCCTCCTGTG3’ and Reverse
5’CACAGGAGGACTGGAGATCTGGGGACCTC3’)
mixture was used:
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and

the

following

reaction

10X Buffer

2.5µl

dH20

16µl

pSPORT6
or pINCY
template
Forward
primer

2.5µl
(50ng
total)
1µl
(100ng
total)
1µl
(100ng
total)
1µl

Reverse
primer
dNTPs

QuikChange 1µl
Enzyme

The reaction mixture was incubated in the following PCR protocol:
Segment
1
2

Cycle
1
30

3

Hold

Temperature
95°C
95°C
55°C
65°C
4°C

Time
1 minute
1min
1min
9min
Hold

The PCR product was incubated at 37°C for 1 hour with addition of restriction
enzyme Dpn1 to degrade parental DNA and the final product was transformed into dH5α
bacterial cells by incubation of 1µg PCR product with 50µl dH5α for 30 minutes
followed by 30 seconds of heat shock at 42°C and incubation on ice for 2 minutes. 1ml of
SOC media was added and the bacterial mixture was shaken at 37°C for one hour in a
heated shaker. After 1 hour, bacteria were spun down at 5000rpm, 900µl of media was
removed, bacteria were resuspended in the remaining 100µl of SOC media and plated
onto ampicillin plates. Control transformations with no plasmid added were also
conducted.
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Multiple colonies from each mutated pCMV-SPORT6 and pINCY were picked
and grown overnight in 3ml of LB+Ampicillin shaking at 37°C. 1.5ml of overnight
culture was centrifuged at 12,000rpm for 30 seconds and the bacterial pellet was lysed in
50µl of EasyPrep lysis buffer (10mM TrisHCl pH8.0, 1mM EDTA, 15% sucrose,
2mg/ml lysozyme, 0.2mg/ml RNase A and 0.1mg/ml BSA). Lysates were incubated at
room temperature for 5 minutes, boiled at 100°C for 90 seconds, chilled on ice for 2
minutes and then centrifuged 12,000rpm for 20 minutes at room temperature. 5µl of each
DNA prep was digested with restriction enzymes in the following manner to determine if
they contained their respective afap1l1 insert. pCMV-SPORT6 vectors were cut with
Not1 and Sal1 to cut out afap1l1 part 1 and pINCY vectors were cut with EcoRI and
Not1 to check for afap1l1 part 2.
pCMV-SPORT6

pINCY

5µl DNA

5µl DNA

2µl dH20

2µl dH2O

2µl Buffer H

2µl Buffer H

0.5µl Not1

0.5µl EcoRI

0.5µl Sal1

0.5µl Not1

Digests were placed at 37°C for two hours and run on a 1% Seakem agarose gel
containing ethidium bromide to determine their banding pattern. If the afap1l1 insert was
present, pCMV-SPORT6 should have produced two bands, 4396bp and 1314bp. The
pINCY vector should create two bands with a molecular weight (MW) of 4080bp and
2607bp. Five colonies from pCMV-SPORT6 and three colonies from pINCY provided
the correct banding patterns. 200µl of pCMV-SPORT6 colonies 2 and 7 and pINCY
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colonies 2, 7 and 11 were grown overnight in 500ml LB+Ampicillin shaking at 37°C to
perform a midi prep of DNA so as to send for sequencing.
Colonies 2 and 7 of pCMV-SPORT6 and colony 11 of pINCY showed mutation
of amino acid 329 from a TCC codon to TCT while keeping the amino acid as a serine
(Figure 2). To ligate together the two halves of afap1l1, it was decided to insert each
mutated portion of afap1l1 in to a pBlueScriptII KS+ vector (Stratagene) followed by
digestion of the vector with the engineered BglII site and a unique ScaI site and ligation
so as to bring together the two halves of KS+ and full length afa1l1. The restriction sites
HindIII and EcoRI in the KS+ vector were chosen because pCMV-SPORT6 contained a
HindIII site which could be used to cut out and ligate afap1l1 part 1. An EcoRI site was
engineered

through

site-directed

5’CGAATTCCTTGTCCAGGTCCAACTT3’,

mutagenesis

(forward
reverse

5’AAGTTGGACCTGGACAAGGAATTCG3’) at the end of the afap1l1 part 1 fragment
so as to insert the afap1l1 sequencing into the KS+ vector. Additionally, pINCY
contained an EcoRI site at the end of the afap1l1 part 2 sequence and an engineered
HindIII site

(forward 5’ATAAGCTTTGCCCAAGGACAGCCGGCA3’, reverse

5’TGCCGGCTGTCCTTGGGCAAAGCTTAT3’) was created in the beginning of the
afap1l1 part 2 sequence so as to ligate to the KS+ vector. PCR mixture and parameters
were as follows:
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pCMV-SPORT6
40 µl dH20
5µl Pfu Buffer
1µl dNTPs(10mM)
1µl pCMV-SPORT6 (100ng/ml)
1µl pCMV-SPORT6 EcoRI forward
primer
1µl pCMV-SPORT 6 reverse primer
1µl Pfu Polymerase (2.5U)

Segment
1
2

Cycle
1
30

3
4

1
Hold

pINCY
40 µl dH20
5µl Pfu Buffer
1µl dNTPs (10mM)
1µl pINCY (100ng/ml)
1µl pINCY HindIII forward
primer
1µl pINCY HindIII reverse
primer
1µl Pfu Polymerase (2.5U)

Temperature
95o
95o
Primer Tm-5o
72o
72o
4o

Time
2min
30sec
30sec
1min per kb
10min
Hold

PCR products were cleaned using the Invitrogen PCR Purification Kit and
digested with their respective restriction enzymes to produce sticky ends compatible for
ligation. 30µl of PCR product were digested using 4µl Buffer B, 4µl H2O, 3µl HindIII
and 3µl EcoRI by incubation at 37°C for two hours. KS+ vector was also cut using
HindIII and EcoRI restriction enzymes for two hours and phosphatased for an additional
hour. Cut PCR products and vector were run on a 1% Seakem agarose gel, stained by
incubation in water containing ethidium bromide for one hour and cut and eluted from the
gel using an Invitrogen Quick Gel Extraction Kit. Afap1l1 part 1 and afap1l1 part 2 were
each ligated separately to KS+ using T4 ligase. 1µl of KS+ plasmid treated with alkaline
phosphatase was incubated with 21µl dH2O, 3µl T4 Buffer, 1µl T4 Ligase and 4µl of
either afap1l1 part 1 or afap1l1 part 2 overnight at 16°C. 2.5µl of each ligation product
was incubated with 60µl dH5α bacterial cells on ice for 30 minutes, heat shocked for 30
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seconds and placed back onto ice for 2 minutes. 1ml of SOC media was added and
bacteria were grown while shaking at 37°C for one hour. Bacteria were spun down, 900µl
of SOC media removed and bacteria brought up in the remaining 100µl SOC media and
plated onto LB plates containing ampicillin. Colonies formed from ligations were grown
overnight in 3ml of LB + Ampicillin. 1.5ml of overnight culture was subjected to
EasyPrep lysis and 5µl used for digestion with EcoRI and HindIII restriction enzymes to
insure that the KS+ vector contained the respective afap1l1 insert. If the digest did drop
out an EcoRI/HindIII band, this bacterial lysate was also subjected to digestion with BglII
to insure that the insert was indeed mutated afap1l1. Once KS+ vectors containing the
correct afap1l1 part 1 and afap1l1 part 2 inserts were determined, 5µg of each of these
vectors was cut using the engineered BglII site in the overlap region of AFAP1L1 and a
unique Sca1 site in the KS+ vector in the following manner:
AFAP1L1 part 1

AFAP1L1 part 2

3µl part 1 (5µg)
4µl dH20

4.5µl part
(5µg)
2.5µl dH2O

1µl Buffer H

1µl Buffer H

1µl BglII

1µl BglII

1µl Sca1

1µl Sca1

2

Additionally, the KS+/afap1l1 part 1 was chosen to be phosphatased for one hour
after digestion. Digests were run on a 1% Seakem agarose gel and stained for one hour
with water containing ethidium bromide. The cut pCMV-SPORT6 vector should produce
two bands, a 2790bp fragment that contains the afap1l1 part 1 insert and an 1158bp
fragment. The cut pINCY vector should produce two bands, a 2479bp fragment that
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contains afap1l1 part 2 and a 1794bp fragment. Fragments containing their respective
inserts were eluted from the gel using the Invitrogen Quick Gel Extraction Kit. The
KS+/afap1l1 part 1 and KS+/afap1l1 part 2 fragments were ligated together using T4
ligase overnight at 16°C and bacteria were transformed and plated onto LB+Ampicillin
plates. Colonies were picked, grown overnight in 3ml LB+Ampicillin and subjected to
EasyPrep lysis. 5µl of lysate was digested using EcoRI and HindIII to look for a fragment
consistent with full length afap1l1. A colony containing the correct banding pattern
consistent with full length afap1l1 was chosen to grow up in 500ml of LB+Ampicillin
overnight for midi prep. Vector KS+ containing full length afap1l1 was subjected to
digestion with EcoRI and HindIII and full length afap1l1 was inserted into a pEGFP
vector so as to utilize GFP tagged AFAP1L1. Additionally, the full length afap1l1 was
also inserted into a pcDNA3.1+ vector so as to utilize an untagged AFAP1L1.
Sequencing of pEGFP-AFAP1L1 confirmed that full length afap1l1 was expressed in the
pEGFP vector.

II. Creation and purification of a rabbit polyclonal antibody against AFAP1L1:
1L1-CT
During early work with AFAP1L1, no commercial antibodies were available for
use in molecular biology techniques. ProSci Incorporated of Poway, CA was
commissioned by our lab to create an antibody against AFAP1L1. ProSci Inc. analyzed
full length AFAP1L1 sequence and provided three possible antibody epitopes based upon
regions of high hydrophilicity (H), antigenicity (A) and surface probability (SP) scored
from 1-10, with 10 being the highest.
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Turns
H
A
SP

Residue
82
DLRDMPEDDGEPSK
1
8
8
8

Residue
198
EGKSPQPRHQWPSE
1
8
8
8

Residue
714
KPKSGETANKPQNS
2
8
10
7

A BLAST search was performed on each epitope to determine suitability for a
unique antibody that would not react with other proteins, including other AFAP family
members. As of August 21, 2007, Residue 82 epitope was discarded due to similarity
with the ubiquitin-protein ligase Tom1. Residue 198 epitope showed homology with
human and mouse forms of AFAP1L1. Residue 714 epitope, which is near the Cterminus, showed homology with the human form of AFAP1L1 and was chosen due to its
lack of similarity with other proteins and also as a recommendation from ProSci Inc. that
N- and C- termini epitopes tend to perform the best for western blotting and can perform
better

than

higher

ranked

internal

sequences.

An

immunogen

of

NH2-

K714PKSGETANKPQNS727-OH was synthesized by ProSci Incorporated and used to
inject two separate rabbits, PAS12219 and PAS12220. 5ml of pre-immune serum was
collected from each rabbit and rabbits were immunized with synthesized immunogen at
Week 0 using 200mg/rabbit in Complete Freud’s Adjuvant. Rabbits were additionally
immunized with 100mg/rabbit of immunogen in Incomplete Freud’s Adjuvant at Weeks
2, 4 and 6. The first production bleed was collected at Week 5 with a 2nd bleed at Week 7,
a 3rd bleed at Week 8 and a final bleed within five days of the 3rd bleed. Serum was
shipped from ProSci Incorporated after each bleed and stored at -80°C.
Beginning with PAS12219, rabbit serum was purified using an Ultralink
Iodoacetyl

Gel

peptide

column

from
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Pierce

with

5mg

immunogen

C-

KPKSGETANKPQNS cross-linked to the gel. The antibody column was prepared by
first capping the end of a column tube and adding 3ml of Ultralink Iodoacetyl Gel bead
slurry to the provided column so as to end with 1.5ml of gel bed as this would hold a total
of 6mg of peptide. The gel bed was allowed to settle for 30 minutes and the bottom cap
was removed to allow gel bed liquid to flow out while re-capping the column as the
liquid meniscus reached the top of the gel bed so as to avoid the potential for air pockets.
Five gel bed volumes (7.5ml) of Coupling Buffer (50mM Tris, 5mM EDTA, pH8.46)
were added to the column and allowed to flow through until liquid neared the top of the
gel bed. 5mg of AFAP1L1 peptide was brought up in 1.5ml of Coupling Buffer, saving a
small portion for before binding optical density (OD) reading, and added to the column.
The column was secured tight with parafilm and rotated at room temperature for 15
minutes. The column was allowed to settle for 30 minutes and remaining buffer was
allowed to flow out while keeping the flow through so as to compare to the before
binding OD reading to determine how much protein was bound. The OD reading at
wavelength 280 for peptide mixture before binding was 0.156. The OD reading for the
flowthrough after binding was 0.050. It was determined that 32% of the protein came
through in the flowthrough and 68% of the peptide remained bound to the column. The
peptide column was washed with 3 gel bed volumes (4.5ml) of Coupling Buffer and
allowed to drain until liquid reached the top of the gel bed. The column was then
incubated with 1 gel bed volume (1.5ml) of Coupling Buffer containing 50mM LCysteine, mixed and rotated for 15 minutes at room temperature so as to block any other
peptide binding sites in the peptide column. The column was allowed to settle for 30
minutes. With Couling Buffer with L-Cysteine still in the column, a column disc was
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floated and soaked in the column so as to remove air bubbles from the disc. Using the
provided cylinder, the disc was pushed down into the column to within 1mm of the gel
bed without touching the gel bed. The column was then washed with 5 gel bed volumes
(7.5ml) of 1M NaCl and then 5 gel bed volumes (7.5ml) of PBS with 0.02% NaN3. 1ml
of PBS with 0.02% NaN3 was added to the column for preservation and it was stored
upright at 4°C when not in use.
To pass serum over the column for the purpose of purifying antibody, the column
and all solutions were allowed to come to room temperature so as to avoid introducing air
bubbles into the column. Serum to be used (PAS12219 Bleed 1 for example) was thawed
on ice and filtered through a 0.45µm filter using a syringe so as to remove any buildup
that would stop flow of the column. Once to room temperature, the column was washed
with 5 gel bed volumes (7.5ml) of PBS with no azide. After washing, the serum was
passed over the column at 4°C in 2ml aliquots, running the entire amount of serum over
the column three times. Returning to room temperature, the column was washed with 5
gel bed volumes (7.5ml) of PBS with no azide. To collect fractions, 750ul of Elution
Buffer (100mM glycine, pH 2.3-3.0) was passed over the column. In the tube to collect
fractions, 1/10 of the volume (75µl) of 1M Tris pH 7.5 was added so as to neutralize the
low pH flowthrough. The OD of each fraction was read at 280nm as each fraction was
collected so as to determine when peptide antibody came out of the column. For
PAS12219 Bleed 1, 10 fractions were collected, resulting in ODs of
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Fraction

OD 280nm

1

.360

2

.327

3

.264

4

1.610

5

1.168

6

.413

7

.413

8

.057

9

.057

10

.051
When graphed, this showed that the antibody eluted from the column in fractions

4-7. After antibody was successfully eluted from the column, the column was washed
with 5 gel bed volumes (7.5ml) of PBS following by 5 gel bed volumes (7.5ml) with PBS
containing 0.02% NaN3 and stored at 4°C with 1ml PBS containing NaN3 until the next
antibody purification would be needed.
In addition to determining the OD reading for each fraction collected, an 11%
acrylamide gel was run and stained with Coomassie stain so as to visualize any heavy and
light chains present in the fractions. Although the OD reading can tell that peptide is
present, visualization of the heavy and light chains is necessary to show that the peptide
is antibody. Once confirmed, antibody can be used in various applications such as
western blotting, immunohistochemistry, immunoprecipitation and other various
molecular biology techniques.
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Figure 1: Amino acid sequence of AFAP1L1 with highlighted overlap
The pCMV-SPORT6 vector contained coding sequence for amino acids 1-340 of afap1l1.
The pINCY vector contained coding sequence for amino acids 274-768 of afap1l1. An
overlap region (highlighted) between the two sequences encompassed 67 amino acids
from amino acid 274 to 340. A BstYI restriction site in the overlap region was changed to
a unique BglII restriction site by mutation of amino acid 329, changing coding sequence
from TCC to TCT to create the BglII site while keeping the amino acid a serine.
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Figure 2

A.
pSPORT6.mut.check.

CGAGAGCAGGCCGAGGAGTGGCTGAAGGTCATCCGAGAAGTGAGCAAGCCAGTTGGGGGA 151

AFAP1L1

CGAGAGCAGGCCGAGGAGTGGCTGAAGGTCATCCGAGAAGTGAGCAAGCCAGTTGGGGGA 960
************************************************************

pSPORT6.mut.check.

GCTGAGGGAGTGGAGGTCCCCAGATCTCCAGTCCTCCTGTGCAAGTTGGACCTGGACAAG 211

AFAP1L1

GCTGAGGGAGTGGAGGTCCCCAGATCCCCAGTCCTCCTGTGCAAGTTGGACCTGGACAAG 1020
************************** *********************************

B.
pINCY.mut.check.

CGAGAGCAGGCCGAGGAGTGGCTGAAGGTCATCCGAGAAGTGAGCAAGCCAGTTGGGGGA 118

AFAP1L1

CGAGAGCAGGCCGAGGAGTGGCTGAAGGTCATCCGAGAAGTGAGCAAGCCAGTTGGGGGA 960
************************************************************

pINCY.mut.check.

GCTGAGGGAGTGGAGGTCCCCAGATCTCCAGTCCTCCTGTGCAAGTTGGACCTGGACAAG 178

AFAP1L1

GCTGAGGGAGTGGAGGTCCCCAGATCCCCAGTCCTCCTGTGCAAGTTGGACCTGGACAAG 1020
************************** *********************************

Figure 2. Mutation of amino acid 329 in afap1l1
Afap1l1 part 1 in the pCMV-SPORT6 vector (A) and afap1l1 part 2 in the pINCY vector
(B) were successfully mutated from TCC to TCT (highlighted) so as to introduce a
unique BglII restriction enzyme site while keeping the amino acid a serine.
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CHAPTER 5

General Discussion
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The Actin Filament Associated Proteins represent a family of adaptor proteins
that have similar overall structure while each displays a signature function. All three
family members share modular domain structure with at least one N-terminal SH3
binding motif, at least one N-terminal SH2 binding motif, two PH domains in the central
portion of the protein which surround a region rich in serine and threonine residues, at
least one SH2 binding motif in the C-terminal region and a helical region at the Cterminus. In AFAP1, this region is known to contain a helical leucine zipper motif and
actin binding domain while AFAP1L1 also contains a putative leucine zipper and actin
binding domain. AFAP1L2 contains a coiled-coil in this region and is hypothesized to
bind actin through a more C-terminal region (Baisden et al., 2001; Lodyga et al., 2010;
Xu et al., 2007). It is the sequence similarity of the PH domains that define the AFAP
proteins as a family. Although PH domains contain a characteristic helix-loop-helix
structure, the amino acids within PH domains vary widely and little conservation is seen
among proteins (DiNitto and Lambright, 2006). This is not true, however, for the AFAP
proteins as they share 44% identity (81% similarity) in the PH1 domains and 40%
identity (73% similarity) in their PH2 domains. The AFAP proteins may be
evolutionarily related by two chromosomal duplications that are hypothesized to have
taken place during the evolution of invertebrates to vertebrates (Dehal and Boore, 2005;
Ohno, 1970). Conservation of overall structure through evolution may explain the high
level of similarity between the PH domains of the different family members. Although
similar in their modular domain, each AFAP family member has its own unique function
that is characterized by its individual amino acid sequence. While AFAP1 has been
intensively studied for its cellular function and binding abilities and AFAP1L2 has
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currently been a topic of study for its role in the PI3K/Akt pathway, this dissertation
served to define the cellular role of AFAP1L1 (Baisden et al., 2001; Lodyga et al., 2009).
So named for their ability to interact with actin filaments, the AFAP proteins may
play pivotal roles in regulation of the actin cytoskeleton. Cytoskeletal rearrangement is
indispensable to a cell and is responsible for a number of processes such as motility in
embryogenesis and wound healing, immune cell adherence and movement, pathogen
infection and invasion. Each AFAP family member has been shown to interact with actin
(Flynn et al., 1993; Lodyga et al., 2010). AFAP1 plays a role in cell contractility by
virtue of its ability to bind actin filaments and multimerize, thus bundling actin filaments
together. The loss of AFAP1 results in a loss of stress fiber integrity (Dorfleutner et al.,
2007). AFAP1L2 translocates from the cytosol to the lamellipodium and interacts with
branched F-actin networks in a Rac-dependent manner (Lodyga et al., 2010). AFAP1L1
is shown to bind actin filaments and may play a similar role to AFAP1 in actin crosslinking due to conservation of a putative leucine zipper. This may give AFAP1L1 the
ability to bind other AFAP molecules and thus also play a role in actin filament crosslinking and stress fiber formation.
While each AFAP family member encodes at least one SH3 binding motif, they
vary in their ability to bind different proteins. The core amino acids of an SH3 binding
motif, a PXXP motif, are surrounded by various amino acids that convey specificity for
the binding of SH3 domains. The SH3 domains of AFAP1 and AFAP1L2 have been
shown to interact with cSrc while the SH3 domain of AFAP1L1 has been shown to
interact with cortactin (Guappone and Flynn, 1997; Xu et al., 2007). This cortactin
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interaction is unique to AFAP1L1 and may play an important role in cell motility and
invasion.
Cortactin is an adaptor protein that is necessary for stabilization of actin
branching in growing actin filaments and also for the formation of invadosomes. In its
inactive state, cortactin displays diffuse cytoplasmic staining around the perinuclear
region. Upon cellular stimulation with growth factors, cortactin moves from its
perinuclear region to active sites of cytoskeletal branching where it binds to the sides of
growing actin filaments and interacts with the Arp2/3 complex to stabilize branching
points (Ammer and Weed, 2008). Cortactin is also found in cellular adhesions such as
invadosomes and is necessary for their formation and function (Ayala et al., 2008). High
levels of cortactin indicate poor prognosis in tumors as these tend to be more aggressive
and have an increased ability to metastasize (Weaver, 2008). Although cellular levels of
AFAP1L1 are relatively low in many cell lines, the cancer cell line MDA-MB-435
expresses high levels of AFAP1L1. When comparing the endogenous localizations of
AFAP1L1 and cortactin in unstimulated MDA-MB-435 cells, AFAP1L1 is found to
decorate actin filaments and have some cytoplasmic staining in the perinuclear region
while cortactin is found in its expected perinuclear location. When active cSrc was
transfected so as to create a transformed phenotype in these cells, both AFAP1L1 and
cortactin moved to invadopodia. Cortactin is a substrate for cSrc phosphorylation on key
tyrosine residues in the helical region and, upon their phosphorylation, is hypothesized to
undergo a conformation change under which cortactin may bind actin filaments more
efficiently and also open up binding sites for other proteins (Ammer and Weed, 2008). It
is through the phosphorylation of cortactin by active cSrc and subsequently activated
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kinases which may have allowed for AFAP1L1 binding to the SH3 domain of cortactin
through its SH3 binding motif. AFAP1L1 and cortactin were then able to localize to
invadopodia and, by virtue of their binding motifs, act as scaffolds for other invadosomerelated proteins.
Interestingly, it was found that upon the overexpression of GFP-AFAP1L1, A7r5
smooth muscle cells expressing high levels of GFP-AFAP1L1 had the ability to
spontaneously dissolve their stress fibers and form podosomes in which both GFPAFAP1L1 and cortactin colocalized. This is similar to the expression of AFAP1 as
AFAP1 is found to decorate actin filaments on an endogenous level. In unstimulated
cells, the AFAP1 binding partner cSrc is found in an inactive state on vesicles in the
perinuclear region. AFAP1 moves to the perinuclear region where it binds to and
activates cSrc which then moves as a complex to sites of actin rearrangement (Walker et
al., 2007). High levels of exogenous GFP-AFAP1 have the ability to induce podosome
formation without cell stimulation in a subset of cells. This was attributed to the culture
conditions of the cells in which endogenous levels of PKCα may become activated, thus
activating the high levels of AFAP1 and in turn activating cSrc and podosome formation
(Dorfleutner et al., 2008). This may also be the case for AFAP1L1; however it is
interesting that while many cells overexpresse GFP-AFAP1L1, cells expressing low
levels of GFP-AFAP1L1 showed highly formed stress fibers while only those with the
highest levels of GFP-AFAP1L1 expression formed spontaneous podosomes. Perhaps
there is an intrinsic ability of AFAP1L1 to induce podosome formation. This ability may
allow AFAP1L1 to move to cortactin and ferry it to invadosomes, much like the activity
of AFAP1 and cSrc.
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Despite the fact that the mechanism for the relocation of AFAP1L1 to
invadosomes remains unclear, AFAP1L1 is a newly described invadosome protein,
adding to the large array of cytoskeletal and signaling proteins found in these complexes.
Invadosomes have both physiological and pathological roles. The ability of a cell to cross
tissue barriers is necessary in the case of immune cells but is exploited by transformed
cancer cells which use the process for metastasis (Linder, 2009). While podosomes have
been extensively studied in a number of different cell types, they have recently been
shown to play a role in acetylcholine receptor clustering on the skeletal muscle side of the
neuromuscular junction and this is their first description for a role in neuronal synapses
(Proszynski et al., 2009). These podosomes are necessary for remodeling of the
postsynaptic membrane and are an integral part of its maturity. The neuromuscular
junction is quite large when compared to typical synapses between neurons, and these
smaller synapses are not large enough to contain conventional podosomes. However,
neuronal synapses do share a similar maturation pathway with the neuromuscular
junction and it is hypothesized that podosome-like complexes may be found within these
synapses as they contain very similar proteins that are involved in actin reorganization
(Proszynski et al., 2009).
The dendrite of a receiving neuron undergoes constant actin cytoskeletal
reorganization, known as synaptic plasticity, to strengthen or weaken its receiving signal.
Dendritic spines are small protrusions from the dendrite which receive signals from the
presynaptic neuron and have the ability to change their shape or number quickly in
response to receiving stimuli. Dendritic spines cluster neurotransmitter receptors to an
area at the tip of the spine known as the postsynaptic density which houses a diverse

174

group of adaptor proteins that link transmembrane neurotransmitter receptors to the
underlying actin cytoskeleton so as to transmit the receiving signal (Boeckers, 2006).
Cortactin is one of the major constituents of the postsynaptic density as its role in
cytoskeletal rearrangement is paramount to the function of the dendritic spine (Hering
and Sheng, 2003; Sekino et al., 2007).
Immunohistochemical detection shows a differential expression of AFAP1L1
from AFAP1 in the adult human brain. AFAP1L1 has a unique localization around the
Purkinje neurons and granule cells of the cerebellum and is also found surrounding the
neurons of the dentate nucleus. Although we cannot identify the exact location of
AFAP1L1 through this immunohistochemical signal, it is possible that these
immunoreactive sites represent the clustering of actin associated proteins at the
postsynaptic density in which AFAP1L1 may play a role. The ability of AFAP1L1 to
localize with actin filaments, bind to cortactin and be involved in podosome formation
may play a role in the maturation of neuronal synapses by neurotransmitter clustering and
up and down regulation of dendritic spines.
Work by Tabakoff et al. supports the hypothesis of a role for AFAP1L1 in the
postsynaptic density. AFAP1L1 was shown to be upregulated in the brains of rats that
became addicted to alcohol and is considered a candidate gene that influences
dependency versus non-dependency. Tabakoff et al. hypothesize that AFAP1L1 plays a
role in receptor trafficking by virtue of its actin filament association and propose its
location in the neuronal synapse to be at the postsynaptic density in association with Factin and other cytoskeletal associated proteins (Tabakoff et al., 2009).
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The Oncomine database predicts high expression levels of AFAP1L1 in cancers
of the nervous system, particular neuroblastoma and glioblastoma. Neuroblastoma occurs
most commonly in children from bundles of immature nerve fibers and has a fairly good
prognosis while glioblastoma arises from glial cells and is the most common and most
aggressive primary brain tumor in humans (Maris, 2010; Miller and Perry, 2007). We
have shown that AFAP1L1 can be detected by immunohistochemistry in glial cells.
AFAP1 has also been shown to play a role in glioblastoma as it is highly expressed in
last-stage glioblastoma cell lines. This expression overlaps with the expression of the Src
family kinases cSrc, Fyn and Lyn. AFAP1 is poised in glioblastoma to relay signals
through SFK that that can promote proliferation and invasion of the tumor (Clump,
2008). AFAP1L1 may play a similar role and its expression in glial tumors may enhance
the aggressiveness of the tumor.
The Oncomine database also predicts high levels of AFAP1L1 in melanoma.
Melanoma arises from melanin-producing melanocytes in the skin and is considered a
very serious and aggressive form of cancer (Berwick, 2006). Cortactin is known to be
highly increased in metastatic melanoma and its aberrant expression may have a role in
tumor progession (Xu et al., 2010). While we have not tested for levels of AFAP1L1 in
melanoma in our studies, our observations of high levels of AFAP1L1 in MDA-MB-435
cells provides as intriguing idea that AFAP1L1 may play a role in melanoma as well.
MDA-MB-435 cells were originally isolated in 1978 from a pleural effusion of a breast
cancer patient (Cailleau et al., 1978). Considered a highly aggressive and metastatic form
of breast cancer, the MDA-MB-435 cell line was used in many studies to determine the
signaling pathways of breast cancer cells until it was noticed by Ross et al. that MDA-
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MB-435 cells did not cluster with other breast cancer cell lines based upon their mRNA
expression patterns and instead clustered among various melanoma cell lines (Ross et al.,
2000). Many studies have taken place since this discovery to determine the exact origin
of MDA-MB-435 cells. Theories range from misidentification of the cell line to
contamination with and eventual succession by the M14 melanoma cell line.
Additionally, it is hypothesized that the MDA-MB-435 cell line was created from an
undiagnosed metastatic melanoma lesion and not a breast lesion from the beginning.
Multiple studies have shown that MDA-MB-435 cells do not express genes typically
found in breast cancer and instead express those involved in melanoma. Through
extensive gene expression profiling, SNP profiling and karyotyping, MDA-MB-435 cells
are considered to be more melanocytic in nature than related to breast cells. Regardless of
their origin, AFAP1L1 expression levels are high in MDA-MB-435 cells. If it is true that
these cells are indeed melanocytic or have taken on a melanocytic genotype, it is
intriguing that AFAP1L1 and cortactin are highly expressed in conjuction with each other
in cancer.
AFAP1L1 represents a newly identified AFAP family member that may have
arisen from AFAP1 through gene duplication and plays a role in the regulation of the
actin cytoskeleton. Through its unique interaction with cortactin, AFAP1L1 may play a
role in motility and invasion as witnessed by its ability to localize to invadosomes and
induce spontaneous podosomes upon high levels of overexpression. The distinct
expression of AFAP1L1 in the area surrounding the Purkinje neurons and granule cells of
the cerebellum as well as the neurons of the dentate nucleus implies that AFAP1L1 may
play a role in these areas, particularly in the postsynaptic density which is a site of high
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actin dynamics. As podosomes have recently been described in the neuromuscular
junction, it is possible that similar complexes occur in neuronal synapses at the
postsynaptic density and AFAP1L1 is a regulator of these complexes to govern receptor
trafficking and clustering. The unique staining of AFAP1L1 in the brain is also supported
by the fact that AFAP1L1 is predicted to be high in cancers of the central nervous
system, particularly glioblastoma, as we find high levels of AFAP1L1 in glial cells. This
interaction with cortactin and ability to alter the actin cytoskeleton may allow AFAP1L1
to play a role in normal cellular physiological processes involving actin dynamics and to
also a play a role in the metastatic ability of cancer.
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ABSTRACT

Enhanced expression and activity of cSrc is associated with ovarian cancer progression.
Generally, cSrc does not contain activating mutations; rather its activity is increased in
response to signals that effect a conformational change that releases its autoinhibition. In
this report we analyzed ovarian cancer tissues for expression of a cSrc-activating protein,
AFAP-110. AFAP-110 activates cSrc through a direct interaction that releases it from its
autoinhibited conformation.

Immunohistochemical analysis revealed a concomitant

increase of AFAP-110 and cSrc in ovarian cancer tissues. An analysis of the AFAP-110
coding sequence revealed the presence of a nonsynonymous, single nucleotide
polymorphism (SNP) that resulted in a change of Ser403 to Cys403. In cells that express
enhanced levels of cSrc, AFAP-110403C directed the activation of cSrc and the formation
of podosomes independently of input signals, in contrast to wild-type AFAP-110. We
therefore propose that under conditions of cSrc over-expression, the polymorphic variant
of AFAP-110 promotes cSrc activation. Further, these data indicate a mechanism by
which an inherited genetic variation could influence ovarian cancer progression and be
used to predict the response to targeted therapy.
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INTRODUCTION
Ovarian cancer, the most lethal gynecological malignancy, is characterized by
tumor disruption of the ovarian capsule and dissemination and seeding of the pelvic and
abdominal cavities (Naora and Montell, 2005). A combination of unreliable screening
techniques, unspecific symptoms, and chemotherapy resistance results in 15,000
mortalities per year in the United States (Jemal et al., 2007). BRCA1 and BRCA2 are
relevant for the disease and mutations of these genes are found in approximately 15% of
ovarian cancer cases (Pal et al., 2005; Risch et al., 2006). However, the majority of cases
consist of inconspicuous associations between inherited susceptibility and the
environment. These associations may be explained by haplotype mapping studies, which
predict that single nucleotide polymorphisms (SNPs) are not inherited independently, but
instead associate with one another, as well as with environmental stimuli, producing the
disease (Goldstein and Cavalleri, 2005). While SNPs that influence drug metabolism and
cancer-related symptoms are described (Reyes-Gibby et al., 2008), little is known about
genetic variants that modulate tumorigenesis. Identification of these genes may enhance
our understanding of the progression of neoplasms such as ovarian cancer. In addition,
these polymorphisms may serve as biomarkers that predict susceptibility to cancer or
response to therapy.
One protein contributing to ovarian cancer progression is cSrc. This tyrosine
kinase is over-expressed and activated in ovarian cancer cell lines and ovarian tumors
(Wiener et al., 2003). cSrc promotes motility and invasion, the alteration of adhesion,
and epithelial-mesenchymal transition (Frame, 2004; Yeatman, 2004). In addition, cSrc
contributes to chemotherapy resistance, as inhibiting cSrc restores sensitivity to paclitaxel
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(Chen et al., 2005; George et al., 2005). cSrc activation does not correlate with intrinsic
mutations or SNPs; rather, signals from growth factors in the tumor microenvironment or
intracellular activators of cSrc direct cSrc activation. A few cSrc activators have genetic
variations that potentially modulate cSrc activity (Chen et al., 2005; George et al., 2005),
and these may eventually serve as biomarkers useful for identifying the tumors most
likely to respond to cSrc inhibition.
One cSrc activator, the actin-filament associated protein of 110 kDa (AFAP-110)
is encoded by a polymorphic gene.

The NCBI dsSNP database identifies a

nonsynonymous C1210G coding substitution in exon 9 that predicts a serine to cysteine
change

at

amino

acid

403

(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=60312).

(AFAP-110403C)
AFAP-110, via its

intrinsic multimerization and a carboxy-terminal actin-binding domain, promotes actin
filament cross-linking (Baisden et al., 2001; Qian et al., 2004). Additionally, AFAP-110
relays signals from PKCα that activate cSrc (Gatesman et al., 2004; Qian et al., 2002).
These functions are autoinhibited by an intermolecular interaction between the carboxyterminal leucine-zipper motif and an amino-terminal pleckstrin homology domain (PH1)
(Qian et al., 2002; Qian et al., 2004). Upon experimental deletion of the leucine zipper
domain (AFAP-110ΔLzip) or upon PKCα activation, AFAP-110 is uninhibited and
facilitates cSrc activation (Qian et al., 2002; Qian et al., 2004). This correlates with
trafficking of activated cSrc to the cell membrane and the formation of the actin-rich
invasive structures, podosomes (Gatesman et al., 2004; Walker et al., 2007).
To determine if AFAP-110 is positioned to activate cSrc in ovarian cancer, we
performed immunohistochemical analysis on ovarian cancer tissues. In doing so, we
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demonstrated that AFAP-110 exhibited a concomitant increase in expression with cSrc.
Using PCR analysis, we discovered that a polymorphism of AFAP-110 was expressed in
1/4th of the population. This polymorphic variant, AFAP-110403C, activated cSrc and
triggered the formation of podosomes, suggesting that this variant of AFAP-110 may
contribute to the progression of ovarian cancer.
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MATERIALS AND METHODS
Reagents
The rabbit anti-human cortactin polyclonal antibody was purchased from Abcam
(Cambridge, MA, USA). The AFAP-110 antibody F1 was previously characterized
(Qian et al., 1999). The mouse anti-avian Src monoclonal antibody (clone EC10) was
obtained from Upstate Biotechnology (Lake Placid, NY, USA). The rabbit anti-human
cSrc monoclonal antibody (clone EG107) was from Novus Biologicals (Littleton, CO,
USA). The rabbit anti-phospho-Src (Tyr416) monoclonal antibody (clone 100F9) was
purchased from Cell Signaling (Danvers, MA) and the rabbit anti-phospho-Src (Tyr418)
polyclonal antibody was from Biosource (Camarillo, CA, USA). Alexa Fluor secondary
antibodies and fluorescently-labeled phalloidins were purchased from Molecular Probes.
TRITC-phalloidin was purchased from Sigma (St Louis, MO, USA).

Cell culture
Mouse embryo fibroblasts (MEF), MEFs devoid of Src, Yes, and Fyn (SYF) and SYF
cells re-expressing cSrc (SYF-cSrc) were obtained from the ATCC (Rockville, MD,
USA). Cell lines were cultured in high glucose Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% fetal calf serum, 2 mM glutamine, 100 U/mL
penicillin and 100 µg/mL streptomycin.

Study subjects and tissue samples
280 normal tissues and 124 serous papillary ovarian carcinomas in stage 3 or stage 4
were obtained from the Cooperative Human Tissue Network, Pediatric Division,
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Children’s Hospital, Columbus, OH, USA and from the WVU Pathology Department.
Samples were collected prior to drug treatment and snap-frozen at –80oC until
RNA/DNA extraction was performed. All specimens were diagnosed and classified by
pathologists.

cDNA preparation and RT-PCR
From the studied specimens, total cellular RNA was isolated and purified by hot
phenol/chloroform extraction. Purified RNAs were precipitated and dissolved in DEPCtreated water. Through reverse transcription, using the SuperScript Preamplification
System, cDNAs were generated with oligo-dT primers from 5 µg of total RNA per
sample (Reverse Transcription System, Promega, Madison, WI, USA). Exon 9 of the
AFAP-110 gene which contains the SNP for 403C was amplified by the polymerase
chain reaction (PCR). The primer set used for amplification contained the sequence of
the 6 intron bases and the 20 exon bases that flank each end of exon 9
(CCGCAGGCTATCTGAACGTGCTCTCC

and

TCCTACCTCCAATACTGCAACCTCCT). The PCR conditions were 95oC for 3
minutes flowed by 40 cycles of 95oC for 30 seconds, 58oC for 30 seconds and 72oC for
45 seconds; and then 1 cycle of 72oC for 10 minutes.

DNA sequencing and genotyping
PCR products were separated on agarose gel and purified using the QIAQuick Gel
Extraction Kit (Qiagen, Valencia, CA, USA). The purified fragments were sequenced to
identify AFAP-110 mutations using the CEQ 8000 Genetic Analysis System with
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GenomeLab DTCS-Quick Start Kit (Beckman Coulter, Fullerton, CA, USA) and then
using ABI Prism DNA Sequencer with BigDye Terminator Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA, USA) to confirm identified mutations.

In

addition, sequence variants were confirmed in duplicate independent PCR amplifications
and sequencing reactions to insure that the mutations were not a result of PCR artifact.

Immunohistochemical methods
Immunohistochemistry was performed on 50 serous papillary ovarian carcinomas that
were paraffin-embedded and cut into 5 μm-thick sections and mounted on positive-charge
coated slides. Tissue sections were dried overnight in a 45º C oven, then deparaffinized,
rehydrated, and subjected to heat-induced epitope retrieval for two hours in 1 mM citrate
buffer (pH 6.00) in an 80º C water bath. Endogenous peroxide activity was blocked with
3% hydrogen peroxide and was followed by treatment with a serum-free protein blocker
to block nonspecific binding. Following each step of the immunoreaction except the
protein blocker, sections were rinsed in Tris-buffered saline with Tween. Tissues were
incubated for two hours with anti-AFAP-110 antibody (F1, 6 μg/mL) at a dilution of 1:10
or with anti-cSrc (EG107, diluted 1:50) in 10% normal horse serum. Negative controls
(i.e., preimmune serum or normal rabbit IgG) were incubated in 10% normal horse
serum. Sections were incubated with biotinylated secondary link antibody, followed by
treatment with streptavidin peroxidase and stained with diaminobenzidine substratechromogen solution. Counterstaining was performed with hematoxylin, followed by a
water rinse and bluing solution. Tissues were then dehydrated and coverslipped.
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Plasmid constructs
Mutagenesis was performed on human AFAP-110 to generate AFAP-110403C. AFAP110 and AFAP-110403C were cloned into pEGFP-C3 (Clontech, Mountain View, CA,
USA) as previously described (Qian et al., 2002).

The pGEX-6P-1 vector from

Amersham Pharmacia Biotech was used to create fusion proteins expressing the PH2
domain of AFAP as previously described (Qian et al., 2004). The pGexX-6P-1 PH2 403C
construct was created by PCR cloning the PH2403C fragment from the pEGFP vector with
BamHI and EcoRI ends and subsequent cloning into the pGEX-6P-1 vector. Human
AFAP-110 wild-type and AFAP110403C cDNA were PCR amplified and ligated into
pFLAG CMV vector using EcoRI and XhoI sites to generate Flag-tagged AFAP-110.

Immunofluorescence
Transfection of either GFP AFAP-110 or GFP AFAP-110403C into MEF, SYF, and SYFcSrc cells for immunofluorescence was carried out using either Lipofectamine PLUS
(Invitrogen, Carlsbad, CA, USA) or Nucleofector (Amaxa, Walkersville, MD, USA)
according to the manufacturer’s specification. Cells were plated on glass coverslips
immediately after transfection or allowed to recover for 24 hr after transfection and then
plated on glass coverslips coated with 10 µg/ml fibronectin (BD Bioscience, San Jose,
CA, USA). Cells were serum starved for 12 hours prior to fixation or left untreated as
indicated in the results section. Fixation, permeabilization, and staining procedures,
including antibody dilutions, were performed as previously described (Gatesman et al.,
2004). Confocal images were acquired with a Zeiss LSM 510 microscope with an
average slice thickness of 1 µm. Fluorescence channels were sequentially recorded using
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the multi-track recording module. Fluorescence images were obtained with a Zeiss
Axiovert 200M microscope.

Images were subsequently analyzed with LSM 510

software, Adobe Photoshop, and Image J (Rasband, W.S., ImageJ, U. S. National
Institutes of Health, Bethesda, Md, USA, http://rsb.info.nih.gov/ij/, 1997-2007).

Quantification of podosomes
Actin-rich structures at the ventral surface of cells were identified as podosomes if three
podosome markers: AFAP-110, cortactin, and phospho-cSrc colocalized. 250 to 300
cells from two independent experiments were analyzed to determine the percentage of
cells forming podosomes. The number of podosomes/cell was also counted from at least
100 podosome-positive cells and the distribution of podosomes/cell was plotted.
Student’s t-test with Bonferroni adjustment was used to detect the statistical significance.

Western Blot analysis and cSrc activation assay
Cultures

or

human

ovarian

tissue

were

lysed

or

homogenized

in

radioimmunoprecipitation assay buffer (RIPA) (50mM TrisHCl, pH7.4, 150mM NaCl,
2mM EDTA, 1% NP-40) containing leupeptin, aprotinin, sodium vanadate, EGTA, and
phenylmethylsulfonyl fluoride (PMSF). Protein concentration was determined by the
BCA assay (Pierce) and equal amount of proteins were resolved on SDS-PAGE and
transferred to PVDF. SYF cells were transfected with either Flag-AFAP-110 or FlagAFAP-110

403C

and cSrc using Lipofectamine PLUS (Invitrogen).

48 hours after

transfection, cells were stimulated and lysed in RIPA buffer. The levels of
phosphorylated Y416 cSrc and total cSrc were assessed in the subsequent western blot
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analysis. Antibody dilutions were performed according to previously described protocols
(Gatesman et al., 2004).

Molecular Modeling
The PH domain of SKAP-hom (PDB ID#1U5E), a SKAP55 homologue and a Srcassociated adaptor protein, was used as a structural template to create a homology model
of the AFAP PH2-WT domain using the homology module of Insight II. SKAP-hom was
chosen as the best template based on a BLAST server analysis and fold recognition
programs such as PHYRE, 123D+, and FUGUE. A sequence alignment was created
using the Clustal W server and manual adjustments were made by integrating secondary
structure prediction data for the PH2–WT domain from the PROF server with the known
secondary structure of SKAP-hom. The model was then minimized with 1000 steps of
steepest descent minimization. The structure was equilibrated for 300ps using explicit
water molecules as solvent. Equilibration was completed using the sander command of
Amber 8. The model was analyzed to ensure no mis-folded regions existed using the
Profiles3D program in Insight II. The sander command of Amber 8 was then used to
create a 700ps trajectory of the protein domain in explicit water molecules and a
hydrogen bond analysis for PH2403S was completed using the default parameters of the
ptraj hbond command in Amber 8. This process was repeated for PH2403C.

Lipid dot-blot
The lipid dot-blot was used to detect interactions between soluble GST proteins and
phospholipids immobilized on nitrocellulose. Lipid spotted membranes (PIP strips,
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Echelon Biosciences, Salt Lake City, UT, USA) were blocked 1 hour with 0.2% BSA in
TBS and incubated overnight with 0.5 mg/ml recombinant GST protein in TBS. Bound
GST protein was detected with rabbit anti-GST antibody (Sigma-Aldrich, St. Louis, MO,
USA).

Preparation of Lipid Vesicles
Large unilamellar lipid vesicles (LUV) were prepared by the extrusion method using 1palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and the indicated lipid (Avanti
polar Lipids, Alabaster, AL, USA). Phospholipids were combined by molar ratio (10%
indicated lipid, 90% POPC or 100% POPC) in chloroform: methanol: water (60: 30: 4),
dried with a stream of N2, and evacuated to remove traces of solvent. The residue was
hydrated with Buffer B (50 mM HEPES, pH 7.2, 80 mM KCl, and 3 mM EGTA) to
attain 2 mM lipid sheets when resuspended by vortex. Samples were subjected to 10
cycles of freeze thaw and then 10 passages through two layers of 0.10 μm polycarbonate
filters under high pressure N2. The resulting LUV were used directly for sedimentation
assays.

Sedimentation assay for PtdIns lipids
To detect pleckstrin homology domain protein associated with membrane phospholipids,
a sedimentation assay was used. Samples containing 1.7 mM vesicle lipid and 0.025 mM
recombinant GST fusion protein (PH1) were prepared in 150 μl binding buffer. Samples
were incubated 60 min and centrifuged with a Beckman Airfuge for 15 min at room
temperature. From each centrifuged sample, 16% of the supernatant and 100% of the
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pellet were analyzed by SDS-PAGE. Gels were stained with SPYRO orange (Invitrogen
Corp., Carlsbad, CA, USA).
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RESULTS

AFAP-110 and cSrc are over-expressed in ovarian cancer
Immunohistochemistry (IHC) determined that AFAP-110 and cSrc were overexpressed in 30/33 and 32/33 ovarian cancer samples, respectively (Supplemental Table
1).

In 60% of the samples, AFAP-110 was over-expressed focally (Figure 1A and B)

while in 86% of samples cSrc expression was diffuse (Figure 1C and D). AFAP-110
expression in blood vessels is observed in Figure 1B.
AFAP-110 and cSrc were not detected in normal ovaries (Figure 2, panels A-C),
although blood vessels exhibited AFAP-110 expression (Figure 2, panel A). AFAP-110
was always expressed with cSrc in well-differentiated tumors (Figure 2, panels D-F).
Further, AFAP-110 and cSrc always co-localized in desmoplastic regions (Figure 2,
panels G-I).

AFAP-110 is over-expressed in undifferentiated tumor specimens (13

specimens analyzed), but co-expression of AFAP-110 and cSrc was observed in only four
of these specimens (Figure 2, panels J-L).

A SNP in AFAP-110
Genetic variation within AFAP-110 was examined.

Analysis of AFAP-110

cDNA isolated from the ovarian cancer cell lines OvCAR-3 and 2008 revealed a
synonymous SNP (G297A, CCG to CCA) not found in the A2780, MCAS or SKOV3
lines. A nonsynonymous SNP (C1210G, TCT to TGT) identified in exon 9 resulted in a
serine to cysteine (S403C) substitution and was also found in the OVCAR-3 and 2008
cell lines.
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Ovarian tissues were screened to determine the prevalence of this nonsynonymous
SNP, C1210G.

C1210G was identified in 19/91 (20.9%) tumor samples and 9/41

(21.2%) tumor-adjacent normal tissues (Supplemental Table 2). In addition, the 33
samples used for IHC were analyzed and revealed the SNP in 9/33 samples (27.3%).
Tissue not associated with cancer was obtained to determine if the SNP was
enriched in ovarian cancer. C1210G was present in 80/280 normal tissues (28.6%)
(Supplemental Table 2). Thus, AFAP-110403C was not enriched in ovarian cancer.
We analyzed ovarian tumor tissues and adjacent normal tissue to confirm that
cSrc was over-expressed in tissues that have either wild type AFAP-110 or AFAP110403C. For comparison, we analyzed the intensity of cSrc expression in SYF cells,
which have no Src family kinases (Klinghoffer et al., 1999), and SYF-cSrc cells, which
over-express cSrc. Western blotting revealed that cSrc expression in tumors
approximated that detected in SYF-cSrc cells (Figure 3A). An antibody that detected both
forms of AFAP-110 indicated a reduction of AFAP-110 expression in adjacent normal
tissues confirming the over-expression in tumors observed by IHC (Figure 3B). Overexpression of cSrc in ovarian tumor samples was also confirmed.

403C is located within the PH2 domain
The serine to cysteine (S403C) substitution is located in the second PH domain
(PH2) of AFAP-110. PH domains are characterized by seven β-strands that are linked by
loop regions. These loop regions differ in length and amino acid composition and
therefore confer the differential binding of PH domains to lipids (Haslam et al., 1993;
Hyvonen et al., 1995; Lemmon et al., 1995; Macias et al., 1994; Mayer et al., 1993;
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Musacchio et al., 1993; Yoon et al., 1994). The S403C substitution occurs in a loop
region between the 5th and 6th β-strand (Figure 4). In AFAP-110, the hydroxyl R-group
of Ser403 is predicted to interact with water 71% of the time (Figure 4 panel B).
However, in AFAP-110403C, the sulfhydryl R-group of Cys403 is not predicted to be an
efficient hydrogen binding partner (36%, Figure 4 panel D), indicating that the PH403C
domain may exhibit differential binding specificity secondary to changes in structural
flexibility.
PH domains participate in protein-protein interactions. For example, PH domains
in pleckstrin and in AFAP-110 (PH1) bind to PKCα (Abrams et al., 1995; Qian et al.,
2002).

Further, the PH1 domain of AFAP-110 binds to AFAP-110, stabilizing the

AFAP-110 multimer (Qian et al., 2004). To determine differential binding between
AFAP-110 and AFAP-110403C, affinity precipitation assays using GST-fusion proteins
were performed.

GST-PH2 was more efficient than GST-PH2403C in pulling down

AFAP-110 (Figure 5). CaOV3 cell lysates were used as a negative control, as they have
AFAP-110 expression levels that are at or below detection limits (Gatesman et al., 2004).
These data indicated that the S403C change may reduce the affinity and therefore the
ability of the PH2 domain to bind to AFAP-110. Pull-down assays using GST-PH2 did
not reveal other binding partners (data not shown).
PH domains are also known to interact with lipids; however, an analysis of the
AFAP-110 PH2 domain demonstrated that it does not contain the conserved basic
residues that mediate electrostatic interactions with negatively charged phospholipids
(Figure 4, panels B and D).

A lipid dot- blot analysis as well as a lipid vesicle

sedimentation assay was used to determine if the GST-PH2 fusion protein would bind
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phosphoinositides (Supplemental Figure 1A-B and Supplemental Methods). Unlike the
positive control, the PH domain from DAPP1 (Dowler et al., 1999), GST-PH2 did not
bind to phosphoinositides.

Effects of AFAP-110403C on actin filament modulation.
Affinity precipitation data indicated that the PH2 domain mediates selfassociation. Earlier work demonstrated that intermolecular interactions that stabilize selfassociation had an autoinhibitory effect on AFAP-110 (Qian et al., 2004). As GSTPH2403C is less-efficient in binding to AFAP-110 than GST-PH2 and destabilization of
the AFAP-110 multimer correlated with an acquired ability to activate cSrc, we sought to
determine if AFAP-110403C had the capacity to activate cSrc.
Co-transfection of Flag-tagged AFAP-110 or Flag-tagged AFAP-110403C with
cSrc into SYF cells confirmed that AFAP-110403C was able to direct cSrc activation in
contrast to wild type AFAP-110 (Figure 6A). The SYF cell lines allowed us to determine
the effect of AFAP-110 on cSrc activity in the absence of other Src family members. This
data indicated that AFAP-110403C can activate cSrc in cells under conditions of dual overexpression.
To further examine the effect of 403C on the function of AFAP-110, fibroblasts
expressing varying levels of cSrc were used. SYF cells do not express cSrc, MEFs
express a low level, while SYF-cSrc cells express a relatively high level of cSrc (Figure
6B). Neither GFP-AFAP-110 or GFP-AFAP-110403C affect detectable changes in cellular
morphology in SYF (data not shown) nor MEF cells (Figure 7A).

Anti-phospho

cSrcY416 which recognizes phosphorylated tyrosine 416 in active cSrc was used to
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assess cSrc activity. Active cSrc was undetectable in both SYF and MEF cells. However,
in SYF-cSrc cells, GFP-AFAP-110403C directed cSrc activation and the formation of
podosomes (Figure 7B).

Podosome formation was confirmed based on the co-

localization of AFAP-110, actin and cortactin in punctate structures on the ventral surface
of the cells (Linder and Aepfelbacher, 2003) (Figure 7C). By quantifying the number of
cells exhibiting podosomes and the number of podosomes/cell, we determined that
podosome formation was strongly associated with expression of AFAP-110403C in SYFcSrc cells, and that cells expressing AFAP-110403C had significantly more podosomes/cell
than that of cells expressing only endogenous or over-expressed AFAP-110 (Figure 8).
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DISCUSSION
Ovarian cancer results from a combination of inherited and acquired genetic
alterations as well as from environmental influences. Detection is limited because of
inadequate screening and nonspecific symptoms. Since this leads to a delayed diagnosis,
ovarian cancer is the most lethal gynecological malignancy. This creates interest in
identifying biomarkers that stratify patients into high risk subgroups, as well as
potentially guide the development of individualized therapy.

The present study

demonstrates that AFAP-110403C results in activation of cSrc under conditions of overexpression. Therefore, we hypothesize that the presence and expression levels of AFAP110403C may have value in predicting risk and treatment strategies for ovarian cancer.
AFAP-110 functions as an actin filament cross-linking protein and an adaptor
protein that relays signals from PKCα that activate cSrc (Chen et al., 1985; Dorfleutner et
al., 2007; Kanner et al., 1991; Qian et al., 2002; Qian et al., 2004). Activated cSrc leads
to an increase in cell motility and the production of podosomes, which may be precursors
to invadopodia (Gatesman et al., 2004; Walker et al., 2007). As podosome formation
requires both cSrc activation and dynamic changes in actin filament integrity, AFAP-110
may be uniquely positioned to regulate these two cellular signals. This ability to activate
cSrc and contribute to the formation of invasive structures may be relevant for cancer
progression (Flynn, 2008).
As AFAP-110 is a cSrc activating protein, this report determined if its expression
or its genetic variant AFAP-110403C was associated with ovarian cancer.

IHC

demonstrated that both AFAP-110 and cSrc were over-expressed in ovarian cancer. In
general, cSrc expression was diffuse, while AFAP-110 expression was focal.
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Interestingly, both AFAP-110 and cSrc were always over-expressed together in welldifferentiated tumors and in desmoplastic regions of the tumor.

Co-localization in

desmoplastic areas may represent dynamic interactions between the host and the invasive
tumor. As cSrc activation correlates with acquisition of the invasive phenotype (Summy
and Gallick, 2006), we hypothesized that AFAP-110 is positioned to activate cSrc and
therefore promote invasion in these discrete areas.
AFAP-110 was scanned for genetic changes in human ovarian cancer cell lines by
isolating the cDNA of AFAP-110. A SNP was identified that affected a nonsynonymous
coding change at base pair 1210, changing Ser403→Cys403.

Additionally, 124 ovarian

tumors were analyzed and determined to contain the SNP in 22% of the samples.
Adjacent, normal ovarian tissue as well as that obtained from women with no known
history of malignancy revealed a similar SNP profile. Thus, although expression levels
of AFAP-110 were elevated in ovarian cancer, the presence of the SNP was not enriched
in tumors. Therefore, this study focused on determining if high expression levels of
AFAP-110 or AFAP-110403C affected differences in cSrc activation or cell morphology.
Serine 403 of AFAP-110 is positioned on the loop between the fifth and sixth βstrands of the PH2 domain. Molecular modeling indicated that the peripherally positioned
R-hydroxyl group of Ser403 forms hydrogen bonding with H2O 71% of the time, while the
Cys403 forms hydrogen bonding with H2O less efficiently (36%). Hydrogen bonds may
stabilize the loops of the PH domain and increase the rigidity in the binding pocket.
There are as many as 258 different proteins that contain PH domains (Lemmon et
al., 2002; McPherson et al., 2001).

Of these, only 10% are predicted to facilitate

phospholipid binding by forming interactions between positively charged Lys or Arg
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residues within the PH binding pockets and the negatively charged phospholipids. The
PH2 domain of AFAP-110 is unable to bind phospholipid.
PH domains also bind to proteins. Affinity precipitation revealed that similar to
the PH1 domain, the PH2 domain also bound AFAP-110. Thus, it is predicted that the
PH2 domain may foster either intramolecular or intermolecular interactions, promoting
multimerization or stabilization of the multimer. However, GST-PH2403C bound less
efficiently to AFAP-110. Loss of AFAP-110 multimer stability correlated with a gain-offunction, including an ability to colocalize and activate cSrc (Gatesman et al., 2004; Qian
et al., 2004; Walker et al., 2007). Thus, we sought to determine if AFAP-110403C
activates cSrc.
Expression of AFAP-110 or AFAP-110403C in MEF cells, which contain
detectable levels of cSrc – estimated around 20,000 molecules per cell (Flynn
unpublished data) did not result in cSrc activation or morphological changes that are
associated with cSrc activation. Ectopically expressed AFAP-110 or AFAP-110403C in
SYF-cSrc cells, which over-express cSrc at levels that are higher than MEFs, was used to
determine if AFAP-110403C has a differential capacity to activate cSrc. Compared to
AFAP-110, AFAP-110403C was a more efficient activator of cSrc and more efficient in
inducing the formation of podosomes.

Thus these data indicate that in cells over-

expressing cSrc, AFAP-110403C more efficiently activates cSrc compared to wild type
AFAP-110. Previous evidence suggested that in chicken embryo fibroblasts transformed
by the Rous sarcoma virus only 5% of AFAP-110 is complexed with v-Src (Kanner et al.,
1991). Since only a subset of AFAP-110 and Src interact, it is possible that in MEF cells
only 5% or less of the cSrc population that is expressed would be engaged with AFAP-
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110403C and that this stoichiometry of binding could be below detection. Further, if 5% of
cSrc were activated in MEF cells, activation may be insufficient to direct morphological
changes characteristic of Src-transformed cells. Thus, under conditions where both cSrc
and AFAP-110403C expression is low, as in normal tissues, cSrc activation is unlikely to
occur or affect cellular changes even in those cells that inherit AFAP403C.

Under

conditions of dual over-expression of AFAP-110403C and cSrc, AFAP-110403C may
independently activate cSrc and promote tumor progression. Since AFAP-110 and cSrc
are over-expressed in the same tumors, AFAP-110 may enhance cSrc activation by
receiving input signals that enable cSrc activation or, alternatively, AFAP-110403C may
result in a reduced capacity to self-associate resulting in the independent activation of
cSrc. Although not enriched in ovarian cancer tumors, the 403C variant may lead to a
more aggressive and metastatic disease through its promotion of cSrc activation in those
tumors in which it is found. Future studies using ovarian cancer cell lines and additional
patient samples should address this issue. These data also indicate a mechanism by which
an inherited genetic variation could influence ovarian cancer progression and be used to
predict the response to targeted therapy.
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Figure 1. Focal and diffuse expression patterns of AFAP-110 and cSrc
Ovarian cancer tissues were sectioned and immunohistochemistry performed with antiAFAP-110 (pAb F1) or anti-cSrc antibody (monoclonal antibody EG107 and the
intensity of immunolabeling (brown color) qualitatively assessed by a pathologist.
Samples that show focal (highly localized) or diffuse immunolabeling that exhibit deep,
robust or weak immunostaining are shown for comparison and these types of images
represent the assessment of tissue immunostaining shown in Supplemental Table 1. (A)
AFAP-110 expressed strongly in focal areas of the tumor, (B) AFAP-110 expressed
weakly in focal areas of the tumor, (C) cSrc expressed strongly and diffusely throughout
the tumor or (D) cSrc expressed weakly and diffusely throughout the tumor.
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Figure 2. Co-expression of AFAP-110 and cSrc in ovarian tumors
Serial sections of normal human ovary tissues, well differentiated, and undifferentiated
human ovary tissues were immunolabeled for AFAP with pAb F1, cSrc antibody EG107,
and H&E staining as described under Material and Methods. (A) Normal ovary/AFAP110; (B) normal ovary/cSrc; (C) normal ovary/H&E; (D) well-differentiated
tumor/AFAP-110; (E) well-differentiated tumor/cSrc; (F) well-differentiated tumor/H&E;
(G) ovarian tumor/AFAP-110; (H) ovarian tumor/cSrc; (I) ovarian tumor/H&E; (J)
undifferentiated tumor/AFAP-110; (K) undifferentiated tumor/cSrc; (L) undifferentiated
tumor/H&E. In comparison to normal human ovaries (A-C), AFAP-110 and cSrc protein
are over-expressed and colocalized in well-differentiated tumors (D-F), as well as
desmoplastic regions of human ovarian tumors (G-I). AFAP-110 is over-expressed in
undifferentiated tissue specimens (J-L); however, colocalization with cSrc was variable.
All images were captured at a magnification of 100x. As stated in Supplementary table 1,
33 ovarian tumors were analyzed. Of these, 20 were differentiatied tumors and 13 were
undifferentiated. Six normal ovaries were analyzed.
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Figure 3

Figure 3. cSrc expression level in ovarian tumors match those levels detected in
SYF-cSrc cells
(A) 50 µg of SYFor SYF-cSrc cellular lysates or human ovarian tissue lysates were
resolved by 8% SDS-PAGE, transferred to PVDF and western blot analysis performed
with anti-cSrc antibodies. Code numbers for de-identified patient samples are shown.
Five samples had Ser403 encoded on at least one allele, and five samples had Cys403
encoded on at least one allele. (B) cSrc and AFAP-110 expression levels are increased in
ovarian tumors relative to normal, adjacent tissue. Western blot analysis with antibodies
to AFAP-110 or cSrc of two ovarian tumor samples (T) and matching, adjacent control
tissues (N) from two patient samples (#77 and #82). Patient #77 has the AFAP-110
Ser403 wild-type isoform, while patient # 82 has the AFAP-110 Cys403 SNP on at least
one allele.
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Figure 4

Figure 4. Molecular modeling of the PH2 domain
Homology models for AFAP-110 PH2-WT (A and B) and AFAP-110 PH2403C (C and D)
demonstrated that the amino acid change occurs in a loop region between the 5th and 6th
β-strand. Performing a hydrogen bond (dashed black lines) analysis for each structure
predicted that AFAP-110 PH2-WT binds to water molecules (solid red lines) 71% of the
time potentially forming a rigid binding region. In contrast, AFAP-110 PH2403C was
predicted to bind to water only 36% of the time.

Labeled amino acids occur at

coordinates predicted to interact with phospholipid head groups. Intrastrand loops: green;
β-strands: blue; α-helix: red.
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Figure 5. Affinity precipitation of AFAP-110 with GST-PH2 and GST-PH2403C
GST-affinity precipitation experiment comparing the differential ability of GST-PH2 and
GST-PH2403C to bind AFAP-110 in MEF, SYF, SYF-cSrc, and CaOV3 cell lysates (A).
Equal quantities of GST-fusion proteins were used to affinity precipitate AFAP-110 from
equal amounts of cell lysates. (A) Western blot analysis with pAb F1 indicate that GSTPH2 is more efficient in binding AFAP-110 then GST-PH2403C. CaOV3 cells serve as
the negative control in these experiments as this cell line has low to undetectable amount
of AFAP-110. Western blots of cell lysates for AFAP-110 (B) and actin loading controls
(C) are also shown.
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Figure 6

Figure 6. cSrc activity in SYF cells expressing cSrc and AFAP-110403C
(A) Flag-tagged AFAP-110 or AFAP-110403C was transfected into SYF-cSrc cells and
expression levels detected with anti-Flag antibodies.

cSrc expression levels and

immunoreactivity with anti-pSrc416 antibodies were determined. (B) 50 µg of MEF, SYF
or SYF-cSrc cellular lysates were resolved by 8% SDS-PAGE, transferred to PVDF and
cSrc detected with anti-cSrc antibodies.
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Figure 7. cSrc activation and podosome formation in SYF-cSrc cells expressing
AFAP-110403C
(A) MEF cells were transfected with GFP-AFAP-110 or GFP-AFAP-110403C and
analyzed for activation of endogenous cSrc or changes in actin filament integrity and
podosome formation. Bars = 20 µm. (B) SFY-cSrc cells similarly transiently transfected
with GFP-AFAP-110 or GFP-AFAP-110403C and immunolabeled with anti-Src antibody
(b and f) and phospho-Src family (Y416) antibody (c and g). Unlike wild-type GFPAFAP-110, expression of GFP-AFAP-110403C resulted in the formation of punctate
structures on the ventral surface of the cells enriched for GFP-AFAP-110403C (e) that
exhibited an increase in c-Src phosphorylation at the Y416 position (merged image, h).
(C) Punctate structures resulting from the expression of GFP-AFAP-110403C were also
enriched for actin and cortactin (merged image, q). In contrast, cells expressing wildtype GFP-AFAP-110 maintained actin filaments and did not exhibit the formation of
actin-rich podosomes (j-m). Bars: 10µm (panels a-d, e-h, n-q) and 20 µm (panels j-m).
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Figure 8

Figure 8. AFAP-110403C directed podosome formation in SYF-cSrc cells
(A) Podosomes were counted in the transfected cells and the percentage of cells
expressing podosomes was quantified. (*p = 0.015, n=500 cells). (B) The number of
podosomes per cell was quantified. The podosome distribution was determineed by
comparing AFAP-110 to AFAP-110403C. While 80% of the cells transfected with AFAP110 wild type (empty bars) exhibit between 0-3 podosomes/cell, cells transfected with
AFAP-110403C (hatched bars) exhibit a broad distribution with greater than 50%
exhibiting more than 8 podosomes per cell.
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Figure W1. The PH2 domain does not bind to phospholipids
(A) Lipid dot blot analysis was used to examine the ability of GST-AFAP1-PH2 domain
to bind immobilized phospholipids. GST-DAPP1-PH was used as a positive control and
bound both PtdIns-3-4-P2 and PtdIns-3-4-5-P3, consistent with published data [36]. The
GST-AFAP-110-PH2 did not bind any immobilized phosphoinositides tested. (B and C)
A lipid vesicle sedimentation assay was performed with GST-PH2 (B) or the positive
control GST-DAPP1-PH (C). After SDS-PAGE of the supernatants (S) and the pellets
(P), the gels were stained sith SYPRO orange. Data are consistent with lipid dot-blot
analysis.
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